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ABSTRACT 
Research into responsive polymeric insulin delivery systems for the management of diabetes 
mellitus is gaining increasing interest due to the rise in the incidence rate and the burden of daily 
multiple subcutaneous insulin injections that needs to be endured by the patient. The present 
study attempted to formulate a nanoparticulate glucose responsive insulin delivery system from a 
natural polymer chitosan, using a safe glucose sensor, phenyl boronic acid (PBA), which is 
known to interact with glucose. In the present project, a new method for the production of 
chitosan tripolyphosphate (TPP) nanoparticles via ultrasonication was developed and optimised. 
The electrostatic method of tagging PBA onto chitosan was unsuccessful, but the method of N-
reductive alkylation of introducing the PBA was successful. Evidence of PBA bonding on to 
chitosan was assessed by FTIR, ToF-SIMS, DSC and glucose adsorption sensitivity 
measurements. Glucose adsorption sensitivity to PBA-bonded chitosan polymer was directly 
related to the amount of PBA functionality within the conjugates and the physical nature of the 
matrices (porous or crystalline) as revealed by scanning electron microscopy (SEM). The 
nanoparticles showed glucose concentration dependent swelling with swelling decrease at a 
glucose concentration above 2.5mg/ml. Encapsulation of insulin into the nanoparticulate matrix 
was achieved by both the ionotropic gelation and polyelectrolyte complexation methods. Smaller 
particles with z-average between 140 ± 150nm, lower Pdi and zeta potential between 17.5-
19.1mV were characteristic of particles produced by PEC, whilst slightly larger particles with z-
averages between 170-200nm, higher Pdi and  zeta potential between +17.6-21.6mV were 
noticed for the particles produced by ionotropic gelation. Higher encapsulation of insulin of 
about 90% was achieved using the PEC method as compared to 34% from the ionotropic 
gelation series. The amount of drug encapsulated in both methods was pH dependent. In vitro 
xxi 
 
glucose dependent insulin release studied on PEC formulations showed a glucose and fructose 
concentration dependent release which was affected by the buffer system used. Lower insulin 
release from higher concentration of the sugars was attributed to the formation of bidentate 
interaction between the diols in the sugar and PBA, which restricts further expansion of the 
nanoparticles and hence reduces insulin release. This was confirmed by the SEM images of the 
nanoparticles after exposure to buffer, glucose and fructose in buffers at pH 7.4. Nanoparticles 
exposed to fructose showed more spherical and intact matrices whilst the buffer samples showed 
fragmented particles. The samples exposed to glucose showed some degree of fragmentation but 
not high as compared to that of nanoparticles exposed to buffer. The release of insulin from this 
formulation was therefore dependent on a complex interplay between the components of the 
buffer and the amount of sugar present. 
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CHAPTER 1 
INTRODUCTION 
1.1 General overview of diabetes and nanoparticulate delivery system 
According to The World Health Organization (WHO), the number of people with diabetes is on 
the rise due to aging, urbanisation and more importantly, increased level of inactivity and 
increasing prevalence of obesity (WHO|Diabetes, 2013). Depending on the stream of 
management, there are two forms of the disease; Type I and Type II diabetes mellitus. Type I 
diabetes comes about due to the loss of pancreatic function.  The loss of pancreatic function may 
be due to disease or injury to the pancreas which ultimately leads to loss of optimum glycaemic 
control. Thus, insulin needs to be injected subcutaneously three to four times daily to compensate 
for the needs of the body (Shaw et al. 2010; Kitagawa et al. 1994).  
Management of Type I diabetes requires adequate skills and proper glucose monitoring since 
fluctuations in glucose concentration in the body can be fatal. On the other hand, in Type II 
GLDEHWHV WKHUH LV DGHFUHDVH LQ WKHERG\¶V VHFUHWLRQDQG VHQVLWLYLW\ WR LQVXOLQZKLFK LV XVXDOO\
caused by obesity. Proper life-style modifications usually ensure adequate glycaemic control 
(Gerstein and Haynes 2001; Owens et al. 2003). 
With regard to Type I diabetes and in the in the light of the above constraints, many researchers 
have embarked on the design of insulin-containing delivery systems, with the aim of delivering 
insulin to the body in response to the variation of glucose concentration. In such delivery 
systems, it is often desirable to effect prolonged insulin delivery ideally through a feedback 
mechanism and ideally, these systems should not require invasive interventions. Many of such 
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attempts have been made in the designing of such delivery systems and various mechanisms of 
glucose sensation have been pursued. Some of these include insulin delivery systems based on 
hydrogels with a specific glucose sensing moiety (Matsumoto et al. 2003; Zha et al. 2011; 
Motornov et al. 2010).  
Many researchers have utilised the combination of glucose oxidase with pH-sensitive hydrogels 
to sense changes in glucose concentration and regulate insulin release, henceforth within the pH-
sensitive hydrogels containing glucose oxidase; glucose is converted to gluconic acid by glucose 
oxidase, thus lowering the pH in the hydrogels and hence the swelling of the hydrogels leading 
to insulin release. Thus, the pH-sensitive hydrogels containing glucose oxidase is made to 
control insulin release in response to the glucose concentration (Albin et al. 1985; Hassan et al. 
1997; Parker et al. 1999; Traitel et al. 2000; Gu et al. 2013) 
Another mechanism proposed is based on insulin-releasing hydrogels where moieties such as 
lectins act as the glucose sensing moiety. These proteins have unique carbohydrate-binding 
properties, and are very useful for the fabrication of glucose-sensitive systems. Therefore, some 
researchers have focused on the glucose-binding properties of concanavalin A (Con A), a lectin 
possessing four binding sites (Yin et al. 2010). The mechanism here is based on insulin being 
released from the hydrogel complex with Con A, in response of free glucose, based on the 
competitive and complementary binding properties of insulin and glucose to Con A (Brownlee 
and Cerami 1979; Kimiko et al. 1990; Obaidat and Park 1997). 
The susceptibility of proteins to degradation by proteolytic enzymes and their inherent instability 
is a major drawback in their usage as glucose sensing moieties. Furthermore, the immunogenic 
reaction induced by lectins is also of concern. 
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Due to some of these drawbacks discussed, current research is beginning to focus on the 
formulation of glucose-sensitive hydrogels without biological components such as proteins, and 
rather utilising complex formation with glucose-sensing chemical moieties. One group of 
compounds with such glucose sensing moiety are the boronic acids. Boronic acids in the form of 
hydroxyboronate anion form a complex with cis-1,2 or 1,3-diol (Bachelier and Verchere 1995) 
and glucose being a diol has both groups, hence boronic acids will have the ability to reversibly 
bind the cis diols in glucose (figure 1.1).  
 
 
Figure 1.1  Reversible binding of boronic acid to diols (Springsteen and Wang 2002) 
 
Boronic acids have been used in the development of feedback controlled drug delivery polymers 
as saccharide sensors and their potential applications pharmaceutically have been widely 
explored in enzyme inhibition, boron neutron capture therapy and antibody mimics for cell 
surface polysaccharides (Yang et al. 2003).  
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Figure 1.2 summarises some of the potential uses of boronic acids. Boronic acids have been 
studied and proven to be safe for use as glucose sensors (Yang et al. 2003; Kikuchi et al. 1996; 
Kataoka et al. 1994).  
 
Figure 1.2 Various uses of boronic acids (Cambre and Sumerlin 2011) 
 
Nanoparticles are receiving considerable attention in the delivery for therapeutic drugs. The 
literature emphasises the advantages of nanoparticles over microparticles (McClean et al. 1998) 
and liposomes (Soppimath et al. 2001). The submicron size of nanoparticles offers a number of 
distinct advantages over microparticles, including relatively higher intracellular uptake compared 
with microparticles. Other important advantages of nanoparticles as drug carriers include: high 
carrier capacity (many drug molecules can be incorporated in the particle matrix); feasibility of 
incorporation of both hydrophilic and hydrophobic substances and possibility of variable routes 
of administration. The nanoparticulate carriers can also be designed to enable controlled 
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(sustained) drug release (Agnihotri et al. 2004; Uner and Yener 2007). Nanoparticles are readily 
produced by various methods depending on the polymer being used. The formulated 
nanoparticulate delivery system must be compatible and desirably biodegradable and the 
formulation process must be simple and reproducible.  
Chitosan is a well-studied polymer that has proven biodegradable and biocompatible properties 
(Kean and Thanou 2010). In the present study, we aimed to formulating glucose responsive 
insulin containing nanoparticles using chitosan as the parent polymer and boronic acid as the 
glucose sensing moiety by adopting a robust and yet a simple method. Nanoparticles have the 
highest surface area-to-volume ratio of any dosage form. This approach is unique, in that several 
of the previously proposed models were formulated as polymer strips or microparticles. Majority 
utilised synthetic polymers which are mostly non-biodegradable. The system presented in this 
study is based on a natural polymer in conjunction with a safe glucose sensing moiety.  
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1.2 Review of diabetes mellitus 
Diabetes is a metabolic disorder which occurs when the pancreas does not produce enough 
insulin, or when the body cannot effectively utilise the insulin it produces. This leads to an 
increased concentration of glucose in the blood (hyperglycaemia) with disturbed carbohydrate, 
fat and protein metabolism (Amos et al. 1997; DiPiro et al. 2005). 
1.2.1 Epidemiology and global estimates 
 According to WHO, the number of people with diabetes is increasing due to population growth, 
aging, urbanisation, and increasing prevalence of obesity and physical inactivity. 347 million 
people worldwide have diabetes (WHO, Diabetes, 2013). The world prevalence of diabetes 
among adults (20±79 years) was 6.4%, affecting 285 million adults in 2010 and is estimated to 
increase to 7.7% and 439 million adults by 2030. Between 2010 and 2030, there will be a 69% 
increase in numbers of adults with diabetes in developing countries and a 20% increase in 
developed countries. These predictions, based on a larger number of studies than previous 
estimates, indicate a growing burden on the management of diabetes, particularly in developing 
countries (Zimmet et al. 2001; Shaw et al. 2010). WHO projects that diabetes will be the 7th 
leading cause of death in 2030 (WHO | Diabetes, 2013). 
Current estimates suggest that, globally, the number of people with diabetes will rise from 151 
million in the year 2000, to 221 million by the year 2010, and to 300 million by 2025 (Amos et 
al. 1997; King et al. 1998). This rise is predicted to occur virtually in every nation, with the 
greatest increase expected in developing countries. Type II diabetes will account for nine patients 
in every ten of these diagnoses. This explosive increase in the prevalence of Type II diabetes, 
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and the consequences of its complications and associated disorders, represents the greatest health 
care challenge facing the world today (Zimmet et al. 2001).  
 
1.2.2 Classification of diabetes mellitus 
1.2.2.1 Type I and Type II diabetes mellitus 
Type I diabetes occurs as a result of deficiency of insulin due to the destruction of pancreatic 
cells and this usually progresses to the stage of absolute insulin deficiency. In the majority of 
Japanese patients with Type I diabetes, an autoimmune process is thought to play a major role in 
cell destruction. Auto-antibodies to islet cell antigens are detected in many patients (70± 90%), 
particularly at the early stages (Kitagawa et al. 1998). Typically, it occurs in young subjects with 
acute onset, but may occur at any age, sometimes with slow progression (Fajans 1990). 
Occasionally, before the occurrence of clinical symptoms or hyperglycaemia, auto-antibodies or 
the loss of acute insulin response to intravenous glucose may be detected. 
0RVWSDWLHQWVSUHYLRXVO\ODEHOOHGDV³1RQ-Insulin Dependent Diabetes Mellitus´1,''0KDYH
now been grouped into Type II category. In this type, the mass of pancreatic cells and their 
function are preserved to some extent and insulin injection is seldom required. Both decreased 
insulin secretion and decreased insulin sensitivity (insulin resistance) are involved in its 
pathogenesis. The relative role of these two factors varies between patients. With regard to 
insulin secretion, the acute insulin response to a glucose load is characteristically defective. The 
majorities of patients are obese or have been obese in the past (Kitagawa et al. 1998). 
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Typically, Type II diabetes develops after middle age, but may occur in younger people. 
Screening by urinalysis of large number of school children has revealed that Type II diabetes has 
been steadily increasing since the 1970s. The incidence of Type II diabetes is very low under the 
age of 10 years, but exceeds the incidence of Type I diabetes in mid-teens. About 80% of them 
are obese (Kitagawa et al. 1994). 
 
1.2.2.2 Gestational diabetes mellitus (GDM) 
GDM is a state of glucose intolerance occurring or detected for the first time during pregnancy. 
Thus, pregnancy is a diabetogenic factor. Etiologically, many GDM patients probably share 
common genetic susceptibilities with Type I or Type II diabetes, and the deterioration of glucose 
tolerance is precipitated by the metabolic effect of pregnancy. The reason to treat GDM as an 
independent category is its clinical importance which requires special consideration. During 
SUHJQDQF\ JOXFRVH LQWROHUDQFH PLOGHU WKDQ µGLDEHWLF W\SH¶ PD\ DIIHFW WKH LQIDQW DQG PRWKHU
adversely. Glucose intolerance during pregnancy is often normalised after delivery, but such 
cases are at higher risk of developing diabetes in the future ( Kim et al. 2002; Jovanovic 2001).  
 
1.2.3 Complications of diabetes mellitus 
There are lots of complications that arise with diabetes mellitus, due to the different metabolic 
derangement that the body is subjected to. It affects the vascular system; leading to peripheral 
neuropathy, retinopathy, hypertension and coronary heart disease, the renal system; leading to 
microalbuminuria and nephropathy. All these complications make diabetes a condition worth 
JLYLQJ DWWHQWLRQ WR DQG LWV PDQDJHPHQW GRQH ZLWK FDUH DQG GLVFLSOLQH RQ WKH SDWLHQW¶V VLGH
(DiPiro et al. 2005).  
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1.2.4 Management of diabetes mellitus 
The management of this condition is multifaceted. It requires quality medical attention and 
discipline also from the patient. The discipline stems out of the needed lifestyle modification by 
the patient for adequate glycaemic control. 
Multiple daily injection of insulin is the main stream of therapy for Type I diabetes coupled with 
lifestyle modification by the patient. Their diet and general health needs to be monitored; any 
complication related to the condition also needs to be attended to (Gerstein and Haynes 2001). 
Type II management is multifaceted, requiring weight reduction, calorie restriction and patient 
education. Adequate self-management remains the cornerstones of management of Type II 
diabetes. However, many patients are unable to sustain satisfactory long-term glycaemic control 
after achieving a temporary response, and medical treatment such as oral hypoglycaemic 
including the biguanides (metformin), sulphonylureas (glizone), glucose oxidase inhibitors 
(acarbose), metiglinides (repaglinde) and the thiazolidines (pioglitazone), or insulin are 
subsequently needed, depending on the severity and the stage of the disease (Guthrie 1997; 
Balfour and McTavish 1993; Bailey 1993; Saltiel and Horikashi 1995). Recently, new breeds of 
antidiabetic drug called the SGLT-2 inhibitors (dapagliflozin, canagliflozin) are under study and 
not yet approved by the FDA. These can be used in conjunction with other oral hypoglycaemics 
(Shah et al. 2012). Results produced so far shows their possible use in the management of Type 
II diabetes. 
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1.3 Insulin  
Insulin is a polypeptide hormone formed, after elimination of C peptide by hydrolysis. It 
comprises of 51 amino acids in the form of two chains of 21 and 30 amino acids, connected by 
two disulphide bridges (figure 1.3). It has a molecular weight of 5808 Dalton. It is secreted by 
the ß cells of the islets of Langerhans of the pancreas (Structural Biochemistry).  
 
Figure 1.3 Amino acid sequence of human insulin (Insulin: Martindale) 
It is the central hormone that  regulate the energy and glucose metabolism in the body and causes 
cells in the liver, muscle, and fat tissue to take up glucose from the blood, storing it as glycogen 
in the liver and muscle. It restrains the use of fat as an energy source (Fajans 1990; Rave et al. 
2000). When insulin is absent, glucose is not taken up by body cells, and the body begins to use 
fat as an energy source.  
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Figure 1.4 shows the hexameric 3D structure of insulin, coordinated by two zinc ions. It is 
believed to be the form in which insulin is stored in the beta-cells of the islets of Langerhans 
prior to release. It belongs to the group of peptides called IGF (insulin like growth factors) or 
somatomedins (Insulin: Martindale, 2013). However, its structure varies slightly between species 
and it has been noted that, insulin from animal differs in strength (carbohydrate metabolism) 
from that of humans. Porcine insulin is especially close to the human version (Richter and Neises 
2003).  
 
Figure 1.4 Hexameric 3D structure of insulin ³%HDXWLIXOSURWHLQV´ 
Subcutaneously injected Insulin is the mainstream therapy for Type I diabetes and sometimes for 
uncontrolled Type II diabetes mellitus. The dosage normally depends on the type of insulin being 
used and the extent of the condition (Kennedy 1991). 
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1.3.1 Classification of insulin 
Insulin may be classified as rapid-acting, very rapid-acting, intermediate-acting, and long-acting, 
based on the number of hours until "peak" therapeutic effect. Peak action occurs when the 
concentration of insulin is greatest in the blood and has its greatest glucose-lowering effect. 
Rapid and very rapid -acting insulin are often used before eating to control the large rise of blood 
glucose that often occurs after a meal. Ideally, short-acting insulin is taken approximately 30-45 
minutes before the meal. Their duration of action is about 2 hours. Example is Humulin® and 
Insulin Lispro® by Eli Lilly (DiPiro et al. 2005; "Insulin Basics", 2013.). 
Intermediate-acting insulins are absorbed 3-4 hours after injection and have their peak action 
after 7-9 hours. Again, there is considerable variation as the duration of action may be as much 
as 12-16 hours after injection. Used in the morning, its peak therapeutic effects could be 
observed in the afternoon. One of the best uses of this type of insulin is its injection at bedtime to 
control the morning glucose of the next day. An example is the Neutral Protamine Hagedorn® 
(NPH) insulin (also known as Humulin N, and Isophane insulin) produced by Novo Nordisk 
(DiPiro et al. 2005). 
Long-acting insulin has a peak effect occurring after 10-12 hours and its duration of action may 
be 16-18 hours. It is not a popular insulin, but may be individuals in whom intermediate-acting 
insulins taken at bedtime act too quickly, resulting in hypoglycaemic reactions during the night. 
By its use, one can slow down the peak action by an hour or two, often preventing 
hypoglycaemia at night, but controlling the fasting sugar of the next day. Examples are Ultra 
Lente insulin, Human Ultra Lente (DiPiro et al. 2005; "Insulin Basics", 2013.). 
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1.3.2 Storage 
Insulin is highly unstable and therefore it is recommended that unopened insulin be refrigerated 
(2oC to 8oC) prior to use. Once the insulin is in use, the manufacturer-recommended expiration 
dates will vary based on the insulin and delivery device. For financial reasons, patients may 
attempt to use insulins longer than their expiration dates, but careful attention must be paid to 
monitoring glycaemic control and signs of insulin decay such as clumping, precipitation and 
discoloration. 
 
 
1.4 Routes of insulin delivery 
The main mode of insulin delivery has been via subcutaneous route. The motivation for the 
search for an alternative route of delivery is to contribute to the avoidance of the burden of 
multiple subcutaneous injections, which will in turn improve compliance and improve the 
pharmacokinetics of insulin. More acceptable alternative routes of insulin administration have 
been and are being investigated including the dermal and oral route, however only the pulmonary 
and buccal insulin has become a feasible commercialised alternative thus far (Kumria and 
Goomber 2011). 
 
1.4.1 Gastrointestinal route  
This route is the most convenient way of delivering drugs and the administration of insulin by 
this route is attractive and has a potential of being utilised for insulin delivery. However, the 
acidic conditions in the stomach make it unfavourable for the delivery proteins, due to the 
susceptibility of proteins and peptides like insulin to degradation by the acidic conditions in the 
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stomach and enzymatic activities in the small intestines. Thus, the delivery of peptides via the 
oral route therefore presents its own challenges. Moreover, the gastrointestinal mucosa prevents 
absorption of large hydrophilic peptides. Several strategies, alone or in combination, have been 
developed to increase intestinal absorption of peptides such as insulin. They include the use of 
permeation enhancers such as bile salts and fatty acids, associated or not  with enzyme inhibitors 
like aprotinin (Bendayan et al. 1994; Mesiha et al. 2002), liposomes, emulsions, 
mucobioadhesives and polymer-based delivery systems (Kisel et al. 2001). The use of polymers 
in encapsulating insulin into microspheres which degrade in the liver to release insulin has also 
been studied. All these strategies have achieved partial success and need further investigation 
(Reis and Damgé 2012).  
 
1.4.2 Intranasal and pulmonary route of delivery 
The epithelial surface of the of the nasal cavity offers a possible route for insulin delivery, but 
the main barriers to absorption include the active mucociliary clearance mechanism and the 
proteolytic enzymes present. 
The respiratory tree offers the greatest potential for the delivery of polypeptides such as insulin, 
due to its high vascularisation and vast surface area. Until the dynamics of aerosol was 
recognised, there was not significant progress in the field of attempting to deliver insulin via 
inhalation (Owens et al. 2003). Though this route is a promising route of delivery, there are key 
factors that affect the delivery and efficiency of inhaled insulin via the route. These are the 
breathing pattern, the presence of air flow obstruction, interstitial lung disease, smoking, exercise 
DQGWKHSDWLHQW¶VGH[WHULW\WRKDQGOLQJGHOLYHU\GHYLFHV 
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1.5 Insulin delivery devices 
Historically, patients injected insulin subcutaneously using glass syringes with detachable 
needles, but these needles were large and made injections very painful. The discovery of 
GLVSRVDEOH SODVWLF µGLDEHWLF V\ULQJHV¶ ZLWK D IL[HG QHHGOH ZDV DQ DGYDQFHPHQW ZKLFK PDGH
injections less painful. Biphasic insulin therapy also solved the problem of dosage inaccuracies 
caused by improper mixing of short- and longer-acting insulin using the syringe.  
The last five years have seen an increase in the range of insulin delivery devices. These devices 
have helped in the revolution of insulin self-care and comes in various forms such as, syringes, 
pens (Novo Nordisk and the Lily pens), insulin pumps and jet injectors (Owens et al. 2003). 
 
1.5.1 Pulmonary insulin delivery devices 
Current pulmonary drug delivery systems include a variety of pressurised metered dose inhalers 
(pMDI), dry powder inhalers (DPI), nebulizers and aqueous mist inhalers (AMI).  
The Nektar/Exubera device is a DPI which uses compressed air to disperse an insulin powder 
formulation into a spacer reservoir prior to inhalation (Owens et al. 2003; Rave et al. 2000), but 
the marketing of this product has been discontinued due to fear of risk of causing lung toxicity 
on long term use (Heinemann 2008). Currently there is only one buccal insulin formulation being 
marketed. It is a liquid formulation that delivers insulin directly into the buccal mucosa. The 
deposition of the drug on the buccal mucosa allows the developers get over the earlier concerns 
about the risk of lung toxicity that was raised regarding Exubera® (Guntu and Dhand 2007; 
Kumria and Goomber 2011). 
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1.6 Insulin assay 
1.6.1 Development of qualitative and quantitative assay for insulin 
Biological assays were developed to assess the potency of insulin based on the measurement of 
the hypoglycaemic response in rabbits and convulsive response in mice because of the lack of 
knowledge of LQVXOLQ¶V FKHPLFDO VWUXFWXUH DIWHU LWV GLVFRYHU\ E\ %DQWLQJ DQG %HVW LQ 
Variations of these approaches have been used since to validate the potency of insulin in 
pharmaceutical preparations. When Banting and co-workers found that insulin induced 
convulsions in rabbits when they are hypoglycaemic, the amount of insulin which produced 
convulsions in a rabbit in 2-4 h was defined as a unit of activity (Marks 1925). The method was 
adopted by the United States Pharmacopoeia and is still retained after a number of refinements in 
experimental design and analysis.  
Unfortunately, the use of an anaesthetic in the procedure whilst obtaining blood for glucose 
measurement wDVNQRZQWRKDYHHIIHFWRQ WKHPRXVH¶VDSSDUHQW UHVSRQVH WR LQVXOLQDQGVRPH
developmental work would be necessary before the technique could be changed.  
 
 1.6.2 Improvements in sensitivity of assay methods 
The mouse convulsion and the rabbit and mouse blood glucose methods are sufficiently sensitive 
to detect insulin at the concentrations found in pharmaceutical preparations. Although they are 
the only currently internationally accepted assay methods, many other bio-assays for the analysis 
of insulin have been developed over the years for research and assay purposes. Among the more 
sensitive methods includes one developed by Bornstein (1950) in which adrenalectomised and 
hypophysectomised rats rendered alloxan diabetic were demonstrated to be sensitive to as little 
as 50 micro-units of insulin, whereas a normal intact mouse is sensitive to only 200 times that 
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amount. However, the skilled surgery required for the Bornstein technique made it generally 
unsuitable for routine insulin assays. About the same time, fairly sensitive in vitro methods were 
developed for the assay of insulin. It was shown by Groen et al. (1952) that, there was a 
relationship between insulin concentration and glucose uptake in the rat diaphragm. This method 
was sensitive to about 10 micro-units of insulin. Another method was developed by Winegrad 
and Renold (1958) based on the glucose uptake by the rat epididymal fat pad and that method 
was sensitive to 30 micro-units of insulin. However, according to Wright (1960), several 
substances, for example, free fatty acids and adrenalin, interfere with the diaphragm method and 
it was further shown by Riesler (1967) that, proteolytic enzymes leaked out of the cut muscle 
fibres to degrade the insulin. Also several authors have queried the specificity of the fat pad 
assay, so in spite of being very sensitive to insulin, both types of in vitro assay lacked precision 
and specificity. 
 
1.6.2.1 Radioimmunoassay procedures 
Yalow and Berson (1960) devised a sensitive, precise and specific radioimmunoassay for the 
determination of insulin at physiological concentrations. The radioimmunoassay technique of 
Hales and Randle (1963) ZDV H[DPLQHG LQ :HOOFRPH¶V /DERUDWRULHV ZKHUH D ODUJH QXPEHU RI
insulin stability samples were considered to be the ideal proving ground for this method. But the 
results obtained were disappointing as they did not always correlate with biological potencies 
obtained for the same samples. It was also suspected that thermally induced changes in the 
configuration of the insulin molecule were causing some changes in molecular conformation, 
such as mono- or di-GHVDPLGDWLRQ OHDGLQJWRLPPXQRDVVD\YDOXHVZKLFKLQ:HOOFRPH¶VKDQGV
were falsely low or in other hands were falsely high, depending on the antibody used. As the 
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radioimmunoassay could not be shown to correlate with clinical or in vitro efficacy, and because 
of the real difficulty of reagent standardisation, it was not considered suitable for adoption by the 
regulatory authorities. However, the radioimmunoassay technique has been regularly used for 
fresh samples to monitor insulin activity during manufacture and purification. This technique 
costs about one sixth of the current in vivo bio-assay method and has the added advantage of not 
using animals. Therefore, it is the method of choice for in-process samples. Other insulin-
orientated radioimmunoassay techniques have also been utilised at Wellcome to determine the 
amounts of hormone impurities, such as proinsulin, glucagon and pancreatic polypeptides, in 
order to ensure that they are present only in the lowest concentration possible in the finished 
product. 
 
1.6.3 Current trends 
The improvements in technology have over the last few years, opened the door to a new era of 
insulin testing. Firstly, improvements in manufacturing and purification processes have resulted 
in the production of very pure, virtually single component insulins. This was followed in 1986 by 
the establishment of separate international standards for human, bovine and porcine insulins by 
the World Health Organization.  
Secondly, the advent of HPLC columns with greater resolving power has enabled further 
development by workers in this field to precisely assay insulins. This enables species to be 
identified and the proteins in the formulations can be separated and quantified. The procedure 
involves the introduction of insulin formulations to an ultra-pore column and the reading of the 
peaks produced. Using this technique, peaks of insulin and desamido insulin can be identified 
and quantified. It is the insulin and desamido insulin components which contribute to the 
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biological activity and calculation of the areas under the peaks produced by these can provide a 
quantitative analysis of the insulin and insulin-like components present in the formulations.  
 
1.6.3.1 HPLC methods for insulin assay 
Much work has been done on the use of HPLC as method for assaying insulin. The main 
variation in the methods has been the choice of column, the nature of mobile phases and the type 
of detection system used. In the assay of insulin, most work utilises reversed phase columns with 
large pore sizes (300 Å). The mobile phases ranges from the aqueous systems such as buffers and 
salt solutions, with the organic phase being mainly acetonitrile with modifiers like triflouroacetic 
acid (TFA) and diethyleneamine. The mode of detection of insulin is usually by ultra violet (UV) 
absorption at a wavelength of 214 nm (Moslemi et al. 2003; Kunkel et al. 1997), but the 
detection of insulin by fluorescence is achievable by labelling the insulin with fluorescein 
isothiocyanate (FITC) (Fisher and Smith 1986; Oliva et al. 2000; Sawicka et al. 2006). 
Mercoloni et al. (2008) and Sato et al. (1996) have however reported the use of fluorescence as 
the detection mode for insulin without labelling with FITC.  
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1.7 Review of nanoparticulate delivery system (NPDS) 
Nanoparticulate delivery systems are defined as solid, submicron-sized drug carriers that may or 
may not be biodegradable (Couvreur et al. 1988;1995). The term nanoparticle is a collective 
name for both nanospheres and nanocapsules. Nanospheres have a matrix type of structure. 
Drugs may be absorbed at the sphere surface or encapsulated within the particle.  
NPDS can be vesicular systems in which the drug is confined to a cavity consisting of an inner 
liquid core surrounded by a polymeric membrane (Couvreur et al. 1995). In this case, the active 
substances are usually dissolved in the inner core but may also be adsorbed to the capsule 
surface.  
Nanoparticles are receiving considerable attention as drug carriers. The literature emphasises the 
advantages of nanoparticles over microparticles (Xuan et al. 2005) and liposomes (Soppimath et 
al. 2001). The submicron size of nanoparticles offers a number of distinct advantages over 
microparticles, including relatively higher intracellular uptake compared with microparticles. In 
terms of intestinal uptake, apart from their particle size, nanoparticle nature and charge 
properties seem to influence the uptake by intestinal epithelia. Intestinal uptake of nanoparticles 
prepared from hydrophobic polymers seems to be higher than that of particles with more 
hydrophilic surfaces (Jung et al. 2000); thus more hydrophilic particles may be rapidly 
eliminated from the gastrointestinal tract. Generally, nanoparticles based on hydrophobic 
polymers such as polystyrene, uncharged and positively charged, provide an affinity to follicle-
associated epithelia as well as to absorptive enterocytes, whereas negatively charged polystyrene 
nanoparticles show only low affinity to any type of intestinal tissues. In contrast, nanoparticles 
based on negatively charged hydrophilic polymers, show a strong increase in bioadhesive 
properties and are absorbed by both M cells and absorptive enterocytes. A combination of both 
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nanoparticle surface charges and increased hydrophilicity of the matrix material seem to affect 
the gastrointestinal uptake in a positive sense (Fleige et al. 2012). 
 
1.8 Methods used for the preparation of chitosan nanoparticles 
In the present work, chitosan was selected as the polymer of choice because it is well-studied 
biocompatible and biodegradable. Chitosan is made from the deacetylation of chitin, a naturally 
occurring and abundantly available biocompatible polysaccharide mainly from marine 
crustaceans. The applications of chitin are limited compared to chitosan because chitin is 
chemically inert (Anthonsen et al. 1993). Acetamide group of chitin can be converted into amino 
group to give chitosan which is carried out by treating chitin with concentrated alkali solution. 
Chitosan is presented as powder, paste or film and in molecular weights. 
Many methods have been proposed for preparing nanoparticles; and these methods can be 
classified into two main categories according to whether the formulation requires a 
polymerisation reaction or is achieved directly from a macromolecule or preformed polymer 
(Couvreur et al. 1995).  
The polymerisation methods can be further classified into emulsion and interfacial 
polymerisation and there are two types of emulsion polymerisation²organic and aqueous²
depending on the continuous phase. Nanoparticles can also be prepared directly from preformed 
synthetic or natural polymers and by desolvation of macromolecules (Pinto Reis et al. 2006).  
Chitosan nanoparticles have been developed to encapsulate proteins such as bovine serum 
albumin, tetanus and diphtheria toxoid (Soppimath et al. 2001), vaccines (Vila et al. 2004), 
anticancer agents (Janes et al. 2001), insulin (Jintapattanakit et al. 2007), and nucleic acids ( 
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Mao et al. 2001). Chitosan has also been reported to have considerably enhanced the absorption 
of peptides such as insulin and calcitonin across the nasal epithelium (Illum et al. 1994). 
 
1.8.1 Ionic or ionotropic gelation 
This technique involves the introduction of a cross-linking agent e.g. tripolyphosphate (TPP), 
into aqueous phase containing chitosan under magnetic stirring, thus leading to the formation of 
chitosan nanogels (Calvo et al. 1997). The process results in the controlled gelation of chitosan 
in the form of spherical, homogeneous and compact nanoparticles, characteristics that are 
expected to benefit the performance of the system both in vivo and in vitro ( Liu and Gao 2009; 
6HGD7Õ÷OÕ$\GÕQDQG3XODW. 
 
1.8.2 Polyelectrolyte complex formation (PEC) 
This is another method that has been used in the production of chitosan nanoparticles containing 
proteins. It is a mild method used to prepare nanoparticles at ambient temperature without the 
use of sonication and organic solvents. Thus, it is a suitable procedure used to encapsulate 
protein and peptides drugs that are sensitive to different stress factors.  Bayat et al. (2008) , 
formulated insulin nanoparticles from chitosan and its quartenized derivatives by direct 
electrostatic interaction between the negatively charged insulin and positively charged chitosan 
and its quartenized derivatives. The manipulation of these PEC systems were pH dependent 
(Dakhara and Anajwala 2010). 
 
23 
 
1.9 Characterisation of nanoparticles 
Nanotechnology offers many advantages to traditional drug design, delivery and medical 
diagnostics. However, nanomedicines present considerable challenges for preclinical 
development. Nanoparticle constructs intended for medical applications consist of a wide variety 
of materials, and their small size, unique physicochemical properties and biological activity often 
require modification of standard characterisation techniques. A rational characterisation strategy 
for nanomedicines includes physicochemical characterisation, sterility and, biodistribution 
(absorption, distribution, metabolism and excretion (ADME) and toxicity characterisation, which 
includes both in vitro tests and in vivo studies.  
 
 
1.9.1 Physicochemical characterisation 
Nanoparticle characterisation is necessary to relate the ultimate performance of particle with its 
physical properties and also establish understanding and control of nanoparticle synthesis and 
applications. Characterisation is done by using a variety of techniques, mainly drawn from 
material science. 
The morphology and size of nanoparticles are very important in their characterisation. Many 
researchers working on nanoparticles indeed need to prove that the particles are nano in 
dimension. Size measurements are normally done using Photon Correlation Spectroscopy (PCS), 
which is also called dynamic light scattering. The system operates on the principle that, when a  
monochromatic light beam, such as a laser, is shone onto a solution with spherical particles in 
Brownian motion, the particles cause a Doppler Shift when the light hits the moving particle, 
changing the wavelength of the incoming light. This change is related to the size of the particle. 
24 
 
This method can give important details such as the computation of the sphere size distribution 
and give a deVFULSWLRQRIWKHSDUWLFOH¶VPRWLRQLQWKHPHGLXPPHDVXULQJWKHGLIIXVLRQFRHIILFLHQW
of the particle and using the autocorrelation function (López-León et al. 2005). The principles of 
measurement on different machines are the same, what differ is the make and the models of the 
instrument. 
The morphology of nanoparticle is also an important parameter that needs to be assessed. 
Common techniques used are electron microscopy which includes Scanning Electron 
Microscopy (SEM), Transmission Electron Microscopy (TEM) and Atomic Force Microscopy 
(AFM). 
The SEM uses a focused beam of high-energy electrons to generate a variety of signals at the 
surface of solid specimens. The signals that are derived from the electron-sample reveal 
information about the sample including the morphology (texture), chemical composition, and 
orientation of materials making up the sample. Areas ranging from approximately 1 cm to 5 
microns in width can be imaged in a scanning mode using conventional SEM techniques 
(magnification ranging from 20x to approximately 30,000x, spatial resolution of 50 to 100 nm) 
(Alexander et al. 2009). 
The TEM operates based on the sample principle as the light microscope but uses electrons for 
imaging other than light. Because TEM uses electrons and low wavelength beams, it is possible 
to get a resolution a thousand times better than with a light microscope. Objects that are a few 
angstroms (10-10 m) such as details in cell or different materials down to the near atomic level 
can be seen on the TEM (Transmission electron microscope, 2013). 
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SEM is based on scattered electrons while TEM is based on transmitted electrons. SEM focuses 
RQ WKH VDPSOH¶V VXUIDFH DQG LWV FRPSRVLWLRQ ZKHUHDV 7(0 SURYLGHV WKH GHWDLOV DERXW LQWHUQDO
composition. Therefore, TEM can show many characteristics of the sample, such as morphology, 
crystallisation, stress or even magnetic domains. On the other hand, SEM shows only the 
morphology of the samples (Transmission electron microscope, 2013). 
AFM can help achieve atomic resolution by using a sharp specially made cantilever tip. Images 
obtained by AFM can distinguish two closely spaced atoms. The image is created by quantifying 
the forces between the probe (cantilever tip) and the sample surface. Highly resolved three 
dimensional images can be obtained and normally, these images are free from large artefacts. In 
electron microscopy, special sample preparation is needed; also the sample viewing chamber 
must be under vacuum but AFM requires neither a vacuum environment nor any special sample 
preparation. Samples can also be viewed in the liquid medium and this implies that samples can 
be analysed in a near original condition (Grobelny et al. 2011). The resolution and power of 
viewing is also instrument-dependent. In each instance, the real shape of the nanoparticles can be 
discerned and if there is aggregation, it can also be observed. 
The zeta potential of a particle is the overall charge that the particle acquires in a particular 
medium and can be measured on a Zetasizer® instrument. The magnitude of the measured zeta 
potential is an indication of the repulsive force that is present and can be used to predict the long-
term stability of the product. If all the particles in suspension have a large negative or positive 
zeta potential then they will tend to repel each other and there is no tendency for the particles to 
come together. However, if the particles have low zeta potential values then there is no force to 
prevent the particles coming together and flocculating. The effect of the pH, concentration of an 
26 
 
additive or the ionic strength of the medium on the zeta potential and rheological properties can 
give information in formulating the product to give maximum stability. 
Other physicochemical characterisation that can be done on nanoparticles iclude powder x-ray 
diffraction (XRD), fourier transform infrared spectroscopy (FTIR), matrix-assisted  laser 
desorption/ionisation, time-of-flight mass spectrometry (MALDITOF), ultraviolet-visible 
spectroscopy and nuclear magnetic resonance (NMR) (Boonsongrit et al. 2008; Harish Prashanth 
and Tharanathan 2006). Each of these can harness valuable information with regard to the 
physical properties of the nanoparticles and its ultimate performance. 
 
1.10 Polymeric controlled release drug delivery systems 
The discovery and development of newer and more therapeutically efficient drugs have led to 
significant attention being focused on the development of methods by which these active 
substances are to be administered or delivered. 
In conventional drug delivery, the drug concentration in the blood rises when the drug is taken, 
later and declines. Since each drug has a plasma level above which it is toxic and below which it 
is ineffective, the plasma drug concentration in a patient at a particular time depends on 
compliance with the prescribed routine. Controlled-release devices can be used to maintain the 
drug in the desired therapeutic range with just a single dose, thus localising delivery of the drug 
to a particular body compartment and reducing the systemic drug level. This gives the possibility 
of preserving medications that are rapidly destroyed by the body.  There is also a reduction in  
the need for follow-up care  and this increases patient comfort and/or improves compliance (Kost 
and Langer 2001). 
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The type of material used for controlled release can be classified as, biodegradable, non- 
biodegradable, non-biodegradable but soluble. These materials can be fabricated into 
microspheres, matrices and membranes. They are normally administered via the parenteral, 
implantation, oral and transdermal routes. Some of these delivery modules have been 
successfully commercialised (Soppimath et al. 2001; Allen and Cullis 2004). 
 
1.10.1 Stimuli responsive polymeric drug delivery systems 
The present research pursuit is aimed at developing a stimuli responsive delivery system 
sensitive to glucose concentration. The review below looks at the historic and future perspectives 
in research in this area. 
In recent years, several research groups have been developing responsive systems which will be 
able to mimic the normal physiological process in which the amount of released drug is 
controlled according to the physiological needs of the individual. These  responsive polymeric 
delivery systems can be classified as open or closed loop systems, depending on the mechanism 
of input and the how the output is effected. In the open-loop systems, the information about the 
controlled variable is not automatically used to adjust the system inputs to compensate for the 
change in the process variables. In closed-loop systems the controlled variable is detected and as 
a result the system output is adjusted accordingly. Open-loop systems are known as pulsed or 
externally regulated and the closed-loop systems as self-regulated (Kost and Langer 2001). The 
externally controlled devices apply external triggers in the form of magnetic, ultrasonic, thermal, 
and electric energy. On the other hand, self-regulated devices release rates are normally 
controlled by feedback information without any external intervention (Fleige et al. 2012).  
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1.10.1.1 Externally regulated delivery systems 
In these modules, drug delivery is controlled by the application an external stimuli. These are 
reviewed below. 
 
1.10.1.1.1 Magnetically modulated systems 
In these release systems, drug release is controlled by the application of a magnetic field to the 
carrier of the drug and hence based on the design; the drug is released for pharmacological 
action. Studies have demonstrated that  insulin and other molecules could be continuously 
released by embedding the hormone in a carrier like ethylenevinylacetate copolymer (Creque et 
al. 1980). These researchers conducted in vitro studies to characterise the parameters affecting 
the release rates, and later a single subcutaneous implant which decreased the glucose levels of 
diabetic rats for 105 days was designed (Brown et al. 1986). This group took a further initiative 
for the designing of a delivery system for use in diabetes. In vitro studies have also been  
conducted showing that the polymer-protein matrices containing magnetic beads exhibited 
enhanced release rates when placed in an oscillating external magnetic field  (Edelman et al. 
1985; Kost et al. 1987).  
In vivo studies showed that when polymeric matrices containing insulin and magnetic beads are 
implanted in diabetic rats, glucose levels can be repeatedly decreased on demand by application 
of an oscillating magnetic field. A design comprising of polymeric matrix containing insulin and 
magnet was studied in diabetic rats. Here, it was discovered that blood glucose level dropped 
more than half of the initial concentration when exposed to external magnetic field. In the 
absence of the magnetic field, the blood glucose level remained high over the 51-day 
29 
 
implantation period. The researchers observed that, every time the magnetic field was applied, 
the blood glucose level reduced (Kost et al. 1987). 
 
1.10.1.1.2 Ultrasonically modulated systems 
Kost et al. (1988) suggested the feasibility of ultrasonically controlled polymeric delivery 
systems in which release rates of substances can be repeatedly modulated at will from a position 
external to the delivery system. Both bio-erodible and non-erodible polymers were investigated 
as drug carrier matrices. The bioerodible polymers evaluated were polyglycolide, polylactide, 
poly bis(p-carboxyphenoxy) alkaneanhydrides and their copolymers with sebacic acid. The 
releasing agents were p-nitroaniline, p-aminohippurate, bovine serum albumin and insulin. 
Appreciable polymer erosion and drug release were observed when the bio erodible samples 
were exposed to ultrasound. The systems response to the ultrasonic triggering was quick, that is 
within 2 minutes and reversible. There was an enhanced release also in the non-erodible systems 
when they were exposed to ultrasound, but this time the release was diffusion dependent.  
Kost et al. (1989) observed that, the release rates of zinc bovine insulin from 
ethylenevinylacetate copolymer matrices were 15 times higher when exposed to ultrasound 
compared to the unexposed periods. It has also been demonstrated that the extent of 
enhancement can be regulated by the intensity, frequency or duty cycle of the ultrasound. 
Ultrasound was also evaluated as an enhancer for drug delivery through the skin. Tyle and 
Agrawala (1989) reviewed the topic of phonophoresis defined as the movement of drugs through 
living intact skin and into soft tissue under the influence of an ultrasonic perturbation. Studies 
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performed in the laboratories on the effect of ultrasound on implantable drug delivery devices 
provided the impetus to conduct studies to evaluate the systemic effect of ultrasound on drug 
permeation through the skin and explore its applicability as transdermal drug delivery enhancer 
or trigger when needed (Kost et al. 1989; Levy et al. 1989). 
A novel ultrasound-responsive doxorubicin (DOX)-loaded nanoparticulate system has been 
developed, using poly(D,L-lactide-co-glycolide)-methoxypoly( ethylene glycol) (PLGA- PEG) 
complexing doxorubicin with a high encapsulation efficiency. Nanodroplets were formulated and 
were stabilised by a PEG shell. These nanodroplets were transformed into nanobubbles at 37 °C. 
Little amounts of drugs were released without the application of ultrasound. The nanodroplets 
demonstrated lower toxicity than the free drug (Du et al. 2011; Fleige et al. 2012). 
 
1.10.1.1.3 Thermoresponsive delivery systems 
Thermoresponsive hydrogels such as N-substituted polyacrylamide have been of interest in the 
field of controlled drug delivery (Okano et al. 1990). The thermosensitive hydrogels can be 
classified into two groups based on the origin of thermosensitivity in aqueous swelling (Bae et 
al. 1989; Hirokawa and Tanaka 1984). The first is based on polymer-water interactions, 
especially specific hydrophobic±hydrophilic balancing effects and the configuration of side 
groups. The other is based on polymer±polymer interactions in addition to polymer±water 
interactions. 
Huffman et al. (1986) synthesised hydrogels based on N-isopropylacrylamide (NIPAAm) or N-
isopropylacrylamide-methacrylic copolymers cross-linked with methylene-bis-acrylamide 
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(MBAAm). This group of researchers studied the absorption and release of vitamin B12, 
myoglobin and chymotrypsin from these hydrogels as a function of temperature. These gels were 
responsive to temperature changes and therefore the quick response of the gel surface to 
temperature changes may be utilised as an on±off switch for drug release (temperature changes 
prevent drug release due to instant surface shrinking). 
Bae et al. (1989) reported that, there was some degree of insulin permeability through thermo 
sensitive hydrogels based on poly (N-acryloylpyrolidine) and its copolymers with styrene or 2   
hydroxyethylmetacrylate cross-linked by ethyleneglycoldimethacrylate. The cross-linked 
poly(N-acryloylpyrolidine) homopolymer exhibited thermo sensitivity in water swelling, with 
weak mechanical strength, which restricted its practical application to diffusion experiments. The 
incorporation of a hydrophobic monomer into the polymer improved the mechanical strength and 
lowered the overall swelling level as well as the thermo sensitivity. It was observed that, insulin 
permeation through the copolymers could be regulated by changing the membrane composition 
and temperature. The permeability was mainly affected by the degree of hydration, regardless of 
chemical composition and temperature. The rate of insulin permeation through 
poly(hydroxyethylmethacrylate) increased with an increase in temperature, but in contrast the 
rate of insulin permeation through poly(N-acryloylpyrolidine) copolymers increased with a 
decrease in temperature. Therefore, temperature responsive polymers can also be used for drug 
delivery. 
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1.10.1.1.4 Electrically controlled responsive systems 
'¶(PDQXHOH et al. (1988), proposed a drug delivery device which consisted of a polymer 
reservoir with a pair of electrodes placed across the rate-limiting membrane. By altering the 
magnitude of the electric field between the electrodes the authors proposed to modulate the drug 
release rates in a controlled and predictable manner. A linear relationship was found between 
electrical current and propanolol hydrochloride permeability through poly (2-
hydroxyethylmethacrylate) (PHEMA) membranes. Buffer ionic strength as well as electrode 
polarity were found to have a significant effect on the drug permeability. 
Grimshaw et al. (1989), demonstrated four distinct electrochemical and electromechanical 
mechanisms for selective controlled transport of proteins and neutral solutes across hydrogel 
membranes: (1) electrically and chemically induced swelling of a membrane to alter the effective 
pore size and permeability; (2) electrophoretic augmentation of solute flux within a membrane; 
(3) electroosmotic augmentation of solute flux within the membrane; and (4) electrostatic 
partitioning of charged solutes into charged membranes. Electric fields can cause changes in 
membrane ionisation states affecting membrane hydration and permeability. Eisenberg and 
Grodzinsky (1987) altered the restricted diffusion of sucrose through collagen membranes via 
electrodiffusion (effect of the electric field on concentration profiles within the membrane), 
producing flux changes up to 25%. Weiss et al (1986) produced a 16-fold increase in the 
permeability of similar PMMA membranes to 10 kDa dextran by using the electrolysis reaction 
at a platinum cathode to alter bash pH and, hence, membrane hydration.  
The mechanisms described for electrically controlled membrane permeability are of current 
interest in the field of electrically controlled or enhanced transdermal drug delivery for example 
iontophoresis (Banga and Chien 1988). Over the past 60 or more years, the principles of 
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iontophoresis have been applied for localised drug delivery to muscles and joints (Okabe et al. 
1986; Chien et al. 1987). 
Current/voltage conditions for the iontophoretic application should: (1) be sufficiently high to 
provide a desired delivery rate; (2) not produce any harmful effects on the skin including a 
permanent alteration in the skin permeability; (3) establish a quantitative relationship between 
the flux and applied current/voltage; and (4) maintain constancy of the current/voltage during the 
experimental period. In addition, the drug should be electrochemically stable (Behl et al. 1989).  
In order to overcome charge build up, irritation and burning of the skin in the area of prolonged 
continuous current electrode application, a pulsed current approach was evaluated. In this 
approach the current was turned on and off in short intervals. Using the pulsed current 
iontophoresis, the skin could tolerate much higher voltage and current conditions (Behl et al. 
1989). 
Films containing negatively charged Prussian Blue (PB) nanoparticles and positively charged 
gentamicin were prepared by Leprince et al. (2010). When oxidised, the negative charge of the 
PB nanoparticles changed to neutral, which led to the dissolution of the film. Control over the 
drug dosage was demonstrated by tuning the film thickness as well as the magnitude of the 
applied voltage. Drug release kinetics was changed to achieve different release by applying 
different electric potential profiles. The in vitro efficacy of this mode of drug delivery was 
confirmed by using a strain of Staphylococcus aureus (Schmidt et al. 2010; Fleige et al. 2012). 
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1.10.1.1.5 Chemically controlled delivery systems 
1.10.1.1.5.1 pH and ionic strength responsive drug delivery systems 
Several studies have been performed on polymers whose charge density depends on pH and ionic 
composition of the outer solution (Gumbleton and Schmaljohann 2006). Altering the pH of the 
solution will cause swelling or deswelling of the polymer. Polyacidic polymers will be unswollen 
at low pH, since the acidic groups become protonated and hence unionised. However at higher 
pH, the polyacid polymer swells. The opposite holds true for polybasic polymers, since the 
ionisation of the basic groups will increase with decreasing pH. Thus, drug release from reservoir 
or matrix devices made from these polymers will display release rates that are pH dependent 
(Kirstein et al. 1985; Fleige et al. 2012). 
The pH range of fluids in various segments of the gastrointestinal tract may provide 
environmental stimuli for responsive drug release. Fildes (1976) developed a membrane to 
E\SDVVWKHUXPHQRIWKHFRZZKLFKDOORZHGUHOHDVHRILWVGUXJLQWKHFRZ¶VIRXUWKVWRPDFK7KLV
polymeric membrane was highly impermeable at the rumen pH (pH 7), the rumen pH, but 
swelled at pH 4, whLFKLVWKHIRXUWKVWRPDFK¶VS+ 
 
1.10.1.1.5.2 Enzyme-sensitive hydrogels 
Biodegradable polymers have become increasingly useful in biomedical fields because of their 
high potential for tissue engineering and drug delivery systems (Chasin and Langer 1991; 
Hollinger 1995). There are some specific enzymes that can digest specific polymers and this 
implies that sensitive hydrogels can be formulated from specific biodegradable polymers that can 
be degraded by these specific enzymes.  
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Some enzymes are used as important signals for diagnosis to monitor several physiological 
changes and specific enzymes in specific organs have become useful signals for site-specific 
drug delivery. Therefore, enzyme-sensitive hydrogels are promising candidates as enzyme 
sensors and enzyme-sensitive drug delivery systems since the incorporated drugs will only be 
released at specific sites. For example, the microbial enzymes that are predominantly present in 
the colon can be used as signals for site-specific delivery of drugs to the colon. Hovgaard and 
Brøndsted (1995) focused on the fact that microbial enzymes in the colon, such as dextranases, 
can degrade the polysaccharide dextran. They prepared dextran hydrogels cross-linked with 
diisocyanate for colon-specific drug delivery. The dextran hydrogels were degraded in vitro by a 
model dextranase, as well as in vivo in rats and in a human colonic fermentation model. Release 
of a drug from the dextran hydrogels could be controlled by the presence of dextranase. Drug 
release from the dextran hydrogels in the absence of dextranase was observed to be based on 
simple diffusion processes, however in the presence of dextranase it was mainly governed by the 
degradation of the dextran. Thus, it follows that dextran hydrogels are dextranase-sensitive and 
may hold promise as intelligent systems for colon-specific drug delivery. 
Azoreductase is also useful for colon-specific drug delivery as it is an enzyme produced by the 
microbial flora of the colon. Few researchers have used azoaromatic bonds which can be 
degraded by azoreductase in the colon to construct azoreductase-sensitive hydrogels for colon-
specific drug delivery. Kopecek et al. (1994) used azoaromatic bonds as cross-linking agents to 
prepare hydrogels and these hydrogels were pH-sensitive and biodegradable as they contained 
both acidic co monomers and azoaromatic cross-links. The hydrogels could protect protein drugs 
against digestion by proteolytic enzymes in the stomach. In the colon, azoreductase becomes 
accessible to the cross-links in the swollen hydrogels and can degrade the matrix to release the 
36 
 
protein drugs. These studies are examples showing that the combination of enzyme sensitivity 
with pH sensitivity enables site-specific drug delivery (Fleige et al. 2012). 
 
1.10.1.1.5.3 Glucose responsive drug delivery systems 
Glucose sensitive hydrogels are very useful in the development of self-regulated insulin delivery 
systems and enables the construction of artificial pancreas that administers the necessary amount 
of insulin in response to the rise in blood glucose concentration. 
One of such system is that which combines glucose oxidase with pH-sensitive hydrogels to sense 
glucose and regulate insulin release. Within these pH-sensitive hydrogels is embedded or 
entrapped glucose oxidase. In contact with glucose, the glucose is converted to gluconic acid by 
glucose oxidase, this lowers the pH in the hydrogels (figure 1. 5).  The lowering of the pH within 
the hydrogel leads to swelling of the hydrogel and hence insulin release. Thus, the pH-sensitive 
hydrogels containing glucose oxidase can be used to control insulin release in response to the 
glucose concentration (Miyata et al. 2002). 
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Figure 1.5 Mechanism of insulin release from a glucose oxidase loaded hydrogel. (Modified 
from Miyata et al. 2002) 
 
For example Ishihara et al. (1984) combined a copolymer membrane of N, N-diethylaminoethyl 
methacrylate (DEA) and 2-hydroxypropyl methacrylate (HPMA) with a cross-linked 
poly(acrylamide) membrane, in which glucose oxidase and insulin were immobilised. The 
presence of glucose enhanced insulin permeability through the membrane which contained 
glucose oxidase. This glucose-sensitive insulin permeation was achieved based upon the 
combination of an enzymatic reaction with a pH-sensitive swelling. In this system, glucose 
diffuses into the membrane and is catalysed by glucose oxidase, resulting in the conversion of 
glucose to gluconic acid. The insulin permeation through the membrane was strongly dependent 
upon the glucose concentration. Furthermore, Ishihara et al. (1986) investigated insulin release 
                3. Swelling  
1. Glucose diffusion 
2. Enzyme reaction 
4. Insulin release 
Glucose permeating hydrogel 
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from polymer capsules containing insulin and glucose oxidase. Insulin release was inhibited in 
the absence of glucose, but was strongly enhanced in the presence of glucose. 
Albin et al. (1985, 1987) entrapped glucose oxidase within hydroxyethyl methacrylate-N, N-
dimethylaminoethyl methacrylate copolymer hydrogel membranes to construct a glucose-
sensitive insulin delivery system. As in the other hydrogels reviewed earlier, the addition of 
glucose resulted in swelling of the membranes and an enhanced permeation of insulin from a 
reservoir via diffusion through the swollen hydrogel membranes.  
Parker et al. (1999) and Hassan et al. (1997) copolymerised methacrylic acid (MAAc) with 
poly(ethylene glycol) monomethacrylate in the presence of activated glucose oxidase in order to 
prepare glucose-sensitive poly(methacrylic acid-g-ethylene glycol) (poly(MAAc-g-EG)) 
hydrogels. Carboxyl groups of MAAc formed a complex with etheric groups of ethylene glycol 
(EG) at a low pH, but the complex dissociated at a high pH, due to ionisation of the carboxyl 
groups. Therefore, the poly(MAAc-g-EG) hydrogels collapsed at a low pH, due to complexation 
between carboxyl groups and etheric groups, but were swollen at a high pH. Thus, poly(MAAc-
g-EG) hydrogels showed pH-sensitivity caused by formation and dissociation of the complex in 
response to pH changes. The glucose oxidase-loaded poly(MAAc-g-EG) hydrogels showed a 
slower swelling rate at high glucose concentrations as seen in hyperglycemic conditions (200±
500 mg/dl) than that at the lower glucose concentrations of normal blood (80 mg/dl). It is 
postulated that the poly(MAAc-g-EG) hydrogels squeeze out insulin during their collapse in the 
presence of glucose. Thus, the poly(MAAc-g-EG) hydrogels containing glucose oxidase showed 
a glucose-sensitivity resulting from the combination of the catalytic reaction of glucose oxidase 
and the pH-sensitive complex formation between carboxyl and etheric groups. Consequently, 
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glucose-sensitive insulin release can be achieved by using pH-sensitive hydrogels containing 
insulin and glucose oxidase (Qi et al. 2009). 
Lectins, which are carbohydrate-binding proteins, interact with glycoproteins and glycolipids on 
the cell surface and induce various effects, such as cell agglutination, cell adhesion to surfaces, 
and hormone-like action. The unique carbohydrate-binding properties of lectins are very useful 
for the fabrication of glucose-sensitive systems. Therefore, some researchers have focused on the 
glucose-binding properties of Con A, a lectin possessing four binding sites.  
Brownlee et al. (1979) and Kim et al. (1990) were pioneers in the development of glucose-
sensitive insulin release systems using Con A. Their strategy was to synthesise a stable, 
biologically active glycosylated insulin derivative able to form a complex with Con A. The 
glycosylated insulin derivative could be released from its complex with Con A in the presence of 
free glucose, based on the competitive and complementary binding properties of glycosylated 
insulin and glucose to Con A. Furthermore, Makino et al. (1990), bound the self-regulated 
insulin delivery systems, enclosed in polymer membranes to soluble bead immobilised or cross-
linked to Con A. Polymer membranes or microcapsules containing Con A and succinyl-
amidophenyl-glucopyranoside insulin (SAPG-insulin) quickly controlled the release of SAPG-
insulin in response to changes in the glucose concentration, based on the mechanism of the 
competitive and complementary binding properties of SAPG-insulin and glucose to Con A. 
Polymer membranes and microcapsules containing Con A and SAPG-insulin were used as self-
regulated insulin release devices in vitro and could be optimised for use in vivo studies. These 
studies provided new concepts with regard to the competitive and complementary binding 
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properties of glucose derivatives and glucose to Con A, as well as their suitability for the 
fabrication of glucose-sensitive hydrogels (Makino et al. 1991) 
Novel glucose-sensitive hydrogels were prepared using complex formation between Con A and 
the pendant glucose groups of PGEMA to produce cross-linked points in the hydrogels 
(Nakamae et al., 1994). The Con A-entrapped PGEMA hydrogels were obtained by 
copolymerisation of a monomer with pendant glucose (GEMA) and a divinylmonomer in the 
presence of Con A. The density of cross-linkage of the resultant Con A-entrapped PGEMA 
hydrogels increased with increasing Con A concentration, suggesting that Con A acts as a cross-
linking agent. The immersion of Con A-entrapped PGEMA hydrogels in an aqueous glucose 
solution resulted in their swelling and the swelling ratios were strongly dependent upon the 
glucose concentration (figure 1.6).  
 
Figure 1.6 Schematic representation of glucose-sensitive swelling changes in a 
poly(GEMA)±Con A hydrogel (Miyata et al. 2002). 
 
Compressive modulus measurements revealed that the cross-linking density of Con A-entrapped 
PGEMA hydrogels decreased with increasing glucose concentration. The glucose-sensitive 
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swelling of Con A-entrapped PGEMA hydrogels was due to the presence of free glucose, which 
resulted in the dissociation of the complex via competitive exchange. Thus, the Con A-entrapped 
PGEMA hydrogels were able to recognise a specific monosaccharide and induce structural 
changes. These results suggest that Con A-entrapped PGEMA hydrogels have many potential 
applications as a novel glucose sensor and as new closed-loop insulin delivery system. 
Lee and Park (1996) and Obaidat and Park (1996) prepared a type of hydrogel capable of sol±gel 
phase-reversible transitions based upon changes in the glucose concentration. It was shown that 
the mixture of a vinylpyrrolidinone-allylglucose copolymer with Con A led to the immediate 
formation of hydrogels, due to complex formation between pendant glucose groups and Con A. 
The addition of free glucose led to a phase transition of the hydrogel into the sol state. The 
concentration of free glucose in the environment had to be at least four times that of pendant 
glucose to induce the phase transition from gel to sol. The gel-sol phase transition in response to 
the free glucose concentration was repeated more than 10 times without any problems. The 
hydrogel was able to sense changes in the glucose concentration of the environment and respond 
to them in a reversible manner. Obaidat and Park (1997) also investigated the release of 
lysozyme and insulin as model proteins through glucose-sensitive hydrogel membranes using a 
diffusion cell. Porous poly(hydroxyethyl methacrylate) (PHEMA) membranes were used to 
sandwich glucose-containing polymers and Con A between the donor and receptor chambers of 
the cell. The release rate of the proteins from the receptor chamber to the donor chamber was 
strongly dependent upon the free glucose concentration. Their studies demonstrate that the 
glucose-sensitive sol±gel phase transition can be used to regulate insulin release in response to 
the free glucose concentration in the environment. 
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Kokufuta et al  (1991), combined the carbohydrate-binding properties of Con A with the 
temperature-sensitive property of poly(N-ispropylacrylamide) (PNIPAAm) to prepare 
saccharide-sensitive hydrogels. Con A was loaded on a cross-linked PNIPAAm hydrogel that 
underwent a volume phase transition at 34°C. The Con A-loaded PNIPAAm hydrogel was 
shown to swell abruptly in the presence of the ionic saccharide dextran sulphate at temperatures 
close to the volume phase transition point. The abrupt swelling of the Con A-loaded PNIPAAm 
hydrogel caused by the ionic saccharide dextran sulphate was attributed to the ionic osmotic 
pressure exerted by the ionised saccharide. The replacement of the ionic saccharide dextran 
sulphate with a non-ionic saccharide led to the collapse of the hydrogel to its native volume. The 
temperature-sensitive property of PNIPAAm in the hydrogel contributed to a dramatic change in 
the swelling ratio, due to a shift in volume phase transition by complex formation. 
All of the preceding studies utilised proteins, such as glucose oxidase or lectins, for the 
fabrication of glucose-sensitive hydrogels. The use of proteins and biological components within 
drug delivery systems has obvious draw-backs. Therefore this current project opts for the use of 
glucose-sensitive hydrogels without biological components such as proteins, but instead complex 
formation between a phenylboronic acid group and glucose. 
Phenylboronic acid (PBA) and its derivatives form complexes with polyol compounds, such as 
glucose in aqueous solution. The complex between phenylboronic acid and a polyol can be 
dissociated in the presence of a competing polyol which is able to form a stronger complex. This 
means that complex formation between PBA and a polyol compound has many potential 
applications as a glucose-sensitive material. 
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Kitano et al. (1991)  synthesised copolymers with PBA moieties (poly(NVP-co-PBA)) by 
copolymerising N-vinyl-2-pyrrolidone (NVP) and 3-(acrylamido)phenylboronic acid (PBA). Due 
to the reversible complex formation between PBA of poly(NVP-co-PBA) and poly(vinyl 
alcohol) (PVA), the competitive binding of phenylboronic acid with glucose and PVA could be 
utilised to construct a glucose-sensitive system. The formation and dissociation of the poly(NVP-
co-PBA)/PVA complex could be investigated by observing the change in viscosity. The viscosity 
measurements revealed that poly (NVP-co-PBA) formed a complex with PVA in the absence of 
glucose. However, the complex dissociated in the presence of glucose. These results led to the 
concept of a glucose-sensitive insulin release system using poly (NVP-co-PBA) and PVA. The 
presence of free glucose resulted in swelling of the poly(NVP-co-PBA)/PVA complex hydrogel, 
due to complex dissociation (figure 1.7).  
 
Figure 1.7 Concept of a glucose-sensitive insulin release system using PVA/poly(NVP-co-
PBA) (polymer capsule type) (Kitano et al. 1991) 
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It was difficult for the researchers to use the poly(NVP-co-PBA)/PVA complex as a glucose-
sensitive insulin release system, because of its intrinsic instability at a physiological pH of 7.4. 
To stabilise complex formation between phenylboronic acid and glucose at a physiological pH of 
7.4, amino groups were introduced either into the polymer or in the vicinity of the PBA moiety 
(Kataoka et al., 1994). Furthermore, a glucose-sensitive hydrogel possessing both PBA and 
amino groups was prepared for the development of a novel glucose-sensitive insulin delivery 
system at physiological pH by Shiino et al. (1995). This glucose-sensitive insulin delivery 
system was based upon the complex formation between gluconated insulin and the PBA groups 
in the hydrogel. The gluconated insulin was released from the hydrogel in the presence of free 
glucose, which induced the dissociation of the complex. This system released insulin in response 
to the glucose concentration at a physiological pH. 
PBA exists in equilibrium between the uncharged and the charged form. Complex formation 
between the uncharged form and glucose was shown to be unstable because of its high 
susceptibility to hydrolysis, while charged PBA groups were able to form a stable complex with 
glucose (figure 1.8). Complex formation between the charged PBA groups and glucose caused a 
shift in the equilibrium towards an increase of charged PBA groups. Therefore, the total amount 
of charged PBA groups increased and uncharged groups decreased when glucose was added. 
(Kost and Langer, 2001) 
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Figure 1.8 Reversible binding between boronic acid and cis diol in aqueous media 
 
Wu et al. (2011) have investigated the utilisation of PBA-bonded chitosan nanoparticles as a 
vehicle for controlled insulin release. They attributed insulin release from the nanoparticles to 
glucose sensitivity of the PBA moiety and the molecular weight of the polymer. 
In the current project, PBA was functionalised onto chitosan using a simple chemical reaction 
process (one pot reaction) which differs from the method used by Wu et al. (2011) in the above 
study. However we recognise that in order to enhance the sensitivity of the PBA-chitosan 
conjugates, the surface area must be increased. Therefore in our approach, we have sought to 
increase the surface area of the conjugate by also fabricating our chitosan PBA conjugates into 
nanoparticles, using methods that are reproducible, scalable and relatively simple. 
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1.11 Objectives of current project 
In the light of the above review, the main objective of this project was to design and develop an 
insulin-containing glucose responsive nanoparticulate delivery system, such that the system will 
be able to release insulin in response to changes in external glucose concentration. 
In order to achieve these objectives, the research was sectioned into the following aspects. 
1. Identification of polymers and sensing moieties to be used. 
2. Functionalisation or incorporation of sensing moiety onto polymer. 
3. Characterisation of functionalised polymer. 
4. Synthesis and characterisation of responsive nanoparticles out of the functionalised 
polymer. 
5. In vitro analyses of the responsive polymers and the nanoparticles as a function of 
external media. 
These aspects are reviewed in detail into the separate chapters that follow. 
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CHAPTER 2 
PREPARATION OF CHITOSAN TRIPOLYPHOSPHATE (TPP) NANOPARTICLES BY 
IONOTROPIC GELATION 
2.1. Introduction 
Ionotropic gelation is one of the simplest approaches that have been utilised by several 
researchers in the preparation of chitosan nanoparticles. This technique is based on the principle 
that polyelectrolytes can cross link in the presence of counter ions to form hydrogels. The 
polyanions form a meshwork of structures by combining with the polyvalent cations and hence 
inducing gelation through binding with mainly the anion blocks. These hydrogel can be produced 
by dropping polyanion solution into an aqueous solution of a polyvalent cation. Different drugs 
and biomolecules can be loaded into these hydrogels during the production where they become 
enmeshed (Sarmento et al. 2006; Sadeghi et al. 2008). The use of chitosan, alginates and gellan 
gum for the encapsulation of drugs are based on the principle of ionotropic gelation. 
There are different types of cross-linkers and a choice may be made based on safety profiles and 
degree of cross-linking. Chitosan nanoparticles and microparticles have been prepared by 
chemical cross-linking with glutaraldehyde, glyoxal and ethylene glycol diglycidyl ether. 
Although these were found to be efficient cross-linkers, they were not preferred in the present 
study owing to their physiological toxicity (Akbuga and Durmaz 1994; Berger et al. 2004). 
Due to the polycationic nature of chitosan, it can interact with different negatively charged 
species such as tripolyphosphate (TPP) and sodium sulphate. 
The interaction between TPP and chitosan leads to the spontaneous formation of biocompatible 
nanoparticles, which can be efficiently employed in the delivery of different drugs like proteins 
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and vaccines. The cross-linking density, crystallinity and hydrophilicity of cross-linked chitosan 
can allow modulation of drug release and extend its range of potential applications in drug 
delivery (Bhumkar and Pokharkar 2006). 
Ionotropic gelation of chitosan with TPP involves the addition of aqueous TPP to the aqueous 
phase containing chitosan under magnetic stirring, thus leading to the formation of chitosan 
nanogels (Calvo et al., 1997). The process results in the controlled gelation of chitosan in the 
form of spherical, homogeneous and compact nanoparticles, characteristics that are expected to 
benefit the performance of the system both in vivo and in vitro. The use of magnetic stirring in 
the production of nanoparticles is time consuming and requires the use of large volumes of 
material.  
Notwithstanding, the present work was aimed at the preparation of nanoparticles by employing 
ultrasonication; a process which imparts high frequency energy to induce electrostatic 
interaction. We theorised that due to the intense energy transmitted, the duration of preparation 
and the time required for the formation of the nanoparticles would be short. The optimal 
conditions to obtain desirable chitosan TPP nanoparticles were investigated. 
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2.2 MATERIALS AND METHODS 
2.2.1 Materials 
Low molecular weight chitosan, purchased from Sigma (Sigma-Aldrich Co. LLC, St Louis, 
Missouri, USA). Sodium tripolyphosphate (TPP), purchased from Thermofischer Scientific, 
Acetic acid, purchased from Merck, Millipore filtered, 18  pure water, all other chemicals were 
of reagent grade. 
 
2.3 Methods 
2.3.1 Nanoparticle preparation by ultrasonication 
Chitosan /TPP nanoparticles were prepared based on the ionotropic gelation of the polyanion and 
the polycation. Various concentrations of chitosan (1-10 mg/ml) were prepared by dissolving the 
required amount of chitosan in 1% acetic acid. The chitosan solution was then filtered and used 
for subsequent investigations. The ratios of chitosan to TPP studied were (3:1, 4:1, 5:1, 8:1 and 
10:1). 5 ml of the chitosan solution was measured into a glass vial, clamped and the 13 mm 
diameter probe of the high intensity ultrasonicator (Vibra Cell, Sonics, VCX 750, USA) (figure 
2.1) inserted into the chitosan solution (whilst ensuring that the tip of the probe does not touch 
the bottom of the vial). 5 ml of the TPP solution (prepared by dissolving the required amount of 
TPP in purified water) was added drop wise into the chitosan solution whilst the ultrasonicator 
was operated for 1 minute. 
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Figure 2.1: Image of the probe ultrasonicator (Vibra Cell, Sonics, VCX 750, USA) 
 
2.3.2 Effect of ultrasonication amplitude on z-average and Pdi of nanoparticles 
For the effect of ultrasonication amplitude on z-average and Pdi of nanoparticles, 5 ml of 
chitosan solution and 5 ml of TPP solution at a ratio of chitosan to TPP 3:1. The amplitude of 
ultrasonication was varied between 20% - 40% (150-300 Watts) and its effect on the z-average, 
Pdi and zeta potential of the nanoparticles were investigated using a Zetasizer Nano ZS® 
(Malvern, UK) equipped with a 4Mw He- Ne laser (633 nm). Each analysis was carried out at 
25oC and performed in triplicate and data expressed as mean ± standard deviation. 
Calculation for ultrasonication power output 
Maximum power output of the probe ultrasonicator =  750Watts at 100% amplitude of 
ultrasonication, if ultrasonicator is operated at 40% amplitude, Power output =   x 750 =  
300 Watts.  
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2.3.3 Effect of time of ultrasonication and volume of formulation on the final temperature 
and z-average of nanoparticles 
For the effect of time of ultrasonication and the total volume of the formulation on the final 
temperature and z-average of nanoparticles, different total volumes of nanoparticle formulation 
(10- 50 ml) were prepared and the time of ultrasonication was varied between 1-5 minutes. The 
chitosan to TPP ratio in each preparation was fixed at 3:1 and the chitosan concentration fixed at 
5 mg/ml. The final temperature of each formulation was then recorded using a digital probe 
thermometer and the z-average measured by Zetasizer Nano ZS® (Malvern, UK) equipped with a 
4Mw He- Ne laser (633 nm). Each analysis was carried out at 25oC and performed in triplicate 
and data expressed as mean ± standard deviation. 
 
2.3.4 Effect of pH of chitosan solution on z-average, Pdi and zeta potential of the 
nanoparticles 
Prior to formulation, the pH of the chitosan solution (5 mg/ml) was adjusted to pH between 3.50 
and 6.00. 5 ml of the pH adjusted solution was measured into a 20 ml glass vials and 5 ml of TPP 
added drop wise to the chitosan solutions whilst ultrasonicating at 40% amplitude (300 Watts) 
for 1 minute. The ratio of chitosan to TPP was fixed at 3:1. The z-average, Pdi and zeta potential 
was measured using a Zetasizer Nano ZS (Malvern, UK) equipped with a 4Mw He- Ne laser 
(633 nm). Each analysis was carried out at 25oC and performed in triplicate and data expressed 
as mean ± standard deviation. 
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2.3.5 Effect of concentration of chitosan and TPP on the z-average, Pdi and zeta potential 
of the nanoparticles 
Various ratios of the chitosan to TPP (3:1, 4:1, 5:1, 8:1 and 10:1) were prepared such that the 
concentration of chitosan in solution was varied between 1.0 mg/ml to 10.0 mg/ml and the TPP 
concentration in solution also from 0.33 mg/ml to 3.0 mg/ml. 5 ml of the TPP solution was added 
drop wise into 5 ml of chitosan solution in accordance with the ratio of study whilst 
ultrasonicating at an amplitude of 40% (300 Watts) for 1 minute. The z-average, Pdi and zeta 
potential was measured using a Zetasizer Nano ZS® (Malvern, UK) equipped with a 4Mw He- 
Ne laser (633 nm). Each analysis was carried out at 25oC and performed in triplicate and data 
expressed as mean ± standard deviation. 
 
2.3.6 Stability behaviour of chitosan TPP nanoparticles produced by magnetic stirring and 
ultrasonication  
For the effects magnetic stirring on the stability of chitosan TPP nanoparticles, 3 mg/ml of 
chitosan solution was prepared in 1% acetic acid and pH adjusted to 5.5 and filtered. A 1 mg/ml 
solution of TPP was also prepared in purified water and filtered. 10 ml of the chitosan solution 
was measured into a beaker and placed on an HTS- 1003 magnetic stirrer operated at 800 rpm. 
The stirrer was started and 10 ml of the TPP was added drop wise into the chitosan solution, the 
resulting nanoparticulate suspension was allowed to stir for 30 minutes. 
For the effects of ultrasonication on stability of the nanoparticles, 5 ml of the filtered chitosan 
solution pH adjusted to 5.5 was measured into a clean vial. 5 ml of the TPP was added drop wise 
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into the chitosan whilst ultrasonicating at 40% amplitude (300 Watts) for one minute. The 
formation of a clear colloidal dispersion was indicative of the formation of the nanoparticles.  
The various formulations were stored at ~25oC and ~4oC (temperature measured by using a TFA 
Dostmann Wertheim digital thermo-hygrometer). The z-average, Pdi and zeta potential were 
measured weekly over a month using a Zetasizer Nano ZS® (Malvern, UK) equipped with a 
4Mw He- Ne laser (633 nm). Each analysis was performed in triplicate and data expressed as 
mean ± standard deviation. 
 
2.4 Physical characterisation of nanoparticles 
2.4.1 Photon correlation spectroscopy and zeta potential 
Photon correlation spectroscopy studies were carried out on the nanoparticles using the Zetasizer 
Nano ZS® (Malvern, UK) equipped with a 4Mw He- Ne laser (633 nm). The parameters of the 
nanoparticles measured were z-average, Pdi and the zeta potential. Particle size analysis was 
evaluated using intensity distribution and hence the z-average diameter is an intensity mean 
diameter; the pdi is the parameter describing the width and variation within the distribution. The 
zeta potential is the measurement of the surface charge of the nanoparticles.  
This parameter is analysed by software based on the Henry equation: 
  ««««««««««Equation 2.1 
(Where İ is the dielectric constant of the dispersant, F(țD) is the Henry function and Ș is the 
viscosity) through the determination of the electrophoretic mobility of the sample.  
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Prior to analysis, undiluted or diluted (1:10) sample was added to the clear disposable zeta cell 
and measurements performed. Each analysis was carried out at 25oC and performed in triplicate 
and data expressed as mean ± standard deviation.  
 
2.4.2 Scanning electron microscopy (SEM) 
Nanoparticle morphology was studied using a field emission electron microscope (FESEM) 
(Model, Quanta 400F, FEI Company, USA) Samples of nanoparticle in solution were placed on 
carbon tapes mounted on metal stubs and air dried for 24 hours and examined on the FESEM 
without coating. 
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2.5 RESULTS AND DISCUSSION 
2.5.1 Effect of ultrasonication amplitude on the z-average, Pdi and zeta potential of 
nanoparticles 
The ultrasonicator works on the principle of generating alternating low-pressure and high-
pressure waves in fluids, leading to the formation and violent collapse of small vacuum bubbles. 
This phenomenon is termed ultrasonic cavitation. This phenomenon in liquids causes high speed 
liquid jets of up to 1000 km/h. Such jets press liquid at high pressure between the particles and 
separate them from each other. Smaller particles are accelerated with the liquid jets and collide at 
high speeds. These effects are used for the deagglomeration and milling of micrometre and 
nanometre-size materials as well as for the disintegration of cells or the mixing of reactants. It is 
therefore desirable to optimise the amplitude of ultrasonication so that nanoparticles with 
desirable properties can be prepared.  
The selection of final amplitude for the production of the nanoparticles was determined by 
factors such reproducibility of desirable z-average and Pdi. Figure 2.2 shows the effect of the 
difference in amplitude on the z-average and the Pdi of nanoparticles. 
 
56 
 
 
Figure 2.2: Effect of amplitude (power output) of ultrasonication on the z-average and Pdi 
of nanoparticles 
 
The amplitude of 40% (300 Watts) appears to be the optimum, because at this magnitude, 
smaller particles were produced with a lower Pdi. The amplitude of 40% (300 Watts) was 
therefore selected for further work.  
A critical look at figure 2.2, brings to light an evidence of a gradual z-average increase as the 
magnitude of the amplitude of ultrasonication increased to 30%, (225 Watts), this can be 
explained based on the principle that, as the amplitude increases more cavitations are created and 
these dampen the efficiency of energy transmission and hence reduces the ultrasonic effect 
(Mason, 1999) hence causing a z-average increase. At very high amplitude however, the energy 
transmitted may surpass the dampening effects thereby resulting in particle size reduction. The 
changes in particle size and polydispersity could have also resulted  from ultrasonic-mediated 
depolymerisation of chitosan chains (Tang et al. 2003). 
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2.5.2 Effect of ultrasonication time and the total volume of formulation on the final 
temperature and the z-average of nanoparticles 
Temperature is an important factor that needs to be controlled when formulating products that 
are thermo labile like proteins. The method developed for the production of nanoparticles by 
ultrasonication was intended to be used for the production of a nanoparticulate product 
encapsulating insulin. Since insulin is a protein and susceptible to degradation at high 
temperatures (Oliva et al. 2000), the temperature increment caused by the ultrasonication process 
of making the insulin containing nanoparticle could not be overlooked. Also the effect of 
processing temperature on the z-average and Pdi of nanoparticles needed to be understood and 
controlled so that products of desirable quality could be made. Hence, to analyse the effect of 
ultrasonication time and volume of material on the above mentioned physical properties of the 
nanoparticles, different total volumes of the formulation (10- 50 ml) were subjected to various 
ultrasonication times between 1-5 minutes and the result is presented in figure 2.3 and table 2.1. 
 
Figure 2.3 Effect of ultrasonication time and the total volume of formulation on the final 
average temperature of nanoparticulate suspension 
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There was an increase in temperature as the ultrasonication time was increased, irrespective of 
the total volume formulation (table 2.1). Interestingly, there was an initial decrease in z-average 
as the ultrasonication time was increased. However it was observed at 10 ml, this initial decrease 
in z-average was followed by increase on extended ultrasonication. It follows that ultrasonication 
causes reduction in z-average however on extended ultrasonication, an increase in z-average is 
observed. A similar observation was made by Chuah et al. (2013) on curcumin containing 
nanoparticles made by ultrasonication.  
Table 2.1 Effect of ultrasonication time and the total volume of formulation on the final 
average temperature and the z-average of nanoparticles 
Total 
volume of 
formulation 
(ml) 
Time of sonication 
(minutes) 
Average temperature recorded 
after sonication 
Z-average (nm) 
 
 
10 
1 39.25±1.65 254.10±4.60 
2 53.75±1.85 212.00±4.70 
3 60.10±2.70 224.65±13.65 
5 63.40±3.50 285.80±10.80 
 
20 
1 39.20±0.40 280.70±2.90 
2 51.00±1.10 229.25±4.45 
3 59.57±0.55 223.73±4.04 
30 3 54.80±0.30 233.13±1.15 
40 1 31.15±0.45 276.19±2.21 
4 50.90±0.70 217.30±2.40 
50 1 29.55±0.15 288.40±1.90 
5 53.25±0.85 224.20±1.00 
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2.5.3 The effect of the pH of chitosan solution on the z-average, Pdi and zeta potential of 
nanoparticles 
A review of literature suggests that, the optimum pH for the formulation of chitosan 
nanoparticles by ionotropic gelation is about 5.5 (Ma et al. 2002). This is in view of the fact that, 
at this pH more than 90% of the amine groups of chitosan are protonated (Mao et al. 2006). 
However the effect of variation of pH on the z-average, zeta potential and Pdi appears to be 
lacking in the literature. Therefore we investigated the effect of the initial pH of chitosan solution 
on the aforementioned properties of the nanoparticles. In all instances pH adjustments were 
carried out with 4M NaOH. 
 
Figure 2.4: Image of chitosan TPP nanoparticle suspensions as a function of pH  
Figure 2.4 shows solutions of chitosan TPP nanoparticles that were produced at different pH. It 
can be seen that, the opalescence of the solutions increased with increasing pH. The opalescent 
appearance of the solution is reported to be indicative of the formation of nanoparticles (Wu et 
al 6HGD7Õ÷OÕ$\GÕQ et al. 2012). This phenomenon can be explained on the basis that, 
chitosan being a polycation has its amine groups protonated at acidic pH and therefore as pH 
pH 3.17 pH 4.00 pH 4.50 pH 5.50 pH 6.00 
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increases there is further protonation. This favours the interaction of the phosphate groups of the 
TPP with the amine groups of the chitosan leading to an increase in the degree of cross linking 
between chitosan and TPP. More of such interactions means that more nanoparticles would be 
produced and hence the observed trend in the opalescence. There is also an increase in the cross-
linking density as the number of amine sites available for cross-linking is increased leading to a 
more compact chitosan TPP matrix. However, as pH was increased (beyond pH 6), there was an 
increase in the opalescence of the nanoparticulate solution with observable aggregates. This 
increase in opalescence may not be due to the interaction of the amine groups of chitosan with 
the phosphate groups of TPP, but rather, due to deprotonation of the amine groups of chitosan 
leading to precipitation of the chitosan out of solution since protonation is the mechanism that 
maintains the chitosan in solution. 
 
Figure 2.5: The effect of pH of chitosan solution on the z-average and Pdi of nanoparticles 
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less protonated amine groups in the chitosan at pH 3.17 may have resulted in the formation of 
loose matrices which may have reflected in the z-average increase. However as the pH increased 
above 4.0 a gradual z-average increase was observed (figure 2.5). In most of the reports in the 
literature, a pH of 5-5.5 has been used in the formation of nanoparticles by ionic gelation from 
chitosan and TPP whilst encapsulating different drugs (Janes et al. 2001; Ma et al. 2002). 
Clearly, in the present study a pH of 4.0 appears to be optimum in terms of size and Pdi. Hence 
pH can be controlled and varied to yield a specific desirable size of nanoparticles. Though the 
size and Pdi are rightly affected by the pH, the molecular weights of the chitosan also affect the 
size. Hence, a pH 4 being optimum for our system that employs low molecular weight chitosan 
may not apply to other molecular weights chitosan.  
The Pdi shows the degree of polydispersity or homogeneity within the nanoparticulate system. 
Though sizes measured are in the nanometre region the interparticulate difference is very 
important. Wide variability within the particle sizes may affect the drug loading and drug 
releasing efficiency of the delivery system. Figure 2.5 generally shows an increase in the Pdi as 
the pH of chitosan solution was increased, though there was an initial increase at pH 3.17 and 
after dropping slightly at pH 4 and then increasing again. Values close to 0 indicate 
homogeneous dispersion, whereas those greater than, 0.3 generally indicate heterogeneity. The 
trend in the current investigation can be explained from the point of view that, at pH approaching 
neutral to alkaline region there is decreased propensity of chitosan to interact with TPP coupled 
with the increased possibilities of deprotonation of amine groups of chitosan within the formed 
nanoparticles. This scenario is likely to manifest in the production of nanoparticles with varied 
degree of chitosan TPP interaction and hence varied z-average which sums up with increased 
Pdi. 
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The zeta potential is an important parameter in nanoparticulate formulation because it can be 
used to predict the stability of the nanoparticles via their propensity towards agglomeration. In 
figure 2.6, the zeta potential of the nanoparticle decreased as the pH of the chitosan solution was 
increased. 
 
Figure 2.6: The effect of pH of chitosan on the zeta potential of nanoparticles 
The zeta potential of the chitosan TPP nanoparticles are normally positive due to the protonated 
amine groups in the chitosan.  An increase in pH increases the chances of the nanoparticles to 
agglomerate due to deprotonisation of the amine groups of chitosan as explained earlier. This 
result is in concert with the data on the effects of pH on z-average and Pdi depicted in figure 2.5.  
It must be added that, a decrease in the zeta potential means that the nanoparticles have a higher 
possibility of agglomerating due to decreased surface charge. Therefore, the observed increase in 
Pdi and z-average with increase in pH can be seen as resulting from increased deprotonation of 
amine groups of chitosan with concomitant decrease in zeta potential. 
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In nanoparticle formulation quality and quantity are factors that cannot be overlooked. Hence 
careful consideration must be given to the choice and amount of starting materials to be used. 
This careful selection of amount of starting materials should give a formulation with desirable 
properties and good yield. The recovery of nanoparticles for further analysis is always a point of 
interest, very low concentrations of starting materials may lead to no yield at all. 
 
Figure 2.7: Pdi (indicated on top of bars) and z-average of nanoparticles as function of 
chitosan concentration at different chitosan to TPP ratios 
 
Figure 2.7 shows that, as the concentration of chitosan was increased in the different 
formulations, there was a gradual increase in the z-average. At the lowest ratio of chitosan 3:1, 
the smallest particles are produced as compared to the ones produced at higher chitosan to TPP 
ratios. The increase in z-average of the nanoparticles can be attributed to an increase in the 
amount of the amine groups available for cross linking with the phosphate groups of TPP. 
However, there would be residual of amine groups since most of the phosphate groups of TPP 
would have reacted with the excess of the amine groups of chitosan.  This will lead to the 
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production of nanoparticles with loosely knit matrices. Such matrices are likely to lose their 
integrity more readily which results in the production of polydisperse particle (Hasanovic et al. 
2009). 
 
Figure 2.8: Pdi and z-average of nanoparticles prepared from 1 mg/ml chitosan solution at 
different chitosan to TPP ratio 
 
In the production of chitosan microspheres, He et al. (1998) observed that when more cross-
linking agent was used, the microspheres were regular, and particle sizes were smaller. This 
appears to be in agreement with observation made in the present study. From figure 2.8, it can be 
seen that, as the concentration of chitosan increased, particle size also increased. 
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Separately, visual images of nano formulations were taken at 3, 5, 8 and 10 mg/ml of chitosan 
and these are depicted in figure 2.9. It can be observed that as the concentration of chitosan was 
increased the solution became more opalescent. At all cross-linking densities, the concentration 
of 1 mg/ml ± 4 mg/ml chitosan produced gave smaller particle sizes between 90 nm ± 300 nm, 
whilst that of 10 mg/ml gave larger particles. The production of larger particles as the 
concentration was increased can be attributed to the limited space of particle movement within 
the solution and hence potential particles agglomeration. Smaller interparticulate distance 
increases the chances of the individual nanoparticulate interaction, hence an increased propensity 
towards agglomeration. 
 
Figure 2.9: Image of chitosan TPP nanoparticles showing variation in opalescence as the 
concentration of chitosan increases 
 
It was expected that, the high zeta potential of chitosan nanoparticles which was recorded as 
above 40 mV should be able to make the various preparations less susceptible to aggregation, but 
it was observed that at chitosan concentration of 10 mg/ml larger particles were produced. In this 
8 mg/ml  5 mg/ml 10 mg/ml 3 mg/ml 
66 
 
respect, the distance between individual nanoparticles was reduced and hence the surface charge 
was ineffective. Though the zeta potential read was high, the reduction in the interparticulate 
distance with more material occupying small volume could be the cause of the observation in the 
change in size of particles prepared at a 10 mg/ml chitosan concentration. Also the effective 
power transmitted through the sample to cause cavitations that produces smaller particles during 
the ultrasonication process may have reduced due to the observed increase in viscosity of the 
chitosan solution as the concentration of chitosan was increased. 
 Nanoparticles can be produced from very low concentrations of chitosan and TPP, but the 
process of recovery is a real challenge. Therefore we need to be cognisant of the concentration of 
the starting materials, in view of possible low nanoparticle recovery. From the present study it 
was noted that, at a 1 mg/ml concentration of chitosan, very low nanoparticle recovery was 
observed but chitosan concentration of 5 mg/ml produced particles with good recovery. At 10 
mg/ml, larger particles were produced which negates the good recoveries observed. Therefore 
initial concentrations between 1 mg/ml and 5 mg/ml of chitosan seemed to produce smaller 
particles with appreciable Pdi and zeta potential and this working concentration range was 
adapted for subsequent work. As observed by Pan et al., 2002, the particle size and other 
parameters of nanoparticles could be controlled by varying the concentration of the counter ions 
and this has also been proved by this current work. 
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Figures 2.10 (a-b) shows the SEM images of chitosan TPP nanoparticles produced by 
ultrasonication. The images shows the tendency of some of the nanoparticles to agglomerate. 
Figure 2.10b shows image of nanoparticles produced from a chitosan concentration 8 mg/ml, the 
population of nanoparticle is increased as compared to figure 2.10a of samples produced from 3 
mg/ml chitosan.  
         
  
 
 
 
 
 
 
 
 
 
 
      
Figure 2.10a: SEM image of chitosan TPP 
nanoparticles. Chitosan to TPP ratio of 3:1 
(3 mg/ml) 
Figure 2.10b: SEM image of chitosan TPP 
nanoparticles. Chitosan to TPP ratio of 3:1 
(8 mg/ml)  
68 
 
2.5.4 Stability behaviour of chitosan TPP nanoparticles produced by ultrasonication and 
magnetic stirring 
The conventional method for producing chitosan TPP nanoparticles has been via magnetic 
stirring. In the present work, we developed and optimised a method for the production of 
chitosan TPP nanoparticles via ultrasonication. In the light of this modification, there was a need 
to assess the stability nanoparticles produced by ultrasonication as compared to that of the 
stability of the conventional. 
 The colloidal stability of chitosan TPP nanoparticles produced via both magnetic stirring and 
ultrasonication was studied over a period of one month. The samples were subjected to different 
storage conditions as described under section 2.5.3 and the z-average, zeta potential and Pdi were 
studied. Since the stability of chitosan TPP nanoparticles produced via magnetic stirring has 
already been studied (López-León et al. 2005), we only subjected nanoparticles produced by the 
newly optimised method to basic stability assessment as normally done on the nanoparticle 
produced  by magnetic stirring. Chitosan degrades in biological environments due to enzymatic 
action, however it has been discovered that, chitosan nanoparticles formulated via ionotropic 
gelation lose their integrity in aqueous media even in the absence of enzymes (López-León et al. 
2005). 
The nanoparticles produced by the two methods were initially assessed with regards to their z-
average, Pdi and zeta potential. The samples were then stored at 25oC (room temperature) and 
4oC (refrigerator). The z-average, Pdi, and zeta potential were measured weekly over a period of 
a month and any changes in the physical appearance was also recorded. 
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Figure 2.11 shows the z-average results obtained with samples stored at 25oC and 4oC. It can be 
seen that, for the two types of nanoparticles prepared by the above stated methods, the particle 
size for nanoparticles stored at room temperature showed a significant increase in z-average over 
the weeks.  
 
Figure 2.11 Z-average of nanoparticles stored at different conditions as a function of time. 
 U.S. = Chitosan TPP nanoparticles prepared by ultrasonication 
 M.S. = Chitosan TPP nanoparticles prepared by magnetic stirring 
 (A) = Nanoparticles stored at 25oC 
 (B) = Nanoparticles stored at 4oC 
 
For chitosan TPP nanoparticles prepared by ultrasonication, by the end of the 4th week of storage 
the z-average increase was more than 8 fold the original, with a significant increase in the Pdi as 
seen in figure 2.12 and a similar observation in z-average increase was also made for the 
magnetic stirred samples. The increase in z-average seemed more pronounced in the 
ultrasonicated system than the magnetic stirred system and the progression of z-average increase 
was slow for the samples prepared by magnetic stirring. Since matrices formed from chitosan 
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depend on how tightly knit the matrices are, there is a possibility that, the matrices in the 
ultrasonicated samples loosened up quickly than those made prepared by magnetic stirring.  
 
Figure 2.12 Average Pdi of nanoparticles stored at different conditions as a function of time 
 U.S. = Chitosan TPP nanoparticles prepared by ultrasonication 
 M.S. = Chitosan TPP nanoparticles prepared by magnetic stirring 
 (A) = Nanoparticles stored at 25oC 
 (B) = Nanoparticles stored at 4oC 
 
It may seem that the energy involved in the formation of nanoparticles via ultrasonication is 
higher than that of production by magnetic stirring. This energy caused the formation of smaller 
particles, but the matrices of these particles may not have been tightly knit as compared to those 
of the magnetic stirred samples. Also, the duration of ultrasonication had to be restricted due to 
the associated increase in temperature generated, which undesirably caused increase in the z-
average of particles. The loss of the matrices integrity leads to changes in the particles spherical 
shape. The significant increase in the Pdi (figure 2.12) also confirms the heterogeneity on the 
system. Heterogeneous systems are not favourable because these systems contain particles with 
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wide variability of sizes and this variability will affect the drug loading and drug release. This 
will in turn affect the usefulness of the nanoparticles as a drug delivery system. 
From figure 2.11 and 2.12, it can be seen clearly that, samples stored at 4oC showed great 
stability than samples stored at room temperature. The z-average and Pdi changes in the samples 
stored at 4oC did not show significant increase as compared to those stored at 25oC. Temperature 
relationship with Brownian motion of particles has been used to explain possible aggregation in 
nanoparticulate systems (Tsai et al. 2011). Lower temperatures reduce the brownian motion of 
particles, thereby reducing their kinetic energy. These reductions lead to an increase in 
interparticulate distance which reduces the tendency for particles to collide with each other and 
aggregate. Hence this may explain the significant difference seen in the stability of samples 
stored at 25oC and those stored at 4oC.  
The zeta potential of both formulations remained stable over the weeks of storage as no drastic 
changes were observed. Nanoparticulate systems with zeta potential values above 25  mV are 
considered stable and those having values below this stipulated range are liable to aggregation 
caused by van der Waal inter particle attractions. Zeta potential is a parameter used in 
ascertaining the state of the nanoparticle surface charge and this can help in determining the 
stability of a nanoparticle suspension, i.e. to what degree aggregation will occur over time.  
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From figure 2.13, the zeta potential of the nanoparticles prepared by either method and stored at 
25oC or 4oC showed little variation during storage over 1 month, albeit a slight rise in values for 
nanoparticles prepared by magnetic stirring. These changes are however insignificant and is a 
feature that may be worth exploring in subsequent modification to the formulation.      
 
Figure 2.13 Average zeta potential of chitosan nanoparticles stored at different conditions 
as a function of time. 
 U.S. = Chitosan TPP nanoparticles prepared by ultrasonication 
 M.S. = Chitosan TPP nanoparticles prepared by magnetic stirring 
 (A) = Nanoparticles stored at 25oC 
 (B) = Nanoparticles stored at 4oC 
 
Figure 2.14 (a and b) shows images of samples stored at 25oC and 4oC for 4 weeks, formulated 
using magnetic stirring and ultrasonication respectively. For nanoparticles by both methods it 
can clearly be seen that the opalescence of the samples stored at room temperature was greater 
than those stored at 4oC.  An increase in the turbidity is indicative of the presence of larger 
aggregates in samples. In addition, it is clear from the image that the nanoparticle prepared by 
ultrasonication was more turbid than the magnetic stirred one. 
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Figure 2.14: Visual images of chitosan nanoparticles formulated by magnetic stirring (a) 
and (b) ultrasonication after storage at 25oC and 4oC for one month 
 
Figure 2.15 ± 2.18 shows the z-average distribution by intensity of the formulation stored at the 
different temperature over the period one month. 
 
Figure 2.15 Variation in z-average distribution in samples formulated by ultrasonication 
after storage at 25oC for one month. 
 
The multi modal distribution seen in the samples stored at 25oC shows the heterogeneity in the 
system and hence a reflection in the drastic changes in the Pdi recorded. The samples stored at 
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4oC always showed a unimodal distribution (representative of a more homogeneous system), in 
contrast to those stored at 25oC and confirming the observations made earlier. 
 
Figure 2.16 Variation in z-average distribution in samples formulated by ultrasonication 
after storage at 4oC for one month 
 
 
Figure 2.17 Variation in z-average distribution in samples formulated by magnetic stirring 
after storage at 25oC for one month.  
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Figure 2.18 Variation in z-average distribution in samples formulated by magnetic stirring 
after storage at 4oC for one month 
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2.7 CONCLUSION 
It can be concluded that, the production of chitosan nanoparticles by ultrasonication is feasible. 
Prolonged ultrasonication causes significant rise in temperature, which appears to manifest in an 
increase in z-average. Increase in pH and also the amount of starting material causes increases in 
z-average of nanoparticle. However working concentrations between 1 mg/ml ± 5 mg/ml of 
chitosan was found to produce consistent particle size, whilst concentrations above 10 mg/ml 
tended to produce precipitates and non-colloidal solutions. Nanoparticles produced by 
ultrasonication were less stable compared to those produced by magnetic stirring during storage 
for one month. On the other hand, the zeta potentials of both types of nanoparticles remained 
essentially unchanged during storage, although the values indicate low stability. The above data 
shows that temperature of storage provides a more meaningful data with regards to stability 
assessment that from zeta potential measurements. 
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CHAPTER 3 
FUNCTIONALISATION OF CHITOSAN WITH PHENYLBORONIC ACID 
3.1 Introduction 
Chitosan is a natural cationic polysaccharide obtained from partial deacetylation of chitin and is 
the main constituent of the crustacean skeleton. It is non-toxic, biodegradable, biocompatible and 
easily modified by chemical and physical methods.  It is widely used in encapsulation 
applications due to its ability to form gels in the presence of certain divalent cations such as 
calcium, barium, and other polyanions. 
Chemical modification of chitosan can improve its bio-functionality and these modifications tend 
to preserve the original physicochemical and biochemical properties while rendering other 
application potential. A major drawback in the functionalisation and application of chitin and 
chitosan is their poor water solubility(Kittur et al. 2002). Major chitosan functionalisation could 
be carried out by: (1) substitution, introducing small groups into the back bone of the chitosan 
and (2) depolymerisation by chemical, physical or enzymatic treatments. Further chemical 
modification of the functionalised chitosan can be pursued to widen their application. 
Chitosan has been modified with different chemical groups for use in the fields of drug delivery, 
medicine, food, chemical engineering and the agriculture industry. For example chitosan and 
alginate modified by acylation with palmitoyl chloride has been used to create an ideal 
encapsulation system for micronutrients to reduce the reactivity of the micronutrient in relation 
to the outside environment. This allowed maximal stability in acidic pH and gave resistance to 
extreme moisture conditions (Han et al. 2008). 
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Chitosan has also been modified by trimethylation to increase its water solubility and this  
trimethyl chitosan (TMC) has been synthesised and characterised by FTIR and NMR, where 
these quartenized derivatives of chitosan possess a positive charge and are soluble over a wide 
range of pH (Mourya and Inamdar 2009).  
Chitosans have also been used as conjugates with bioactive excipients for the delivery of active 
ingredients such as calcitonin. Enzyme inhibitors of trypsin were conjugated to chitosan and this 
conjugation has demonstrated a potential in the delivery of small peptides by inhibiting the 
degradation of the encapsulated calcitonin by the enzymes (Guggi 2003). Smoum et al. (2006) 
developed a chitosan-pentaglycine-phenylboronic acid conjugate for the colon specific delivery 
of calcitonin. Novel chitosan gel modified by phenylboronate with selective glucose adsorption 
capacity was synthesised by Matsumoto et al. (2002) and these gels have demonstrated a 
potential for use in the recognition of saccharides. 
Wu et al. (2011) have investigated the utilisation of phenyl boronic acid (PBA)-bonded chitosan 
nanoparticles as a vehicle for controlled insulin release and insulin release from the nanoparticles 
was attributed to the glucose sensitivity of the PBA moiety and the molecular weight of the 
polymer. 
In the present project various methods and approaches were adopted to introduce the PBA group 
onto chitosan, these methods explored the chemistries of both chitosan and phenylboronic acid. 
Both physical and chemical methods were pursued and the successful functionalisation of the 
chitosan by PBA was thoroughly studied by various techniques in order to ascertain the degree 
of functionalisation. 
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3.2 Materials, methods and equipment 
Low molecular weight chitosan was purchased from Sigma Aldrich (Missouri, USA); 
tripolyphosphate (TPP), phenylboronic acid (PBA), 4-formylphenyl boronic acid (4-FPBA) and 
sodium borohydride (Thermofischer Scientific New Jersey, USA), sodium hydroxide pellets 
(Merck, Darmstadt, Germany), acetic acid, methanol, acetonitrile and glucose (Thermofischer 
Scientific New Jersey, USA). All other chemicals were of reagent grade. 
Bruker S4-Explorer X-ray fluorescence (XRF), Field emission scanning electron microscopy 
(FESEM) (Model Quanta 400F, FEI Company, USA) with an Energy dispersive x-ray detector 
(EDX) (EDAX Inc. U.S.A.), Perkin Elmer FTIR spectrometer (Spectrum RX 1), Time-of-flight 
secondary ion mass spectrometry (ToF-SIMS, ION-TOF equipped with a liquid metal, Bi ion 
gun, GmbH, Munster, Germany), Mettler Tolledo DSC system, CE440 Elemental analyzer 
(Exeter Analytical (UK) Ltd), CHRIST Freeze drier Alpha 1-2 10 plus S/N1-1521with 
Vacuubrand rotary vane vacuum pump R22.5 S/N 31219013. 
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3.2.1 Methods 
3.2.1.1 Nanoparticle formulation via electrostatic interaction between chitosan and PBA 
Chitosan was dissolved in 1% acetic acid under magnetic stirring and filtered. PBA was 
dissolved in water and its pH adjusted to 10.0 to make it anionic. The PBA was added drop wise 
into the chitosan solution whilst ultrasonicating for 1 minute as was done for the production of 
chitosan TPP nanoparticles in section 2.3.1. Various ratios of the chitosan to PBA were prepared, 
namely: chitosan:PBA ratios of 1:1, 1:2 and 1:3 respectively, and the z-average and Pdi of the 
nanoparticles were assessed by Zetasizer Nano ZS® (Malvern, UK) equipped with a 4Mw He- 
Ne laser (633 nm). Each analysis was carried out at 25oC and performed in triplicate and data 
expressed as mean ± standard deviation. SEM imaging was performed by field emission 
scanning electron microscope (FESEM, Quanta 400F, FEI Company, USA) under low vacuum 
and at a viewing voltage of 20.0 kV. 
 
3.2.1.2 Tagging of PBA electrostatically onto chitosan 
It was theorised that, chitosan and PBA could be formulated into nanoparticles by cross linking 
with TPP. TKHUHIRUHFKLWRVDQZDVµIXQFWLRQDOLVHG¶ZLWKWKH3%$E\SK\VLFDODGPL[WXUHDQGWKHQ
formulated into nanoparticles using TPP as a cross-linker. Chitosan in 1% acetic acid and PBA 
dissolved in distilled water and pH adjusted to 10 were mixed together and stirred using a 
magnetic stirrer at a speed of 700 rpm, the stirring times were between 1 hour and 24 hours. 
Different amounts of chitosan and PBA were used and different stirring times were also 
investigated. The resulting solutions were either precipitated out by pH adjustment using 1M 
NaOH or collected without precipitation. In either case, the formulations were then freeze-dried.  
The presence of PBA within chitosan polymer was ascertained by FTIR, DSC, XRF and EDX. 
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3.2.1.3 Formulation of chitosan TPP/PBA nanoparticles 
Tagging of PBA electrostatically onto chitosan also appeared to be non-feasible. In a subsequent 
method, chitosan-TPP nanoparticles were produced as described in section 2.3.1 whilst PBA was 
entrapped or incorporated in the matrix. 
PBA was dissolved in water, filtered and added to the chitosan solution and stirred for different 
times. Filtered TPP solution was then added to the PBA chitosan solution and ultrasonicated at 
40% amplitude (300 Watts) for one minute to form the nanoparticles. Chitosan to PBA ratios of 
1:1, 1:2 and 1:3 were studied and the ratio of chitosan to TPP was fixed at 3:1. The nanoparticles 
were then recovered by centrifugation at 10000 rpm, washed with water, and freeze-dried. The 
freeze-dried samples were subjected to FTIR and EDX analyses. 
In an alternate procedure, chitosan was dissolved in 1% acetic acid. The TPP and the PBA were 
dissolved in deionised water together and filtered. The TPP/PBA solution was added to the 
chitosan solution and then ultrasonicated at 40% (300 Watts) for 1 minute (this time not 
chitosan-PBA alone but TPP being incorporated as a cross-linker). The nanoparticles were 
recovered by centrifugation at 10000 rpm, washed with deionised water, and then freeze-dried. 
The z-average of the particles produced was determined by Zetasizer Nano ZS® (Malvern, UK) 
equipped with a 4Mw He- Ne laser (633 nm). Each analysis was carried out at 25oC and 
performed in triplicate and data expressed as mean ± standard deviation and images were viewed 
on the FESEM. The success of incorporation of PBA onto the nanoparticles was monitored by 
FTIR and EDX. 
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3.2.1.4 Synthesis and purification of chitosan-PBA conjugates by N-reductive alkylation  
50 mg of chitosan (0.3 mmol of NH2) was dissolved in 5 ml of 1% acetic acid and the mixture 
was stirred for 1 hour to obtain a 1% w/v solution. Various amounts of 4-formylphenylboronic 
acid (table 3.1) dissolved in 3ml of methanol were added to the chitosan solution, which was 
stirred at room temperature. After 1 hour, sodium borohydride (NaBH4) (1.5%w/v) in 2 ml of 
methanol was added. The reaction mixture was then incubated for 24 hours at room temperature 
under continuous stirring. The precipitate formed was centrifuged and washed with methanol, 
ethanol and water thoroughly. The success of N-alkylation was monitored with FTIR, DSC, 
EDX, and ToF-SIMS. 
Table 3.1 Quantities of starting material used in the production of chitosan-PBA 
conjugates by N-reductive alkylation 
Formulation Aldehyde equivalence(eq) Aldehyde weight (mg) 
F1 0.40 17.99 
F2 0.80 35.98 
F3 1.00 44.97 
F4 1.50 67.45 
F5 2.00 89.94 
F6 3.00 134.91 
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Sample calculation 
50 mg of chitosan has 0.300 mmol of NH2 groups 
Therefore: 0.40 equivalence of aldehyde converted to mmol   =  0.300 x 0.40 = 0.12 mmol of 
aldehyde. 
Molecular weight of 4 ± formylphenylboronic acid =  149.90 gmol-1 
Amount of substance (n) =  mass/ molecular weight 
Therefore 0.12 mmol aldehyde = mass/149.9 gmol-1 
Mass =  0.12 mmol x 149.9 gmol-1 
=  0.017799 g =  17.99 mg 
Same calculation was done for the rest of the formulae 
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Equation of the reaction  
NaBH4
MeOH/ACOOH
Chitosan 4 -formylphenylboronic acid
conjugate
Figure 3.1 Equation of reaction between chitosan and 4-formylphenylboronic acid in the 
presence of NaBH4 
 
 
3.2.1.5 Fourier transform infra-red analysis 
FTIR spectra of chitosan, TPP, chitosan-PBA conjugate and chitosan TPP PBA nanoparticles 
prepared by electrostatic tagging and N-reductive alkylation were obtained using a Perkin Elmer 
FTIR spectrometer, Spectrum RX 1. Lyophilised samples were gently mixed with about 250 mg 
of micronised KBr powder that was oven dried at 120oC for 4 hours. The mixture was 
compressed at a pressure of 6 tons (5000 psi) and made into a disc, using a pneumatic table 
press.  Spectra were collected in the range of 4000 ± 400 cm-1. All determinations were done in 
triplicate. 
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3.2.1.6 Differential scanning calorimetry  
Thermograms were obtained using Mettler Tolledo DSC system, equipped with a STARe® 
software version 9.01. About 5 mg of the lyophilised powder was crimped in standard aluminum 
pans and heated from 25oC to 500oC at a constant heating rate of 10oC/min under constant purge 
of nitrogen at 20 ml/min with an empty pan as the reference. The enthalpies for samples prepared 
by electrostatic tagging of PBA onto chitosan (as described in section 3.2.1.2 - 3.2.1.3) and 
samples of conjugate synthesised by N- reductive alkylation (as described in section 3.2.1.4) 
were determined using the STARe software. 
 
3.2.1.7 Energy dispersive x-ray spectroscopy (EDX) analysis  
The success of the tagging of boronic acid moiety onto chitosan was determined by the presence 
of boron. Samples mounted on a carbon tape were analysed using Field emission scanning 
electron microscopy (FESEM) (Model Quanta 400F, FEI Company, USA) with an Energy 
dispersive x-ray detector (EDX) (EDAX Inc. U.S.A.). EDX maps were collected for samples 
prepared by electrostatic tagging of PBA onto chitosan (as described in section 3.2.1.2 - 3.2.1.3) 
and samples synthesised via N- reductive alkylation (as described in section 3.2.1.4). 
 
3.2.1.8 ToF-SIMS of functionalised chitosan 
The success of tagging PBA onto chitosan via N-reductive alkylation was also monitored on 
Time-of-Flight Secondary Mass Ion Spectrometer (ToF-SIMS) IV (ION-TOF GmbH, Münster, 
Germany), equipped with a Bi ion gun (LMig). The presence of PBA onto chitosan was 
monitored based on the element boron and ionic fragments from boronic acid. These secondary 
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particles were analysed by mass spectroscopy (parallel acquisition with the time-of-flight 
analyser). 
 
3.2.1.9 Determination of percentage yield 
The percentage yield of conjugate recovered from synthesising via N-reductive alkylation was 
calculated based on the amount of functionalised chitosan recovered after freeze-drying for 48 
hours as a percentage of the amount of chitosan (the initial weight of polymer) used at the start of 
the reaction. Analyses were performed in triplicate and expressed as the mean ± standard 
deviation. 
Percentage yield =   x 100% «««(quation 3.1  
 
 
3.2.1.10 Elemental analysis of functionalised chitosan 
The elemental composition of the functionalised chitosan was determined using CE440 
Elemental analyser (Exeter Analytical (UK) Ltd).  1.7 mg of conjugate synthesised via N-
reductive alkylation was weighed into aluminium capsules. The sample was injected into a high 
temperature furnace and combusted in pure oxygen under static conditions. At the end of the 
combustion period, a dynamic burst of oxygen was added to ensure total combustion of all 
inorganic and organic substances. The resulting combustion products were passed through 
specialised reagents to produce the elements carbon, hydrogen, and nitrogen; as the gases carbon 
dioxide (CO2), water (H2O) and nitrogen (N2) and nitric oxides. Analysis was done in triplicate 
for each sample. 
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3.3 Results and Discussion 
3.3.1 E lectrostatic tagging of PBA onto chitosan 
3.3.1.1 Formulation of chitosan-PBA nanoparticles 
It was assumed that using pH adjustments, chitosan-PBA nanoparticles could be formulated. 
Table 3.2 shows z-average, Pdi and zeta potential of the chitosan-PBA nanoparticles formulated 
by electrostatic tagging onto chitosan. The z-averages recorded were all in the microparticle 
range. Figure 3.2 shows the SEM image of the chitosan-PBA nanoparticles produced at a ratio of 
chitosan to PBA of 1:2.  
Table 3.2 Z-average, Pdi and zeta potential of chitosan-PBA nanoparticles 
Formulation 
ratio of chitosan to PBA 
Z-average (nm) Pdi Zeta potential 
(mV) 
1:1 1417 ± 69.60 
 
0.594 ± 0.24 40.9 ± 5.20 
1:2 1245 ± 35.20 0.545 ± 0.38 42.5 ± 3.20 
1:3 1017 ± 45.20 0.587 ± 0.14 44.9 ± 2.40 
 
 
Figure 3.2 SEM image of chitosan phenylboronic acid nanoparticles 
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It can be seen that the structures are not spherical but appear to be spindle-shaped; such spindle-
shaped structures have been reported by Harish and Tharanathan (2006) who attributed these to 
the structure of chitosan. It can therefore be concluded that, the spindle shaped structures seen 
are chitosan and that PBA did not electrostatically interact with chitosan as expected to produce 
nanoparticles. 
3.3.1.2 Formulation of chitosan-PBA conjugates 
In a refined approach, PBA was first made to  react with chitosan by stirring for different times 
and the conjugates were precipitated out by addition of 1M NaOH, washed with deionised water 
and then freeze-dried, whilst a portion of the conjugates were also freeze-dried directly without 
precipitation and washing. The FTIR spectra and DSC thermograms of the freeze-dried 
conjugates (precipitated and non-precipitated) were compared to those from pure chitosan 
(figures 3.3 and 3.4).  
 
Figure 3.3 FTIR spectra of conjugate (formulated by stirring for 24 hours), chitosan and 
PBA 
(Precipitated) 
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Figure 3.4 FTIR spectra of precipitated and non-precipitated conjugates stirred for 
different times  
 
It is observed that conjugates recovered by the above mentioned methods, washed and freeze 
dried has similar spectra to that of chitosan. Characteristic peaks of PBA appearing at 1442 cm-1 
has been attributed to a mixture of several motions including C-C and B-O stretching, while the 
band centred around 1367 cm-1 is likely due to vibrational modes involving B-O stretching 
motions and peaks at 1080-1110 cm-1 have been attributed to B-C stretching mode in arylboronic 
acid (Faniran and Shurvell 2011), these characteristic peaks are seen in the pure boronic acid and 
the conjugates that were not precipitated out (figure 3.3 and 3.4) (table 3.3), but none of the 
above mentioned peaks characteristic of PBA was seen in the conjugate that was precipitated 
out, washed and freeze dried (figure 3.3). The washing step in the procedure after precipitation 
might have washed all the unreacted PBA and hence no characteristic peak of PBA seen in the 
washed conjugate but the reverse is seen in the unprecipitated conjugate because the unreacted 
(Precipitated) 
(Precipitated) 
(Precipitated) 
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PBA was not washed and hence the presence of characteristic boronic acid peaks in those 
conjugates (figures 3.3 and 3.4) 
Figure 3.4 also shows the effect of stirring times on the tagging of boronic acid onto the chitosan, 
the spectra shows that increasing the stirring times of the reaction did not have significant effect 
on the extent of incorporation of the PBA into chitosan. 
Table 3.3 FTIR peaks (cmí1) of interest from chitosan, TPP, PBA and chitosan-PBA 
conjugates (n=3) 
Possible 
assignment Chitosan TPP PBA 
Chitosan-PBA 
conjugate 
-NH2 and -OH 
stretching vibration 3459.69±12.97 - - 3430.87±9.30 
carbonyl (CONH2) 1654.77±1.88 - - 1652.77±1.20 
Secondary amide 1380.31±0.73    
C-C and B-O 
stretching - - 1442.20±0.25 - 
Vibrational modes 
involving B-O 
stretching 
- - 1367.64±0.51 - 
B-C stretching 
mode in 
arylboronic acid 
- - 1086.92±14.98 - 
Amine groups in 
Chitosan 
interaction with 
TPP 
1637.57±0.50  -  
1540.54±1.52   - 
Characteristic 
absorption band of 
para-substituted 
benzene 
   1559.54±0.53 
   1514.85±0.43 
   830.90±0.37 
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Figure 3.5 shows the DSC thermogram of chitosan. There are two characteristic peaks at 95oC 
which is endothermic and an exothermic peak at 310oC. These peaks have also been reported by 
other researchers (Kittur et al. 2002; Mourya and Inamdar 2009; Sreenivasan 1996; Sarmento et 
al. 2006). Endothermic peak have been correlated with evaporation of water associated to 
hydrophilic groups of polymers, whilst the exothermic peaks have been related to degradation 
due to dehydration, depolymerisation and pyrolitic reactions.  
 
Figure 3.5 DSC thermogram of chitosan 
 
 
Endo 
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Figure 3.6 DSC thermogram of PBA 
Figure 3.6 represents the DSC thermogram of pure PBA. There is a characteristic sharp 
endothermic peak at around 220oC; endothermic peaks have been associated with melting points 
of chemicals. The melting point of PBA is reported to be in the range 219-222oC (Sigma Aldrich, 
2013), hence the endothermic peak at around 223oC can be ascribed to the melting point of PBA. 
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Figure 3.7 DSC thermogram of chitosan-PBA conjugate 
A: DSC thermogram of unprecipitated chitosan phenylboronic acid conjugate 
B/C: DSC thermogram of precipitated and washed chitosan phenylboronic acid conjugate 
 
Figure 3.7 is the thermogram of the freeze-dried conjugates that were precipitated with sodium 
hydroxide and one that was not. It appears that the endothermic peak of chitosan has shifted to 
higher temperature (110oC) whilst the exothermic peak appears to have been retained (figure 3.7 
B and C). In addition, there appears to be two endothermic peaks, one at 60oC and a smaller one 
at around 220oC from the unprecipitated conjugate and these peaks (figure 3.7 A) may be akin to 
PBA. The endothermic peak at 60oC is also present in the washed conjugate albeit somewhat 
smaller and shifted to lower temperatures, but the peak at around 220oC disappears. It follows 
that the washing procedure is necessary in removing the unreacted PBA from the conjugate. 
 
Exo 
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Table 3.4 XRF compositional analysis of conjugate weight percentage of sample PBA in 
oxide and elemental form 
Oxide Element Concentration (%) Oxide Concentration (%) Element 
CO2 C 95.00 26.00 
Na2O Na 5.10 3.80 
Cr2O3 Cr 0.10 0.07 
Fe2O3 Fe 0.17 0.12 
- O - 70.18 
Total  100.37 100.17 
 
X-Ray fluorescence spectroscopy (XRF) is used for detection of elements on the periodic table 
between beryllium (Be) and uranium (U). Conventional methods for elemental analysis are not 
sensitive enough to quantify elements such as boron. Since boron is a major element that can be 
monitored as prove presence of PBA on chitosan, boron content was measured by XRF. From 
table 3.4, the XRF data show that no boron was detected, except for C and O which is attributed 
to elements in chitosan. Traceable amounts of sodium and other elements were also found. This 
also shows that functionalisation of chitosan by electrostatic tagging for the preparation of 
chitosan-PBA conjugates was not successful. 
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3.3.1.3 Formulation of chitosan-TPP-PBA nanoparticles 
The assumptive tagging of phenylboronic onto chitosan TPP nanoparticles was also attempted 
which was based on the premise that, the negatively charged boronic acid will seemingly react 
with the positively charged chitosan as TPP will do. The recovered nanoparticles prepared by 
ultrasonication were taken through FTIR analysis and EDX analysis to check the success of 
tagging by this method also. It was observed from the FTIR that there were no peaks attributable 
to PBA, but that of chitosan and TPP (figure 3.8).  
 
Figure 3.8 FTIR spectra of chitosan, PBA, TPP and chitosan TPP PBA nanoparticles 
 
A broad peak around 3450 cmí1 in the chitosan TPP PBA nanoparticles is indicative of enhanced 
hydrogen bonding. The intensities of (CONH2) band at 1655 cmí1 which can be observed in 
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chitosan decrease dramatically and two new sorption bands at 1637 and 1539 cmí1 (table 3.3) 
appear and this is indication that the ammonium groups in chitosan are cross-linked with 
tripolyphosphate molecules. Thus it is postulated that polyphosphoric groups of sodium 
polyphosphate interact with the ammonium groups of chitosan, which serves to enhance both the 
inter- and intramolecular interaction in chitosan nanoparticles (Qi et al. 2004).  
The EDX for the plain carbon tape which was used to mount the samples also seem to have 
traces of boron as seen in figure 3.9 and table 3.5 and this implies that there would be a source of 
interference from the carbon tape. 
Table 3.5 EDX of carbon tape 
Element Weight% Atomic% 
B K 6.41 7.41 
C K 75.44 78.47 
N K 0.00 0.00 
O K 17.98 14.04 
Al K 0.17 0.08 
Totals 100.00 
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Figure 3.9 EDX of Carbon tape 
The elements carbon, oxygen and phosphorous were detected by EDX for the chitosan TPP PBA 
nanoparticles (figure 3.10).  
 
Figure 3.10 EDX of chitosan TPP PBA nanoparticles  
The carbon and oxygen can be ascribed to chitosan whilst TPP contributes the phosphorous. The 
sodium present may also be from the TPP, because it comes as a sodium salt.  
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As seen in table 3.6 and 3.7 and figures 3.10 and 3.11, there is no difference between the EDX of 
chitosan TPP nanoparticles and chitosan TPP PBA nanoparticles. The percentage of boron seen 
is attributable to the traces of boron from the carbon tape. 
From the above methods employed which were met with no success, it was inferred that, the 
electrostatic tagging of the phenylboronic acid to chitosan was not feasible. 
Table 3.6 EDX of chitosan TPP PBA nanoparticles 
Element Weight% Atomic% 
B 6.73 8.62 
C 46.51 53.58 
O 40.40 34.94 
Na 0.15 0.09 
P 6.20 2.77 
Totals 100.00 
 
 
Table 3.7 EDX of chitosan TPP nanoparticles 
Element Weight% Atomic% 
B 5.40 7.01 
C 42.09 49.17 
O 47.20 41.39 
Na 0.16 0.10 
P 5.14 2.33 
Totals 100.00 
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Figure 3.11 EDX of chitosan TPP nanoparticles 
Nanoparticles cannot be produced from the positively charged chitosan and negatively charged 
phenylboronic acid alone. The method of incorporating the phenylboronic acid in the process of 
production of the chitosan TPP nanoparticles also does not bring about the tagging or the 
incorporation of the phenylboronic acid into the nanoparticulate system. 
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3.3.2 Tagging of PBA onto chitosan via N-reductive alkylation 
After the unsuccessful attempts at electrostatic tagging phenylboronic acid onto chitosan, PBA 
was made to chemically react with chitosan. There are several methods in the literature that 
describe the tagging of PBA onto chitosan but the one most reviewed is based on the N-reductive 
alkylation of the amine groups within chitosan (Smoum et al. 2006). This same method was used 
also by Matsumoto et al (2002) to synthesise a novel chitosan gel modified by phenylboronate 
with selective glucose adsorption capacity. In the present study the tagging of the boronic acid 
JURXSZDVGRQHYLDWKH6FKLII¶VEDVHPHWKRGZKHUHWKHphenylboronate group (p-formylboronic 
acid) was introduced into chitosan by reductive N-alkylation. A second method was also used by 
the same group to introduce the phenylboronic acid group onto chitosan. In that method the 
amino group in chitosan reacted with carboxyboronic acid to form the amide compound in the 
presence of thionyl chloride in dimethylformamide (figure 3.12b) and the resulting gels were 
then filtered, washed with methanol and ethanol, and dried in vacuo (Matsumoto et al. 2002).  
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The second pathway of reaction (figure 3.12b) had more steps in the reaction than the first 
pathway (figure 3.12a).  
 
 
Figure 3.12 Reaction of N-  reductive alkylation of chitosan, A- E\WKH6FKLII¶VEDVHPHWKRG
and B- by amide bonding. (Smoum et al., 2006). 
 
 
 
a 
b 
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Figure 3.13 Reaction mechanism of a single chitosan monomer with (4-FPBA) via a schiff 
base intermediate.  
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Figure 3.13 outlines the chemical process of the N- reductive alkylation. The initial reaction of 
the chitosan with FPBA produces an imine intermediate which is further reduced to an amine by 
the sodium borohydride. 
Moreover, based on the selective adsorption work done by Matsumoto et al. (2002), it was found 
out that the gels produced by the N± UHGXFWLYHDON\ODWLRQYLD6FKLII¶VEDVHPHWKRGKDGVHOHFWLYH
adsorption for glucose and since this current project is dealing with the development of a glucose 
responsive insulin delivery system, it was deemed appropriate to adopt the schiff base method. 
Chitosan derivatives were synthesised by direct reductive N-alkylation of chitosan with 4-
formylphenylboronic acid and the degree of N-substitution could be controlled by increasing or 
decreasing the amount of the aldehyde (FPBA) in the reaction mixture (Table 3.1 in section 
3.2.1.4) 
3.3.2.1 Percentage yield 
The percentage yield of the PBA functionalised chitosan was calculated using equation (3.1). 
Table 3.8 shows the average of yield of each formulation coded F1-F5.   
Table 3.8 Percentage yield of the formulation F1 to F5 (see table 3.1) after centrifugation 
Formulation Percentage yield 
F1 79.30 ± 1.80 
F2 83.97 ± 4.70 
F3 90.40 ± 2.59 
F4 107.24 ±6.50 
F5 112.42 ±3.06 
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Smoum et al (2006) used the filtering method for the recovery of the functionalised chitosan 
after production. In this current project, it was observed that the precipitate recovered after 
production was colloidal and sticky to the filter paper.  
 
Figure 3.14 Image of precipitate of functionalised chitosan after filtration and drying in 
vacuo 
Figure 3.14 is the image of functionalised chitosan recovered by filtration and dried in vacuo, the 
colloidal precipitate was difficult to recover from the filter paper and after vacuum drying 
samples stuck onto the filter and an attempt to remove it introduced contamination from the filter 
paper. Therefore the conjugates were recovered by centrifugation at 6000 rpm for 10 minutes 
with several washing cycles using methanol, ethanol and water. The yield from the recovery by 
centrifugation was better than Smoum HWDO¶V (2006) filter paper method. A minimum percentage 
yield of about 46% and a maximum of about 76% were recorded by Smoum et al. (2006). From 
table 3.8 above, there was a significant increase in the percentage yield. In this regard the method 
of centrifugation was considered a better way for recovering the precipitate than filtration 
because there is minimal loss in the process. 
Also comparing the method of washing using methanol and ethanol only as employed by 
Matsumo et al (2002), in the production of chitosan phenylboronic acid conjugate for saccharide 
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recognition and that of Smoum et al (2006) using water and methanol, it was observed that, the 
process and solvents used in the washing of the conjugate had effect on the final appearance, 
texture and acetic acid solubility of the formulation. Therefore a combination of water, ethanol 
and methanol washings was employed in present study as an improvement on the previous 
methods used. F4 ± F5 when washed with ethanol and methanol combination alone yielded a 
yellow crystalline material. Methanol, ethanol and water washings on these same formulations 
yielded an off white amorphous powder with better solubility in 1% acetic acid. Also the method 
of drying had an influence on the physical appearance of the conjugate. (Matsumoto et al. 2002) 
dried their conjugates in vacuo, but when this mode of drying was attempted in the present study, 
hard crystalline products with less solubility in 1% acetic acid were recovered. Freeze drying 
yielded near amorphous powders with good solubility in 1% acetic acid and hence this latter 
method of drying was used throughout the project.  
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Figures 3.15-3.19 show the production and the recovery process used for the synthesising the 
conjugates. 
               
 
                
 
Figure 3.15 Image of the process of 
production of functionalised chitosan 
Figure 3.16 Image of precipitate of 
functionalised chitosan before centrifugation 
Figure 3.17 Image of functionalised 
chitosan after centrifugation 
Figure 3.18 Image of functionalised 
chitosan before freeze drying 
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3.3.2.2 Elemental analysis of conjugates prepared by N-reductive alkylation 
Elemental analysis is an experiment that determines the amount (typically a weight percent) of 
an element in a compound. Just as there are many different elements, there are many different 
experimental methods for determining elemental composition. The most common type of 
elemental analysis is for carbon, hydrogen, and nitrogen (CHN analyses). This type of analysis is 
especially useful for organic compounds (compounds containing carbon-carbon bonds). 
Elemental analyses on the different functionalised chitosan revealed an increase in the carbon 
percentage as the amount of FPBA used in the initial reaction increased. From table 3.9, it can be 
seen that the percentage of carbon increased, indicating the addition of more chemical groups to 
the chitosan. The percentage of nitrogen (N) due to amine groups within the chitosan decreases 
because there are more carbon (C) groups (contributed by the formylphenylboronic acid 
substitution) being added to a fixed number of amine groups within chitosan. The difference in 
the composition of the various elements across the different formulation proves that, the degree 
of substitution of the boronic acid onto chitosan depend on the initial amount of the FPBA 
added. 
Figure 3.19 Image of functionalised 
chitosan after freeze drying 
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Table 3.9 Elemental analyses of functionalised chitosan 
Formulation C (%) H (%) N (%) 
Chitosan 40.29 6.58 7.22 
F1 41.31 6.10 6.55 
F2 42.20 6.14 6.19 
F3 42.87 6.09 6.12 
F4 44.34 5.78 5.50 
F5 45.48 5.19 4.61 
 
3.3.2.3 FTIR analysis of the conjugates prepared by N-reductive alkylation 
 In the FTIR spectra of chitosan (figure 3.20), the characteristic peak for chitosan appear at about 
3430.24 cm-1  indicative of  OH and NH2 stretching vibrations and a peak at 1654.29 cm-1 
attributable to an amide ± linked carbonyl group (C=O)  and the   C-O bond peak appear at 1080 
(table 3.3). The 1381.02 cm-1 corresponds to a secondary amide, most likely due to incomplete 
de-acetylation of chitosan (Osman and Arof 2003; Vandeveld and Kiekens 2004). These are in 
agreement with previous works done (Matsumoto et al. 2002; de Moura et al. 2008; Bruno 
Sarmento et al. 2006). 
Figure 3.20 FTIR spectra of chitosan 
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The newly synthesised chitosan-PBA conjugates showed characteristic bands at 1559.54, 
1514.85 and 830.90 cm-1, (figure 3.21-3.23) (table 3.3) which are characteristic absorption bands 
of para substituted benzenes. These peaks are sharper and higher in intensity in proportion to the 
degree of substitution (figure 3.23). The conjugate with the highest amount of substitution 
showed the greatest peak. 
The peak relating to the primary amine of chitosan at 1590 cm-1 became less apparent from F1 
through F6 and virtually disappeared in F6 (figure 3.23). This strongly suggest that the PBA 
resides at the primary amine group (-NH2). This confirms the successful functionalisation of 
chitosan with the boronic acid group (Smoum et al., 2006; Matsumoto et al., 2002). 
 
Figure 3.21 FTIR spectra of Conjugate F4 
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Figure 3.22 FTIR spectra of conjugate (F6) and chitosan  
In figure 3.23, an increase in the intensities of the peaks of the para substituted benzene (1559, 
1514, 831 and 647 cm-1 (table 3.3)) is observed as the degree of substitution increases. 
Figure 3.23 FTIR spectra of chitosan and conjugates F1 through F6  
 
F2 
F1 
F6 
F5
F4 
F3 
Chitosan 
111 
 
3.3.2.4 Differential scanning calorimetry (DSC) of conjugates prepared by N-reductive 
alkylation 
To study the change in material organisation in chitosan due to bonding with FPBA, DSC 
analysis of the functionalised chitosan were performed and are presented in figures 3.24 -3.26. 
Thermograms of chitosan and the conjugates are very different as seen in figure 3.23 below. This 
indicates the presence of additional chemical functionality. Chitosan has an endothermic and 
exothermic peak and these are characterised at 80oC and 300oC respectively. Endothermic peak 
have been correlated with evaporation of water associated to hydrophilic groups of polymers, 
whilst the exothermic peaks have been related to degradation due to dehydration, 
depolymerisation and pyrolitic reactions (Bruno Sarmento et al. 2006; Bhumkar and Pokharkar 
2006).  
 
Figure 3.24 DSC Thermogram of conjugates (F2, F3 and F5) and chitosan  
The thermograms of the new conjugates made by N-reductive alkylation exhibit a wide 
endothermic peak at around 75oC which is slightly shifted from the endothermic peak of pure 
            CHITOSAN 
F5 
F2 
F3 
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chitosan at 83oC. The exothermic peaks in the new conjugates are slightly shifted from the 
temperature where the chitosan peak occurs which is around 308oC to 320oC (figure 3.24). This 
is indicative of chemical modification of chitosan by another chemical group. The existence of 
the endothermic peak has always been attributed to the evaporation of water from hydrophilic 
groups of polymers and the existence of this peak in the conjugate shows that the polymeric 
nature of the new conjugate is retained. The existence and slight shift of the conjugate 
exothermic peaks can be related to degradation due to dehydration, depolymerisation and 
pyrolitic reactions as seen in chitosan. The shift can be attributed to the new group substitution 
onto chitosan making it more bulky a polymer than what it used to be and hence a higher 
temperature of degradation. There appears to be no report on chitosan-PBA conjugate 
thermogram in the literature and these are new observations that have been made. 
In order to ascertain that the tagging of PBA to chitosan was successful and also monitor the 
purity of the conjugate, a physical admixture of pure chitosan and pure 4- FPBA was made and 
its thermogram taken. This thermogram was compared to that of pure chitosan, pure FPBA and 
the newly synthesised conjugates. The endothermic peak in pure FPBA is seen as two peaks 
(figure 3.25), a broader peak occurring around 125oC and a sharp peak at around 155oC and also 
two exothermic peaks occur around 300oC and 350oC.  
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Figure 3.25 DSC Thermogram of pure 4-formylphenylboronic acid 
  
 
Figure 3.26 DSC Thermogram of conjugates, chitosan and FPBA admixed with chitosan 
In the thermogram of the physical admixture (figure 3.26), there are three endothermic peaks and 
these peaks can be attributed to that of chitosan occurring around 70oC and the broad peak of 
pure FPBA at 125oC and the small sharp one at 155oC. The endothermic peaks of FPBA at 125 
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and 155oC are retained. The exothermic peak seen in the physical admixture is very unique and 
different from the exothermic peak of the chitosan or FPBA, the exothermic peak of chitosan and 
FPBA occur above 300oC. The fusion of the exothermic peaks in the two compounds shows as a 
characteristic peak 270oC as seen in figure 3.26. This is a confirmation that the new conjugates 
produced are a result of a definitive chemical reaction process, also the method used in the 
collection and purification of conjugate was effective, because if there was any unreacted FPBA 
LWZRXOGKDYHEHHQVHHQLQWKHQHZFRQMXJDWH¶VWKHUPRJUDPas a broad endothermic peak with a 
small sharp one attached.  
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3.3.2.5 Time-of-flight secondary ion mass spectrometry (TOF-SIMS) of conjugates 
prepared by N- reductive alkylation 
The FTIR data for F1 and F2 shown in figure 3.23 suggest a non- existent PBA functionality, 
i.e., at lower 4-FPBA loading, since the peaks representing the para di-substituted benzene is not 
apparent. The ToF-SIMS analysis, however (figure 3.27-3.29), revealed the presence BO and 
BH2O2 (boronic acid) fragments and the boron ions (B-) at 11.0 m/z in F1, F3 and F5 (figure 
3.28) also revealed the successful functionalisation of chitosan because the boron fragment was 
absent in chitosan.  
 
Figure 3.27 TOF-SIMS spectra of pure chitosan and selected conjugates 
The intensities of the different fragments shown correlates with the FPBA load (figure 3.28 and 
3.31). Thus the ToF-SIMS is in concert with the FTIR analysis in that there is a direct correlation 
between the degree of PBA bonding onto chitosan and the 4-FPBA loading during the reaction, 
albeit the ToF-SIMS is more sensitive than the FTIR.  
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A further analysis of boron oxide (BO-), boron dioxide (BO2-) and boronic acid (BO2H2)- 
fragments confirms the presence of boronic acid moiety onto conjugates in proportion to the load 
at preparation (figure 3.28-3.30). 
 
Figure 3.28 TOF-SIMS spectra of BO- fragments of functionalised chitosan F1-F4 
 
 
Figure 3.29 TOF-SIMS spectra of BO2- fragments of functionalised chitosan F1-F4 
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Figure 3.30 TOF-SIMS spectra of boronic acid+ fragments of chitosan and functionalised 
chitosan F1-F4 
 
Figures 3.31 and 3.32 represents the total counts of C7BO2H8+ and BO2- for conjugate F1 to F4, 
the counts of ion fragments in the above conjugates increased as the degree of substitution of the 
FPBA on the chitosan increases. Figures 3.33 and 3.34 shows the colour of mapping of B+ and 
BH2O2+, the image brightness at each point is a function of the relative concentration of the 
mapped element or molecule. The brightness of the image increases as the concentration of 
BH2O2 fragment increase across the formulation F1 to F5, the lateral resolution is less than 0.1 
ȝP IRU HOHPHQWV DQG DERXW  ȝP IRU ODUJH PROHFXOHV ,PDJHV DUH DFTXLUHG WR YLVXDOLVH WKH
distribution of individual species on the surface and these chemical images are generated by 
collecting a mass spectrum at every pixel as the primary ion beam is rastered across the sample 
surface. The above data backs the FTIR showing that the degree of substitution of FPBA onto 
chitosan increases across as the initial amount of the FPBA aldehyde in the reaction is increased.  
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Figure 3.31 Total count of C7BO2H8+ fragments from F1 to F4 
 
 
Figure 3.32 Total count of BO2- from F1 to F4 
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Figure 3.33 B+ data mapping of chitosan and conjugates F1-F4 
 
 
Figure 3.34 BH2O2+ data mapping of conjugates F1-F5 
 
3.3.2.6 Energy Dispersive X-ray (EDX) of conjugate prepared by N-reductive alkylation 
EDX was carried out to further confirm the success of tagging of the boronic acid onto the 
chitosan. In the previous EDX analysis done on the conjugates prepared by electrostatic tagging 
(figure 3.9 and 3.10), the EDX showed that PBA was not tagged onto chitosan. EDX was done 
on different conjugates prepared by N-reductive alkylation to ascertain the degree of substitution 
of the boronic acid group onto chitosan in each of the formulation in the series. There was a 
detectable amount of boron in the carbon tape on which the samples were mounted and from 
table 3.10 and figure 3.35 the amount of boron in the carbon tape was about estimated to be 
about 6% (weight percentage).  
 
 
400
300
200
100
0
4002000ȝP
B+
MC:     3; TC: 2.910e+002
ȝP ȝP ȝP
400
300
200
100
0
4002000ȝP
B+
MC:     3; TC: 6.220e+002
ȝP ȝP ȝP
400
300
200
100
0
4002000ȝP
B+
MC:     3; TC: 8.720e+002
ȝP ȝP ȝP
400
300
200
100
0
4002000ȝP
B+
MC:     3; TC: 2.189e+003
2.8
2.4
2.0
1.6
1.2
0.8
0.4
0.0
ȝP ȝP ȝP
400
300
200
100
0
4002000ȝP
B+
MC:     3; TC: 3.123e+003
ȝP ȝP ȝP
ȝP
400
300
200
100
0
4002000ȝP
BH2O2+
MC:     7; TC: 9.282e+003
6.0
5.0
4.0
3.0
2.0
1.0
0.0
ȝP ȝPȝP
400
300
200
100
0
4002000ȝP
BH2O2+
MC:     7; TC: 9.158e+003
ȝP ȝPȝP
400
300
200
100
0
4002000ȝP
BH2O2+
MC:     7; TC: 3.213e+004
6
5
4
3
2
1
0
ȝP ȝPȝP
400
300
200
100
0
4002000ȝP
BH2O2+
MC:     7; TC: 4.062e+004
6
5
4
3
2
1
0
ȝP ȝPȝP
400
300
200
100
0
4002000ȝP
BH2O2+
MC:     7; TC: 7.228e+004
6
5
4
3
2
1
0
ȝP ȝP
Chitosan F1 
F1 
F2 F3 F4 
F2 F3 F4 F5 
120 
 
Table 3.10 EDX of carbon tape 
Element Weight% Atomic% 
B K 6.41 7.41 
C K 75.44 78.47 
N K 0.00 0.00 
O K 17.98 14.04 
Al K 0.17 0.08 
Totals 100.00 
 
 
 
Figure 3.35 EDX of carbon tape 
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Table 3.11 EDX of conjugates prepared by N-reductive alkylation 
Conjugate Element Weight% Atomic% 
 
 
F1 
B K 10.95 13.06 
C K 54.65 58.69 
N K 5.59 5.15 
O K 28.44 22.92 
Al K 0.37 0.18 
 
 
 
F2 
B K 8.62 10.35 
C K 56.38 60.91 
N K 4.19 3.88 
O K 30.43 24.68 
Al K 0.28 0.13 
Si K 0.10 0.05 
 
 
F3 
B K 8.08 9.75 
C K 57.55 62.46 
O K 33.74 27.49 
Al K 0.62 0.30 
 
 
F4 
B K 9.59 11.43 
C K 60.02 64.36 
O K 29.59 23.82 
Na K 0.16 0.09 
Al K 0.64 0.30 
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F5 
B K 9.55 11.39 
C K 58.05 62.32 
N K 2.87 2.64 
O K 29.05 23.41 
Na K 0.11 0.06 
Al K 0.37 0.18 
 
 
 
F6 
B K 9.42 11.26 
C K 57.51 61.88 
N K 3.15 2.91 
O K 29.22 23.60 
Na K 0.14 0.08 
Al K 0.56 0.27 
 
From above table 3.11, the amount of boron measured increased in the conjugates in contrast to 
boron content in the plain carbon tape (table 3.9, figure 3.35) and this proves that there is an 
increase in the amount of a substituents that contributes to the increase of the concentration of 
carbon and this is in all likelihood is PBA. However the amount of boron does not appear to 
show any increasing pattern as expected and this might be due to the fact that the scanning of the 
samples during EDX is limited to the surface of the sample and amount of element picked is 
determined by the area being scanned and therefore the concentration of the element being 
determined in that sample in that specific area may not be a true representation of the entire 
elemental concentration within the sample. Since the scan is mainly limited to the surface of 
mounted sample, inner residing elements may not contribute to the analysis. We believe this is 
the source of the apparent lack in trend in the presence of Boron element in the samples. 
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3.4 CONCLUSION 
The electrostatic tagging of PBA onto chitosan was not feasible. Functionalising chitosan with 
PBA was achieved via N- reductive alkylation and the conjugates were easily purified from 
excess reactants by washing with methanol, ethanol and water. The procedures used in the 
washing also affected the physical appearance of the functionalised chitosan which makes the 
conjugate either amorphous or crystalline. The process of centrifugation used in the recovery of 
the conjugates was better because higher yield was observed and there was minimisation of 
contamination and loss. Freeze-drying is also the best method for drying the conjugate other than 
in vacuo. 
The characteristic FTIR spectra of the conjugates as compared to chitosan proved that the 
boronic group had been introduced and the DSC thermograms, though not conclusive gave 
information on the pure reactants and that of the new and showed that the conjugates produced 
were different from the physical admixture of chitosan and FPBA and also the purification 
process used was optimum after the synthesis of the new conjugate. The results from the EDX 
reflected an increase in the boron content more than the traces picked on the carbon tape further 
proved that another group had been introduced onto chitosan. The EDX was a qualitative tool 
and not a quantitative tool in this instance, since the results did not reflect the increasing amount 
of the boronic acid group in each conjugate. The TOF-SIMS data shows the trend of increment 
as the amount of boronic acid is increased in each formulation. The tagging of the boronic acid 
group onto chitosan was therefore successful and the functionalised chitosan has been rightly 
characterised by employing different analytical techniques and equipments. In the subsequent 
chapters, attempts would be made at further characterising the conjugates and then fabricating 
into nanoparticles accordingly. 
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CHAPTER 4 
GLUCOSE ADSORPTION CAPACITY OF THE CONJUGATES 
4.1 Introduction 
Boronic acids have been used in the development of feedback controlled drug delivery polymers 
as saccharide sensors and their potential applications pharmaceutically have been widely 
explored (Yang et al. 2003).  
Matsumoto et al. (2002) synthesised a novel chitosan gel modified by phenylboronate for the 
selective adsorption of glucose and these gels were synthesised via N-reductive alkylation and by 
the introduction of the phenylboronate by amide formation and their glucose adsorption 
capacities were determined. In an observation made by the group, the conjugates synthesised via 
N-reductive alkylation selectively adsorbed glucose whilst those produced by the introduction of 
the phenylboronate group by amide formation did not. The m-acrylamidophenylboronic acid 
needed for the amide reaction had to be synthesised and its microspheres were chemically 
unstable. Functionalised chitosan synthesised via N-reductive alkylation could easily be prepared 
with readily available commercial compounds and the resulting conjugates were chemically and 
physically stable. In the light of the above, the N-reductive alkylation method of introducing the 
phenylboronate onto chitosan was adapted and pursued in the present work as discussed in 
chapter 3.  
The glucose adsorption capacities of the PBA functionalised chitosan were ascertained with the 
idea of correlating their glucose adsorption capacities to their potential glucose sensitivity and 
selectivity when used as sensors in a glucose responsive insulin delivery system. The adsorption 
capacity study was done to aid the selection of the conjugate(s) that would be further formulated 
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into a glucose responsive nanoparticulate insulin delivery system, since there was a possibility of 
correlating the glucose adsorbing capacity sensitivity of the functionalised chitosan to its 
potential use as a glucose sensor in the nanoparticulate delivery system. 
The glucose adsorption capacities of the conjugates were determined by an HPLC method 
adapted from Lee et al. (2004). Glucose cannot be detected spectrophotometrically by ultra-
violet (UV) light so the hexokinase reaction was used as an indirect way of quantifying glucose.  
In this reaction the glucose is converted to phosphogluconate and nicotinamide adenine 
dinucleotide in the reduced from (NADH) in the presence of the enzyme hexokinase, the NADH 
can then be quantified spectrophotometrically at 340 nm. The amount of NADH produced in the 
reaction is directly proportional to the initial amount of glucose (figure 4.1).  
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Outline of glucose conversion to detectable NADH using the hexokinase reagent.  
 
 
 
 
HK= Hexokinase in reagent 
G6PDH = Glucose-6-phosphate dehydrogenase in reagent  
ATP/ATP = Adenosine triphosphate/Adenosine 
diphosphate 
NAD = Nicotine adenine dinucleotide in reagent 
ADP 
HK 
Glucose ATP from reagent Glucose-6-phosphate 
Glucose-6-phosphate NAD 6-phosphogluconate H+ 
NADH 
G6PDH 
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4.2 Materials and equipment 
Functionalised chitosan (Chapter 3), HPLC grade acetonitrile and methanol, purchased from 
Thermofischer Scientific New Jersey, USA, Glucose hexokinase reagent set (Pointe Scientific 
Inc. USA), Type one ultrapure Milli-Q® ZDWHU  RKPV DW Û& '-glucose (R&M 
Chemicals). All other chemicals were of reagent grade.  
HPLC system (PerkinElmer, Shelton, Connecticut, USA), Phenomenex Jupiter C18 column, 5 um 
with pore size 300Å, Beckman Coulter Microfuge 16 centrifuge and WiseCube WIS-20, precise 
shaking incubator, Sartorius basic pH meter PB-11. 
4.3 Methods 
4.3.1 HPLC analyses 
The HPLC solvent system used consisted of 20 mM potassium dihydrogen phosphate (KH2PO4) 
solvent A and acetonitrile solvent B. The solvent composition was 95% of A and 5% of B, at a 
flow rate of 1 ml/min at a detection wavelength of 340 nm. The column used was a Phenomenex 
Jupiter C18 with pore size of 300Å. 
The calibration curve was constructed from glucose solutions between 0.25 mg/ml ± 10.00 
mg/ml. Prior to injection into the HPLC system, 1 ml of glucose hexokinase reagent was 
measured into a 1.5 ml tube and 10 µl of various concentration of glucose was added and 
incubated for 10 minutes at room temperature and then 20 µl of the above solution was injected 
into the HPLC system. A graph of average peak area was plotted against concentration and the 
coefficient of determination (R2) and the equation of the line determined. Each reading was done 
in triplicate. 
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4.3.2 Determination of optimum complete reaction time for hexokinase reagent and glucose 
10 µl of the 1 mg/ml D-glucose solution was reacted with 1 ml of the hexokinase reagent and the 
reaction was allowed to go on for different times between 2-30 minutes and 20 µl of the reacted 
glucose converted to NADH was injected into the HPLC system (PerkinElmer, Shelton, 
Connecticut, USA) and the peak areas determined. The peak areas were converted to mass (using 
the calibration curve) to find the exact amount of glucose reacted at a specified time and hence 
the optimum time for complete reaction determined from data. Each experiment was done in 
triplicate. 
 
4.3.3 Correlating the amount of glucose adsorbed as a function of pH using the 
functionalised chitosan conjugate (F3) 
4.3.3.1 Preparation of buffers  
Buffers were prepared according to the USP method for preparing a simple phosphate buffer, 
namely, a stock solution of 1000 ml of 0.2 M potassium phosphate was prepared by dissolving 
27.22 g of monobasic potassium phosphate (mw = 136) in 18  millipore water. A stock solution 
of 1000 ml of 0.2 M NaOH was made by dissolving 8.0 g of NaOH pellets in Millipore water. 50 
ml of the 0.2 M potassium phosphate solution was then measured into a 200 ml volumetric flask. 
Depending on the desired pH a specific volume of NaOH 0.2 M was added (table 4.1) before 
making up to 200 ml volume with millipore water.  
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Table 4.1 Volumes of NaOH required for making phosphate buffer solutions at various pH 
(USP)  
Desired pH 5.8 6.0 6.2 6.4 6.6 6.8 7.0 7.2 7.4 7.6 7.8 8.0 
Volume of NaOH 
(ml) to be added 
3.6 5.6 8.1 11.6 16.4 22.4 29.1 34.7 39.1 42.2 44.5 46.1 
Based on this method buffers at pH 6.0, 6.4, 6.8, 7.2, 7.4, 7.6, 8.0 were made up and the actual 
pH of the buffer was then recorded using the Sartorius basic pH meter PB-11. 
 
4.3.3.2 Correlating the amount of glucose adsorbed by F3 conjugate as a function of pH 
The adsorption of glucose by 20 mg of F3 was determined by dispersing conjugate in 1 ml of 1 
mg/ml glucose and the amount of glucose adsorbed over a 2 hour period at pH of 6.4, 7.4 and 
8.33 were recorded (as per method in section 4.3.2). The adsorption of glucose after 30 minutes 
was also monitored at recorded pH of 6, 6.40, 7.10, 7.4 and 8.33.  
The amount of glucose adsorbed onto the conjugate was calculated based on the difference in the 
peak areas of NADH obtained from the initial 1 mg/ml glucose buffer without conjugate and the 
glucose buffer after its exposure to the conjugate. Each experiment was done in triplicate. 
 
4.3.4 Glucose adsorption of conjugates 
10 µl aliquot of the glucose solution (unexposed to conjugate) was reacted with the hexokinase 
reagent for 10 minutes and 20 µl of the resulting solution was injected into the HPLC to 
determine the baseline of glucose concentration. 5 ± 40 mg of conjugate was weighed and 
dispersed in 1 ml of 1 mg/ml glucose solution buffered at various pH. The sample was then 
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equilibrated in the WiseCube WIS-20, precise shaking incubator at a speed of 100 rpm and at 
predetermined time intervals 50 µl supernatant glucose solution was isolated by centrifugation at 
14000 rpm for 2 minutes. 10 µl of this supernatant glucose solution was reacted with the 1 ml of 
the hexokinase reagent and 20 µl of the reacted sample was injected into the HPLC 
(PerkinElmer, Shelton, Connecticut, USA). The amount of glucose adsorbed was determined by 
subtracting peak area of the buffered glucose solution after exposure to conjugate from the initial 
peak area of glucose before exposure to the conjugate and further calculations done using the 
calibration curve. Each experiment was done in triplicate. 
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4.4 RESULTS AND DISCUSSION 
4.4.1 The glucose hexokinase reaction for the quantification of glucose 
In the hexokinase reaction, adenosine triphosphate (ATP) is consumed when glucose is 
converted to glucose-6-phosphate and the ATP to adenosine diphosphate (ADP) in the presence 
of the enzyme hexokinase (HK). In the presence of NAD the enzyme glucose-6-phosphate 
dehydrogenase (G6PDH) oxidises glucose-6-phosphate to 6-phosphogluconate which in turn 
becomes reduced to NADH. The increase in NADH concentration is directly proportional to the 
glucose concentration. The formation of NADH causes an increase in absorbance at 340 nm and 
this increase is directly proportional to the amount of glucose in the sample.  
 
Figure 4.2 Calibration curve for the glucose hexokinase reaction 
A calibration curve (figure 4.2) constructed by plotting the average peak area with the glucose 
concentration gave a calibration curve with good linearity which is reflected by the coefficient of 
determination (R2) value of 0.999.  
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Two clearly resolved peaks were obtained in each chromatogram, one for a component of the 
hexokinase reagent (at 5.8 minutes) and the other for NADH (at 6.1 minutes) the area of which is 
directly proportional to the concentration of glucose in the sample (figure 4.3). 
 
Figure 4.3 HPLC chromatogram showing peaks of NADH and hexokinase reagent 
 
The hexokinase glucose reaction is an enzymatic reaction and since this method is an indirect 
way of quantifying the amount of glucose in solution, it will be expedient to have a complete 
reaction before the NADH is detected by HPLC, so that any errors due to incomplete reaction in 
the quantification process can be avoided. The molar ratio of glucose conversion to NADH is 1:1 
and therefore an incomplete reaction will lead to errors in the quantification of glucose present. 
In the light of the above observation, the optimum reaction time for the complete glucose 
hexokinase reaction was determined by profiling the amount of glucose converted to NADH at 
specific times of reactions for a 1 mg/ml solution of glucose.  
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Figure 4.4 shows that, the complete conversion of glucose to NADH was before 10 minutes and 
this implies that a reaction time of 10 minutes was enough or optimum for a complete reaction 
before the sample was injected into the HPLC system. Therefore, a 10 minute reaction time was 
used for glucose hexokinase reaction prior to injection of samples into the HPLC system. The 
rate of an enzyme catalysed reaction depends directly on the proportion of the enzyme (Tzafriri 
2003), in the current reaction the ratio of reagent to glucose used for the reaction was 100:1 and 
therefore the substrate concentration was very low and this implies that the reaction would be 
completed in a short time.  
 
Figure 4.4 Amount of glucose converted to NADH over time 
The Michaelis-Menten model for enzyme kinetics presumes a simple 2-step reaction: where step 
1 involves the binding of substrate to the enzyme and step 2 being catalysis which is the 
substrate conversion to product and the initial amount of enzyme for a specific substrate if high, 
leads to a high turnover of product and also increases the velocity of the reaction (Tzafriri 2003). 
In this regard, the less amount of substrate present in comparison to the amount of enzyme is also 
a possible explanation for the reaction going to completion in less time. Also, since all the 
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substrate which was glucose was consumed within the reaction, the amount of product (NADH) 
plateaued as seen in figure 4.4. 
The amount of detected NADH was stable over a 30 minutes period (figure 4.4), and this implied 
that, the products formed after the enzymatic reaction were stable and did not break down. Hence 
samples reacted earlier could also be quantified accurately, thus widening the time frame within 
which accurate quantification of the NADH could be done.  
 
4.4.2 The effect of pH on the glucose adsorption capacity of the conjugates 
For boronic acid to bind to diols, it is commonly believed that the higher the pH of the medium, 
the higher the binding constant between the boronic acid and the diol. Also other researchers 
suggest that the optimal pH for binding of a boronic acid to a diol must always be above the pKa 
of the boronic acid. The delivery system being developed in the present study is meant to be used 
at physiological pH and ideally the PBA in this system should be able to bind to glucose and 
cause the needed reaction which will lead to drug release at physiological pH. Therefore the 
correlation between the amount of glucose adsorbed on the conjugate and pH was studied by 
quantifying the amount of glucose adsorbed by F3 at different pHs.  
At pH below 7 (figure 4.5), low glucose adsorption occurred with only 0.12 mg being adsorbed 
after 30 minutes at pH 6.40, lower pH of 6.0 showed even less adsorption of glucose. The low 
adsorption of glucose by F3 at the pH below 7 was related to the fact that at pH < 7, the pH of 
the system was below the pKa of 4-FPBA as calculated by Yan et al. (2004) to be 7.6. Although 
this value may be affected by conjugation to chitosan, gross deviation is unlikely as chitosan is 
neither strongly electron withdrawing or donating. At pH below the pKa, the boronic acid groups 
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will be in their protonated unionised form and therefore in a less favorable conformation for 
binding to glucose, hence the adsorption of glucose by conjugate F3 being minimal at those pH 
(figure 4.5). 
 
Figure 4.5 Adsorption of glucose by conjugate F3 after 30 minutes. 
 
This agrees with a similar study by (Matsumoto et al 2002) which showed no adsorption of 
glucose by 4-FPBA chitosan conjugates in a similar adsorption study at pH 6.  
 
Figure 4.6 Adsorption of glucose by conjugate F3 over 120 minutes 
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Referring to figure 4.6, at pH 7.4 the quantity of glucose adsorbed increased over the two hour 
period peaking with 0.67 mg adsorption after 2 hours and the amount of glucose adsorbed at this 
pH was more than that adsorbed at pH 6.4 and 8.33 at equivalent time points and this supports 
data from figure 4.5 which shows optimum adsorption of glucose at pH 7.4 with 0.40 mg glucose 
adsorbed after 30 minutes. Clearly, at pH closer to the pKa of 4-FPBA the boronic acid groups 
can become ionised taking up a favourable conformation for glucose binding, hence glucose is 
adsorbed. This appears to be in disagreement with data from Matsumoto et al. (2002), as in their 
study, 4-FPBA gels could only adsorb glucose at pH in excess of pH 8. Work done by 
Springsteen et al. (2002) emphasised on the fact that the optimal pH for binding of boronic acids 
to diol was not always above the pKa of the boronic acid and that the nature, concentration of 
buffer and temperature could dramatically affect the boronic acid binding affinity. Whereas a 
buffer system based on potassium dihydrogen phosphate and sodium hydroxide at room 
temperature were used in this present study, the previous study by Matsumoto et al. (2002) 
utilised a buffer system based on potassium hydrogen phthalate solution and potassium 
K\GUR[LGHVROXWLRQDWÛ&+HQFHWKHUHVXOWVLQWKHSUHVHQWZRUNPD\KDYHGLIIHUHGIURPUHVXOWV
presented by Matsumo et al. (2002) because of the difference in experimental set ups. 
 In view of the above results it is important to note that, the binding affinity of a boronic acid at a 
given pH to a diol is not simply determined by the pKa of the boronic acid but also the nature of 
the buffers, solvent systems  and temperature used in the study, taking also into consideration the 
nature of the different chemical groups bonded to the boronic acid (Springsteen and Wang 2002). 
At a higher 8.33, the conjugate F3 could still adsorb about 0.23 mg of glucose after 30 minutes, 
but unexpectedly the amount of glucose adsorbed was less than the amount adsorbed at pH 7.4. 
At higher pH more of the boronic acid groups were expected to be ionised and so should be able 
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to bind more glucose. However from figures 4.5 and 4.6 it can be seen that less amount of 
glucose was adsorbed at pH above 8.  In a detailed examination of boronic acid and diol binding 
by Springsteen et al. (2002) using the binding of Alizarin red (AR) with PBA as function of pH, 
they observed that, the AR binding with PBA increased with increase in pH from 4 to 7 but 
began to drop at pH above 7. They concluded that, the maximum binding pH for their system 
was around 7 and anything above this pH resulted in less binding and this finding gives a 
possible explanation to the observed decrease in adsorption of glucose on F3 at pH above 7.4 in 
this current work. 
 
4.4.3 Comparative glucose adsorption capacities of functionalised chitosan conjugates 
The glucose adsorption capacities of the conjugates were determined by the use of the same 
glucose hexokinase reagent method described in section 4.3.1.1 and the glucose adsorption 
capacities of the conjugates were studied in order to correlate the adsorption of glucose to the 
sensitivity and selectivity of the conjugate. This would guide our selection from the conjugates 
for their further development into glucose responsive nanoparticulate insulin delivery systems.  
Different relationship exists between the binding of boronic acids and diols in relation to their 
pKa, pH and binding constants. The binding of boronic acids to diols are determined by various 
conditions and mostly these bindings are pH dependent. There is a general concept that the 
higher the pH of the medium, the higher the binding constant of the boronic acid and the diols, 
but this appears to be the case up to a point as observed in the present study.  
From the results of the pH study on the conjugate F3, a pH of 7.4 was used for the study  of the 
glucose adsorption by the conjugates (F1-F6). 
137 
 
Figure 4.7 is the adsorption curves of the different conjugate formulations which shows  that the 
amount of the glucose adsorbed is dependent on the type of conjugate in respect to their of 
degree of substitution with boronic acid.  
 
Figure 4.7 Glucose adsorption curves of the conjugates (F1-F6) compared 
There appaears to be a direct correlation between the  amount of boronic acid bonded chitosan 
with glucose adsorption sensitivity of F1, F2 and F3, conversely, the sensitivity to glucose 
adsorption on F4, F5 and F6 reduced in that order.  
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Figure 4.8 Adsorption of glucose as a function of the weight of conjugate 
 
There was also an increase in amount of glucose adsorbed on the conjugates as the amount of 
conjugate was increased (figure 4.8). An increase in the amount of conjugate presents an increase 
in the amount of boronic acid groups available for interaction with glucose and hence more 
interaction of glucose with boronic acid leads to increased glucose adsorption.  
In order to explain this unusual phenomenon whereby the highly boronic acid substituted 
conjugates showed the lowest adsorption propensity, the relationship between the surface 
topography and the degree of substitution was studied and used to correlate the adsorbing 
capacities of the conjugates. Visual examination of the various conjugates revealed that  F1 to F3  
had soft and fluffy textures, whilst F4 to F6 had coarse, gritty  and crystalline texture.  
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Furthermore, SEM examination (figure 4.9) of the conjugates showed that, conjugates F1 to F3 
had porous and spongy-looking surfaces whilst conjugates F4 ± F6 (figure 4.9) showed flat hard 
surface images which looked more crystalline than those in the F1 to F3 series.  
 
Figure 4.9 SEM images of conjugates F1 through F6. 
 
The surface interaction of the boronic acidic with the glucose will certainly rely on the 
availability of the boronic acid group for interaction. The hard and crystalline nature of F4-F6 
conjugates might have reduced the degree of interaction between glucose and the conjugates 
whilst the seemingly porous and fluffy nature of  conjugate F1 ±F3 might have contributed or 
promoted the interaction of boronic acid on them with glucose and hence the highest degree of 
adsorption exhibited by conjugates in this series. The seemingly porous nature of conjugates F1 
± F3 meant that the surface area available for interaction between glucose and the boronic acid 
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moiety was enhanced. Conversely, in the series F4 ± F6, fewer surfaces was available for 
interaction with glucose. 
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4.5 CONCLUSION 
The conjugates demonstrated glucose adsorption capacity, with F3 showing the conjugate 
showing highest adsorption propensity. It appears that, the surface nature and stereochemistry of 
conjugate plays a role in the adsorption process wherein. The presence of PBA also modified the 
appearance of the conjugates from porous matrices to crystalline ones with increasing PBA 
bonding. The crystalline conjugates were less sensitive to glucose adsorption due to 
inaccessibility of glucose to the PBA moiety. Thus, sensitivity to glucose adsorption by the 
conjugates appears to require an optimum content of boronic acid, beyond which crystalline 
domains form which reduces access to glucose. These results have clear implications for the 
development of glucose sensing and in particular for delivery systems based upon boronic acid-
tagged chitosan. 
In Chapter 5, conjugates F1, F3 and F5 (representing low, medium and high load of 
phenylboronic acid respectively) will be selected and formulated into nanoparticles. The size 
changes prompted due to exposure to glucose will then be investigated. It is presumed that size 
increase would precede release of any encapsulated drug, in the present case insulin. 
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CHAPTER 5 
DETERMINATION OF THE GLUCOSE RESPONSIVENESS OF FUNCTIONALISED 
CHITOSAN NANOPARTICLES 
5.1 Introduction 
Stimuli-responsive controlled-release systems have recently attracted much attention because of 
their potential applications in drug delivery. The incidence of diabetes mellitus is rising 
worldwide and is a condition that demands daily multiple injections (for type I diabetes) or oral 
therapy (for type II diabetes) to help maintain normal glycaemic levels (Kim et al. 2003). Due to 
the burden of multiple injections and associated trauma, much focus and attention have been 
directed to the development of glucose responsive insulin delivery systems which can respond to 
physiological glucose changes in the body and release insulin in return. 
In the development of glucose responsive insulin delivery systems different sensing mechanisms 
have been  proposed including those requiring the enzymatic reaction of glucose oxidase with 
glucose which causes the hydrogel to swell or shrink to release the encapsulated insulin (Kost et 
al. 2004; Kost and Langer 2001), or the of use of con A, a carbohydrate binding lectin formed 
into a matrix and used for the delivery of glycosylated insulin. Due to the preferential binding of 
glucose to con A, the release of the encapsulated insulin within the matrix is facilitated (Obaidat 
and Park 1996; Cefalu 2004; Brownlee and Cerami 1979).  
Recently the use of boronic acids as potential glycol sensors has also attracted attention due to 
their selective reaction with 1,2 and 1,3 cis- diols in aqueous medium and these boronic acids 
when incorporated into polymers renders them glucose sensitive. The reaction of boronic acids 
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with glucose in these polymeric vehicles causes structural changes within the polymer which 
leads to the release of the encapsulated insulin (Yang et al. 2003; Cambre and Sumerlin 2011).  
In the present project, our focus was on the development of glucose responsive nanoparticulate 
insulin delivery system out of the natural polymer chitosan which is biodegradable and 
biocompatible whilst employing phenylboronic acid as the sensing moiety. Figure 5.1 represents 
the proposed model for the release of insulin.  
 
Figure 5.1 Proposed model of insulin release from the nanoparticles  
Chitosan was functionalised with a phenylboronic acid group via N-reductive alkylation as 
described in chapter 4 and nanoparticles were produced using the ionotropic gelation method by 
cross-linking the functionalised with TPP. The glucose responsiveness of the nanoparticles was 
determined by the Nanosight nanoparticle tracking system (NTA). NTA is a technique that uses 
a laser light scattering microscopy coupled with a charged-coupled device (CCD) camera which 
enables visualisation and recording of nanoparticles in solution in real-time and an in-built 
software to identify and track individual particles moving under Brownian motion which then 
relates the movements to particle size.  
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Our aim was therefore to explore the potential of the NTA for the studies of the glucose 
responsive behaviour of the functionalised chitosan nanoparticles developed when they were 
exposed to different buffered sugar media. Size changes prompted by the addition of glucose 
were pursued and the mechanisms and findings are discussed. 
 
5.2 Materials 
PBA functionalised chitosan (F1, F3 and F5) were prepared as described in section 3.2.1.4. D- 
glucose and D-fructose were purchased from Sigma Aldrich (Missouri, USA); tripolyphosphate 
(TPP), 4-formylphenyl boronic acid, Dubelco phosphate buffered saline tablets and sodium 
borohydride from Thermofischer Scientific New Jersey, USA; acetic acid, methanol, acetonitrile 
were purchased from Thermofischer Scientific New Jersey, USA, Millipore 18  pure water. All 
other chemicals were of reagent grade. 
 Field emission scanning electron microscope (FESEM, Quanta 400F, FEI Company, USA), 
Nanosight LM 10 with LM 14 viewing (Nanosight, Amesbury, United Kingdom), Ultrasonicator 
(Vibra Cell, Sonics, VCX 750, USA). 
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5.3 Methods 
5.3.1 Preparation of functionalised chitosan TPP nanoparticles (FCTN) 
2.5 mg/ml of functionalised chitosan (F1, F3, or F5) were dissolved in 1% v/v acetic acid and 
stirred overnight and filtered. To 5 ml of each conjugate solution the required amount of filtered 
TPP (table 5.1) dissolved in water was added drop wise whilst ultrasonicating at amplitude of 
40% (300 Watts) over 1 minute. The resulting formulations were designated as FN1, FN3 and 
FN5. Freshly prepared samples were used each time for the glucose responsive study. 
Table 5.1 Ratios of TPP to functionalised chitosan used in the formulation of nanoparticles 
Formulation Ratio of TPP to functionalised chitosan 
FN1 1:3.0 
FN3 1:4.2 
FN5 1:5.0 
 
 
5.3.2 Characterisation of nanoparticles 
The z-average, Pdi and zeta potential of the FCTN were measured by photon correlation 
spectroscopy (PCS) (Zetasizer Nano ZS® (Malvern, UK) equipped with a 4Mw He- Ne laser 
(633 nm). Each analysis was carried out at 25oC and performed in triplicate and data expressed 
as mean ± standard deviation. 
Nanoparticle morphology was studied by mounting sample of nanoparticle in solution on carbon 
tape mounted on a metal stub and air-dried overnight at room temperature and examined on a 
Field Emission Scanning Electron Microscopy (FESEM). 
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5.3.3 Determination of glucose responsive propensities of PBA functionalised chitosan 
nanoparticles 
5.3.3.1 Standardisation of nanoparticle tracking equipment 
Different concentrations of glucose and fructose solutions in the concentration range of 0.1 
mg/ml - 5 mg/ml were prepared using filtered phosphate buffer pH 7.4. 
1 ml of buffer, glucose or fructose solution was measured into a small clean vial and 1 µl of 
polystyrene bead solution was added (1 in 1000 dilution was chosen because it gave particles 
concentration reading of 107-109/ml as required by the instrument for accurate measurement and 
analysis). Approximately 0.3 ml of the sample was injected into the viewing chamber (equipped 
with a 405 nm laser wavelength) with sterile syringe until the liquid reached the tip of the nozzle. 
All measurements were performed at room temperature. Videos lasting for 1 min 30 seconds 
were captured at 30 frames per second and analysed using the NTA software (figure 5.2 and 5.3). 
All measurements were performed at room temperature. The size distribution of the polystyrene 
beads in buffer and the different sugar media was studied and the distributions compared.  
The rate of particle movement is related to a sphere equivalent hydrodynamic radius as 
calculated through using the Stokes-EinsWHLQ¶VHTXDWLRQ 
       «««««(TXDWLRQ 
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Figure 5.2 Nanoparticle Tracking Analysis set up 
 
Figure 5.3 Schematic presentation of the operational mode of the NTA for size analysis 
(Malloy 2011) 
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5.3.3.2 Determination of glucose responsive behaviour of functionalised nanoparticles 
Different glucose solutions in the concentration range of 0.1 mg/ml-5 mg/ml were prepared in 
filtered phosphate buffer pH 7.4. 
1 ml of buffer or glucose solution was measured into a clean vial and 2-10 µl of the 
nanoparticulate suspension of each formulation (FN1, FN3 or FN5) was added to the plain buffer 
or buffered glucose solution and approximately 0.3 ml of the sample was injected into the 
viewing chamber (equipped with a 405 nm laser wavelength) with sterile syringe until the liquid 
reached the tip of the nozzle. Videos lasting for 1 min 30 seconds were captured at 30 frames per 
second and analysed using the NTA software. All measurements were performed at room 
temperature. 
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5.4 RESULTS AND DISCUSSION  
5.4.1 Formulation of functionalised chitosan TPP nanoparticle (FCTN) 
Chitosan-TPP nanoparticles have been studied by various groups in the delivery of drugs ranging 
from small (furosemide) to large molecules (proteins such as insulin) (Mao et al. 2006; Illum et 
al. 1994; AkbuᑈDDQG'XUPD]$NWDúet al. 2005). This polymer has also been modified by 
different groups to impart specific desirable properties onto it for the delivery of specific drugs 
or for the performance of specific functions. The modified chitosan may be used as such or 
formulated into micro or nanoparticles. The process of formulation normally depends mostly on 
the inherent polycationic nature of chitosan and its ability to form cross-links with other 
polyanions or negatively charged molecules (De Moura et al. 2008; Mourya and Inamdar 2009; 
Mao et al. 2006; Smoum et al. 2006; Prego et al. 2006).  
From the above works, the possibility of formulating nanoparticles from chitosan that has been 
modified by different groups is feasible and the feasibility of these methods has led to the 
exploration of chitosan modified by the attachment of phenylboronic acid as a potential for the 
development of glucose responsive nanoparticulate insulin delivery system. Matsumo et al. 
(2002) modified chitosan with a phenylboronic acid group via N- reductive alkylation and 
determined its ability to adsorb glucose and they observed that the chitosan maGH E\ 6FKLII¶V
base method adsorbed D-glucose and not 1-methyl-Į-D-glucoside. Since this functionalised 
chitosan made by N-reductive alkylation could selectively adsorb glucose, its potential as an 
insulin delivery vehicle could be explored. 
The focus of this project was therefore the formulation of functionalised chitosan prepared by the 
N-reductive alkylation into nanoparticles for the delivery of insulin and this nanoparticle was 
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expected to be glucose responsive because of the selectivity in the adsorption of glucose. The 
novelty in the present approach lies in the formulation of the functionalised chitosan with a 
phenylboronic acid prepared by the above mentioned method into nanoparticles as this has not 
been studied before. The formation of nanoparticles should ensure a faster reaction time or 
sensitivity with glucose due to the larger surface area to volume ratio. 
Figure 5.4 represents the SEM image of nanoparticles from formulation (FN3). It can be seen 
that the nanoparticles are spherical and well formed. 
 
Figure 5.4 SEM of PBA functionalised chitosan TPP nanoparticles (FN3) 
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Table 5.2 Z-average, Pdi and zeta potential of the different functionalised chitosan TPP 
nanoparticle 
Formulation Z-average (nm) Pdi Zeta Potential (mV) 
FN1 139.40 ±4.20 0.232±0.0078 21.06±0.18 
FN3 147.57±8.50 0.239±0.0101 20.30±0.35 
FN5 158.82±18.35 0.240±0.0058 20.46±2.45 
 
Nanoparticles produced by ultrasonication out of the selected conjugates had average sizes 
between 110-160 nm (table 5.2). The sizes of the nanoparticles normally depend on formulation 
and processing parameters such as pH of the polymer and the cross-linker solution, the initial 
amount of polymer and the amount of cross linker used as thoroughly studied in chapter 2. This 
implies that desirable nanoparticle size can be obtained by varying the initial parameters as stated 
above in the production of the nanoparticles. 
The Pdi of the different formulations was about 0.2 (table 5.2), values closer to 0 have been 
reported to be an indication of homogeneity and the data above shows that the formulations have 
some degree of homogeneity. Sizes of nanoparticles in a formulation can be in the nanometre 
range but one must bear in mind that the interparticulate difference is of much importance also, 
because a wide variability within the particle sizes may affect the drug loading and drug release 
of the delivery system. 
Zeta potential values of chitosan-TPP nanoparticles are normally positive due to the positive 
charge contribution from the amine groups in chitosan. Not surprisingly, the zeta potential of the 
boronic acid-functionalised chitosan nanoparticles was about +20 mV (table 5.2) and the positive 
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magnitude is a result of the positive charge density from the amine groups of the chitosan. The 
zeta potential values obtained from the boronic acid-functionalised chitosan were however lower 
due to substitution of some of the amine groups in chitosan with the boronic acid. 
 
5.4.2 Nanosight tracking analysis on the glucose responsive behaviour of the boronic acid-
functionalised nanoparticles 
Nanoparticle Tracking Analysis (NTA) is a unique methodology for visualising nanoparticles in 
suspension and the high resolution particle size against concentration distributions are derived 
through image analysis. The particle size is calculated using the Stokes-Einstein equation 
(equation 5.1). Its mode of particle size determination overrides some of the inherent errors and 
constraints in dynamic light scattering mode of particle size determination. The major 
advantages this technique presents for the measurement of particle size over that of dynamic 
light scattering (DLS) or photon correlation spectroscopy) is that, the latter has the inherent 
weaknesses of being heavily skewed towards the larger particles in the particle size distributions 
of a sample. This is due to the fact that DLS is strongly influenced by the intensity of light 
scattered from a particle and as such larger particles scatter significantly more light than smaller 
particles and the scattered light obscures the signal from the smaller particles. NTA on the other 
hand works by tracking the movement of each particle on a particle-by-particle basis and relates 
the degree of movement to the sphere-equivalent hydrodynamic diameter thus the biasing 
observed in DLS is overcomed. NTA also provides real-time monitoring of the subtle changes in 
the characteristics of particle populations with all of these analyses uniquely captured by visual 
validation. 
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With this idea in mind the NTA was used to study the behaviour of FCTN in different glucose 
concentration media and the certainty was that even minimal changes in the particle size as 
determined by the nature of the medium in which the particles were subjected to could be 
detected. 
NTA requires several optimisation steps in order to be able to reproduce, capture and analyse the 
videos obtained for accurate size distribution determination. Therefore the effect of the 
concentrations of the buffers used was investigated on standard polystyrene beads. If size 
changes prompted by the nature of the buffers were seen in these polystyrene beads, then errors 
in the size profiles of the responsive nanoparticles was a possibility. From figure 5.5 it can be 
seen that the size of the standard 200 nm polystyrene beads in the different media did not show 
any changes. This implies that, the nature of the media has no effect on the size of these standard 
particles and hence any size distribution changes in our formulation when exposed to the 
different media would mainly be a result of the components of the nanoparticle reacting with the 
components of the buffer system.  
 
Figure 5.5 Size responses of standard 200 nm polystyrene beads in various media 
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One important parameter on the NTA software is the detection threshold. The effect of the 
detection threshold on the size distribution of standard polystyrene beads was also ascertained so 
as to know the right detection threshold to set for the detection of the functionalised 
nanoparticles. Wrong setting of the detection threshold can exclude some particles from the 
analysis by the NTA software. The sizes of standard 200 nm polystyrene beads were determined 
at different detection thresholds, the higher the threshold, the higher the probability that very 
small particles will not be counted and also very low detection threshold will result in the picking 
up noise and particle flurrying as particles and introduce error in the data analysis.  
The size distribution of 200 nm polystyrene beads was analysed using different threshold of 
detection values and its effect of the mean particle sizes was compared. It can be seen from 
figure 5.6 that the detection threshold did not have significant effect on the average size of the 
polystyrene beads and the size of polystyrene beads did not change. This was not directly 
applicable to our sample.  
 
Figure 5.6 Size of standard 200 nm polystyrene determined at various detection thresholds 
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Laser scattering by colloidal polymeric nanoparticles such as FCTN are not intense as compared 
to that of polystyrene beads, so this implies that detection of polystyrene beads will be easier on 
the nanosight than detection of colloidal particles. Hence not all parameters optimised for 
studying the polystyrene beads distribution in the different media in this current experiment was 
directly applicable to the FCTN colloidal nanoparticles. In this regard, separate definite 
parameters were optimised for the colloidal nanoparticles so that instrumental errors due to 
wrong parameter settings when analysing the videos could be avoided. In the light of the above 
raised issues, the processing parameters for each video captured for the FCTN nanoparticles 
were carefully optimised to help in the accurate analysis of each of the videos. 
The FCTN formulations also exhibited unique characteristics as their videos were captured and 
analysed, for example it was very challenging capturing and analysing videos for chitosan-TPP 
nanoparticles, but it was relatively easier with FCTN. The highest light intensity was used when 
capturing videos for formulation FN1 but the intensity had to be lowered when capturing for 
FN3 and FN5. In this regard, it could be concluded that, the degree of functionalisation of the 
conjugate also affected the light diffracting properties of their respective nanoparticulate 
formulations.  
The introduction of the PBA moiety onto chitosan was expected to make the functionalised 
chitosan nanoparticles glucose sensitive, therefore an experiment was designed to ascertain the 
changes that occur in nanoparticles in response to different glucose concentration as the external 
media. The average normal post prandial blood glucose level of a human being is around 1.4 
PJPO³%ORRGVXJDUOHYHOUDQJHVDQGWKLVLPSOLHVWKDWDQ\PRGHORIDJOXFRVHUHVSRQVLYH
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insulin delivery system must be able to sense and release insulin at glucose concentration above 
1.4 mg/ml and not concentrations lower. 
In these series of experiments, FCTN was introduced in to plain buffer and glucose buffer (0.1± 
5 mg/ml) at pH 7.40. A wide range of glucose concentrations was selected and studied to help 
ascertain the behaviour of the functionalised nanoparticulate formulation at, below and above 
physiological blood glucose concentration. Three different formulations FN1, FN3 and FN5 
prepared via ionotropic gelation were studied for their behaviour in different concentrations of 
glucose media. Considering fact that the required physiological blood glucose concentration 
targets for non-diabetic and diabetic must be maintained at 0.72-1.6 mg/ml (table 5.3), it will be 
expedient that none of the aforementioned formulations show any significant response to low 
concentrations of glucose.  
Table 5.3 Target levels of blood glucose for diabetic and non-diabetic patients  
Target Levels Pre-prandial glucose 
concentration (mg/ml) 
Post prandial glucose 
concentration (mg/ml) 
Non - diabetic 0.72-1.06 Under  1.40 
Type I 0.72-1.26 Under 1.53 
Type II 0.72-1.26 Under 1.62 
(http://www.diabetes.co.uk/diabetes_care/blood-sugar-level-ranges.html) 
Across all the formulations investigated none showed any size changes due to glucose at 
concentrations below 1 mg/ml. Figures 5.7 -5.11 are a representative and comparative size 
distribution profiles of the three selected formulations used to study the behaviour of the 
functionalised nanoparticles in the presence of plain buffer and glucose. The data shows that the 
nanoparticles under study were not responsive to glucose at the low glucose concentration and 
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this was desirable because the system being developed in this current project was purported to 
show significant response at glucose concentration above 1.4 mg/ml at which patients were 
considered diabetic. 
FN1 among the series showed the least responsiveness to glucose at the different concentrations 
of glucose, possibly because the amount of boronic acid substituted on F1 was less that on FN3 
and FN5 as seen from the elemental analyses results in table 3.8 (chapter 3). The lower amount 
of boronic acid substitution meant less interaction with glucose and hence less size changes in 
the particle matrix on interaction with glucose producing less change in the size distribution 
profile (figure 5.7). 
 
Figure 5.7 Particle size distribution of formulation FN1 after exposure to phosphate buffer 
and 1 mg/ml phosphate buffered glucose solution. 
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A histogram of size of distribution at different percentiles determined for the formulation FN1 
(figure 5.8) showed that no significant changes were seen in the percentiles for glucose 
concentrations at 1 mg/ml to 5 mg/ml. This data was also in support of the fact that the lower 
degree of substitution of boronic acid in F1 caused it to be less responsive to glucose, which is 
also in concert with the results from the adsorption studies in section 4.4.3, where F1 showed the 
lowest glucose adsorption. 
 
Figure 5.8 Percentiles of size distribution from FN1 in various concentrations of glucose  
 
From the adsorption studies on conjugates in chapter 4 (section 4.43), F3 showed the highest 
glucose adsorbing capacity than F5 and we correlated the surface topography, crystallinity and 
possible orientation of the boronic acid within the conjugate to their glucose adsorbing 
capacities. The adsorption study was done using the solid powdered conjugates and therefore it 
was not automatic that the behaviour of the nanoparticulate formulations will follow the same 
trend as the solid conjugates. It would have been interesting to relate the behaviour of the solid 
conjugates directly with those of the nanoparticles made from them, although there was no 
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guarantee that exposure of the boronic acid to glucose within the nanoparticulate matrix in 
suspension and that of the solid conjugate will be directly related or exhibit the same behaviour. 
Hence F5 which showed a lower glucose adsorption capacity than F3 was also studied on the 
nanoparticulate level for its glucose responsiveness. F3 and F5 in the experiment showed size 
changes on interaction with glucose especially at a 2.5 mg/ml concentration (figure 5.9 and 
5.10).  
 
Figure 5.9 Particle size distribution of formulation FN3 after exposure to phosphate buffer 
and 1 mg/ml, 2.5 mg/ml and 5 mg/ml phosphate buffered glucose solution. 
 
Figure 5.10 Particle size distribution of formulation FN5 after exposure to phosphate 
buffer and 2.5 mg/ml phosphate buffered glucose solution. 
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The histogram (figure 5.11) of the different percentiles of FN3 on exposure to different 
concentrations of glucose shows changes in the percentiles indicating that the particles gradually 
increased in size as they interacted with glucose. 
 
Figure 5.11 Percentiles of size distribution from FN3 in phosphate buffer and various 
concentrations of glucose 
 
Though the different formulations have their characteristic properties, the changes in their size 
distribution profiles upon interaction with 2.5 mg/ml of glucose could not be over emphasised. It 
is evident that the statistics of the nanoparticles behaviour changes as the concentration of 
glucose changes. Though these changes might be small, they are significant because, these 
changes results from the behaviour of individual particles as they are tracked by the NTA, hence 
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An increase in the specific percentage percentiles of the particle size across the different 
concentration of glucose as compared to that of the plain buffer (table 5.4) also proves that the 
presence of glucose does effect the particle size changes in the nanoparticles. 
The responsive behaviour of polymeric nanoparticles is considered as a combination or sequence 
of several events: reception of an external signal (physical or chemical) followed by chemical 
reaction of the material or changes of the material's properties to release the encapsulated drug 
(Motornov et al. 2010). It is expected that, under normal circumstance nanoparticles which are 
glucose responsive demonstrates continuous size increase in their size distribution profile in the 
presence of increased amounts of glucose, but this was not so with the FCTN when they were 
exposed to increased concentrations of glucose. The size distribution profiles representing 
nanoparticles exposed to 5 mg/ml glucose did not show continuous increase in size in 
comparison with those exposed to glucose concentration of 2.5 mg/ml (figure 5.9 and 5.10) and 
this observation was made across all the formulations studied. The possible inference will be 
that, the nanoparticles under development have glucose dependent swelling ability, but this 
swelling ability is significantly affected by the concentration of glucose of the medium. Work 
done by Alexeev et al. (2003) suggests that, at high glucose concentration a bidentate complex is 
formed between the glucose and the boronic acid derivatives. In view of the bidentate binding of 
glucose by two boronic acid moieties, the glucose molecule in itself can act as a cross-linker and 
hence impede swelling (Asher et al. 2003; Jin et al. 2009; Alexeev et al. 2003). Results 
presented here therefore reinforce the above observation by Asher et al (2003). This glucose 
mediated cross-linking of the nanoparticle by glucose explains the decrease in size of 
nanoparticles at glucose concentration of 5 mg/ml in contrast to an increase in size at 2.5 mg/ml. 
From the above, it is apparent that the more boronic acid groups present within the nanoparticles, 
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the higher the chances of these groups interacting with glucose and the better the manifestation 
of the bidentate knitting of the nanoparticle matrix with glucose. This explains the constrained 
size increase in FN5 (figure 5.12) compared to that observed in FN3 or FN1. 
 
Figure 5.12 Particle size distribution of formulation FN5 in buffer and 5 mg/ml phosphate 
buffered glucose solution  
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5.5 CONCLUSION 
Chitosan was successfully functionalised by boronic acid and nanoparticles were successfully 
formulated out of the functionalised chitosan via ionotropic gelation using ultrasonication and 
these nanoparticles have exhibited a glucose responsive behaviour. However, the increase in the 
size of the nanoparticles was dependent on both the amount of boronic acid groups present 
within the nanoparticles and also the concentration of glucose. The glucose acts as a cross-
linking agent when its concentration is high and also when the boronic acid substitution within 
the nanoparticulate matrix increases. 
In the subsequent chapter an attempt would be made to encapsulate insulin in the functionalized 
chitosan TPP nanoparticles matrices in the process of the fabrication of the nanoparticle and an 
attempt will be made to correlate the size changes as studied in this chapter with the amount of 
insulin released in different sugar media at physiological pH. 
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CHAPTER 6 
ENCAPSULATION AND RELEASE OF INSULIN FROM FUNCTIONALISED 
CHITOSAN NANOPARTICLES 
6.1 Introduction 
Drug delivery involving the use of polymers has attracted much attention in recent years; in this 
regard the choice of polymers is often tailored to meet specific physiological challenges. Both 
biodegradable and non-biodegradable polymers have extensively been researched into and these 
polymers can be either synthetic or natural. Ideally a polymer for drug delivery must be 
biocompatible, biodegradable and easily modified for specific functionalities.  
Of interest to the current project is the chitosan polymer, which a polysaccharide derived from 
the alkaline deacetylation of chitin, a natural cellulose derivative from crustaceans such as 
shrimps and crabs. It is mucoadhesive, enhances permeation of biomolecules across the epithelia 
and does not cause mucosal damage (Kumar 2000). Chitosans have been formulated into 
different pharmaceutical dosage forms such as beads, microparticles and nanoparticles and out of 
the above mentioned; nanoparticles have perhaps the widest applications in medicine. 
It is possible to modify the chemical properties of chitosan by adding specific moieties and these 
chemical moieties may be tailored to achieve specific drug delivery outcomes. The concept of 
imparting stimuli responsive properties onto chitosan has also been pursued widely. For example 
chitosan as a pH responsive hydrogel (Goycoolea et al. 2003; Lin et al. 2009; Shantha and 
Harding 2000) or  chitosan as a glucose responsive polymer by functionalising with glycol 
sensors such as con A (Yin et al. 2010),  glucose oxidase (Wu et al. 2009) and boronic acids (Wu 
et al. 2011). 
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Micro and nano encapsulation methods have recently drawn attention as an attractive method for 
drug formulation since these delivery systems offer several advantages over conventional 
delivery systems.  Site-specific drug delivery, controlled release, minimising side effects and 
protection of sensitive drugs (McGee 1995) are few of such attributes. Different methods have 
been employed in encapsulating proteins and peptides into chitosan nanoparticles and these 
methods include ionotropic gelation (Fernández-Urrusuno et al. 1999), polyelectrolyte 
complexation (Mao et al. 2006) and layer - by- layer adsorption ( Fan et al. 2006). 
Encapsulation of insulin into chitosan tripolyphosphate (TPP) nanoparticles via ionotropic 
gelation has been extensively studied and its feasibility has been proven beyond doubt. Trimethyl 
chitosan nanoparticles have also been formulated incorporating insulin using ionotropic gelation 
and polyelectrolyte complexation (Yin et al. 2009). Chitosan functionalised by an amino boronic 
acid has also been formulated into nanoparticles with insulin via polyelectrolyte complexation 
(Wu et al. 2011). 
In the present project, exploration of the formulation of functionalised chitosan (chitosan 
phenylboronic acid conjugates) into glucose responsive nanoparticles employing ionotropic 
gelation and polyelectrolyte complexation will be explored with much focus and emphasis on the 
encapsulation efficiency, stability, ease of nanoparticles recovery and insulin release as a 
function of different external media. The choice of nanoparticle dosage form over other types 
stems from the fact that with nanoparticles, there is a higher surface area to volume index. This, 
we aim to exploit, so as to impart sensitivity and hope that insulin release from the eventual 
dosage form is fast and orchestrated. Since the addition of insulin was likely to perturb the 
previously established characteristics of nanoparticles by ionotropic gelation or polyelectrolyte 
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complexation, it was necessary to study how incorporation of insulin might modulate the 
responsiveness of the nanoparticles when exposed to glucose. 
 
6.2 Materials  
Functionalised chitosan (FC) was prepared as described in section 3.2.1.4, Human recombinant 
zinc insulin from P. pastoris (28.5 IU/mg) (Merck, Darmstadt, Germany), HPLC grade 
acetonitrile and methanol, (Thermofischer Scientific New Jersey, USA) and ultrapure Milli-Q® 
ZDWHURKPVDWÛ&. All other chemicals were of reagent grade  
 
6.3 Methods 
6.3.1 Preparation of functionalised chitosan TPP insulin nanoparticles (FCTIN) via 
ionotropic gelation 
Functionalised chitosan (FC) was dissolved in 1% acetic acid at a concentration of 3.2 mg/ml 
and the pH adjusted to 4.50 and 5.50 with 4 M NaOH using a Sartorius basic pH meter PB-11. 
Insulin was dissolved in 0.01 N HCl at a concentration of 2.56 mg/ml and TPP was dissolved in 
deionised water at a concentration of 0.844 mg/ml. All three solutions were filtered through a 
200 nm regenerated cellulose membrane. 
A 0.5 ml aliquot of insulin was added to the required volume of TPP solution (table 6.1) and the 
mixture was added drop-wise into the 4 ml FC solution whilst stirring at 600 rpm on an HTS-
1003 magnetic stirrer for 45 minutes at room temperature. The formulations were designated as 
NI (insulin containing), thus formulations made from F1-F5 conjugates, were labelled as F1NI - 
F5NI accordingly and DN (Dummy nanoparticle). 
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Table 6.1 Formulation of FCTIN via ionotropic gelation 
Formulation Polymer Volume of TPP at 0.844 mg/ml (ml) Ratio of FC to TPP 
F1NI F1 5.0 3.0:1 
F2NI F2 5.0 3.0:1 
F3NI F3 4.0 3.8:1 
F4NI F4 3.6 4.2:1 
F5NI F5 3.1 5.0:1 
 
6.3.2 Preparation of functionalised chitosan insulin nanoparticles (FCIN) via 
polyelectrolyte complexation (PEC) 
In addition to preparing nanoparticles by ionotropic gelation, nanoparticles were also prepared 
by PEC. In this procedure, 2 mg/ml of functionalised chitosan (F3 or F5) solution was prepared 
in 1% acetic acid, pH adjusted to 5.5 with a Sartorius basic pH meter PB-11 and then filtered. A 
1 mg/ml solution of insulin was prepared in a mixture of 0.01 N HCl and 0.1 N Tris base at a 
ratio of 87:13, respectively and pH adjusted to 8.50 with 1 N NaOH.  1 ml of the functionalised 
chitosan solution was measured into a vial and 2 ml of 1 mg/ml insulin was added drop wise 
whilst stirring at room temperature at 600 rpm on an HTS-1003 magnetic stirrer for 20 minutes. 
The sample was allowed to stir for an additional 20 minutes. The samples were analysed visually 
where an opalescent dispersion was indicative of nanoparticle formation. The formulations were 
designated F3PN and F5PN accordingly. All experiments were performed in triplicate. 
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6.3.3 Characterisation of nanoparticles 
Z-average, Pdi and zeta potential of the nanoparticles were assessed by Zetasizer Nano ZS 
(Malvern, UK) equipped with a 4Mw He- Ne laser (633 nm). Each analysis was carried out at 
25oC and performed in triplicate and data expressed as mean ± standard deviation. The 
morphological examination of NPs was performed by field emission scanning electron 
microscope (FESEM, Quanta 400F, FEI Company, USA) under low vacuum and at a viewing 
voltage of 20.0 kV. 
 
6.3.4 Evaluation of encapsulation efficiency of NPs 
The encapsulation efficiency (EE) of insulin was determined upon separation of NPs from the 
aqueous medium containing free insulin by centrifugation at 14000 rpm for 45 min at 15ƕC using 
a Beckman Coulter Microfuge 16 centrifuge. The amount of free insulin in the supernatant was 
measured using a Perkin Elmer quaternary HPLC system equipped with UV detector with 
detection wavelength set at 214 nm and the amount of the unencapsulated insulin was deduced 
from the calibration curve. 
The insulin encapsulation efficiency within the nanoparticles was calculated as:  
EE% =  x 100%  «««(TXDWLRQ 
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6.3.5 Recovery of nanoparticle 
6.3.5.1 FCTN recovery by centrifugation  
1.5 ml of freshly prepared FCTN suspension was placed in a 2 ml eppendorf tube, and the 
Eppendorf microcentrifuge, (5417R) was operated at different speeds between 4000-14000 rpm 
for 45 minutes. The amount of nanoparticle recovered was weighed. The redispersibilty of the 
pellet was studied at the different speeds of centrifugation. 
 
6.3.5.2 FCTIN recovery by ultrafiltration 
40 ml of the F3NI suspension was concentrated to a volume of 1 ml using the Millipore stirred 
ultrafiltration cell (Model 8010) with a 25 mm regenerated cellulose membrane with molecular 
weight cut-off of 100 kDa. The system was operated under nitrogen pressure operated at 60psi 
with continuous magnetic stirring and the concentrate was washed repeatedly with deionised 
water to remove all the un-incorporated insulin and the concentrate was then used for further 
analyses. 
 
6.3.6 Stability behaviour of FCIN  
Formulation F3PN and F5PN were prepared according to the method described in section 6.3.2. 
Samples of the formulations were then stored at 25oC and 4oC and the z-average, Pdi and zeta 
potential were measured weekly over a period of one month. 
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6.3.7 In vitro insulin release studies 
Insulin release from the nanoparticles was studied in (1) Phosphate buffer, pH 7.4 (2) glucose (1-
5 mg/ml) buffered solution (pH 7.4) and (3) fructose (1-5 mg/ml) buffered solution (pH 7.4). 
Several replicas of 100 µl of F3PN were placed in eppendorf tubes containing 1 ml of the 
different release media mentioned above and incubated at 37 ± 0.20ƕC with horizontal shaking at 
100 rpm on a WiseCube WIS-20, Precise Shaking Incubator. At predetermined time points, the 
seeded tube was taken and 100 µl of solution was centrifuged at 14000 rpm for 15 minutes using 
a Beckman Coulter Microfuge 16 centrifuge and the supernatant removed. 20 µl of the 
supernatant was injected into the Perkin Elmer quaternary HPLC system equipped with UV 
detector with detection set at 214 nm and the amount of insulin released was determined based 
on reference to the standard curve. The value reported is an average of triplicate readings. 
 
6.3.8 HPLC analysis 
The mobile phase consisted of 0.1% aqueous triflouroacetic acid (TFA) (A) and 0.1% TFA 
acetonitrile (B). Elution was gradient starting with 75% of A decreasing to 40% over 8 min at a 
flow rate of 1 ml/min with detection of insulin set at a wavelength of 214 nm. The columns used 
were an Agilent Zorbax 300SB-4.6 x 250 mm C18, with particle size of 5 µm and pore size of 
300 Å and Viva 2.1 x 150 mm C18 column 863/ZLWKȝPSDUWLFOHVL]HDQGSRUHVL]HRI
300 Å. 
The calibration curve was constructed from pure insulin dissolved in 0.01 N HCl solutions at a 
concentration range of 0.625 µg/ml ± 100 µg/ml.  20 µl of various concentrations of insulin 
solutions was injected into the HPLC system, each reading was done in triplicate. A graph of 
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average peak area was plotted against concentration and the coefficient of determination (R2) and 
the equation of the line determined. 
The effect of temperature on the retention time, peak height and area of insulin was studied on a 
Viva 2.1 x 150 mm C18 column (USP L1) with 3 ȝP SDUWLFOH VL]H DQG SRUH VL]H  c by 
keeping the column at temperatures between 25oC and 60oC. 20 µl of 50 µg/ml of insulin 
dissolved in 0.01 N HCl was injected and the retention time, peak height and peak area at each 
temperature was recorded. Each reading was done in triplicate. 
 
6.3.9 Study of size changes of F3PN prepared via PEC in different sugar media 
F3PN was prepared according to method in section 6.3.2. 100 µl F3NP was added to 1 ml of 
freshly prepared and filtered buffer or buffered glucose or fructose solutions in the concentration 
range of 1±5 mg/ml at pH 7.4 in a capped zeta sizing cuvette. The z-average was recorded at 
different time points and the size changes in each media over the period of 60 minutes were 
recorded.  
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6.4 RESULTS AND DISCUSSION 
6.4.1 Formulation of functionalised chitosan  
The insulin containing nanoparticles were formulated by ionotropic gelation of the cationic FC 
polymer with TPP anions (FCTIN) and also by polyelectrolyte complexation of the cationic FC 
polymer with anionic insulin (FCIN). These mild techniques involve the mixing of aqueous 
solutions at ambient temperature and do not require the use of organic solvents and therefore 
favourable for preparing protein-loaded nanoparticles. In the attempt to incorporate insulin into 
the FCTIN, a 10% drug weight with reference to the polymer weight was used as the drug 
loading whilst in the formulation by PEC, the ratio of conjugate to insulin was 1:1.  
All the conjugates (F1-F5) formulated by ionotropic gelation (NI series) were evaluated for 
insulin encapsulation efficiency however, only F3 and F5 conjugates formulated by PEC (PN 
series) were evaluated for insulin encapsulation efficiency. The z-average diameter of the 
dummy nanoparticles prepared by ionotropic gelation (DN) ranged between 140 nm -170 nm, the 
Pdi was around 0.2 and the zeta potential ranged from +17 mV to +21 mV (table 6.2). However 
on incorporation of insulin, there was an increase in the z-average of all the nanoparticles, with 
the average Pdi and the average zeta potential remaining essentially unchanged. The zeta 
potential for F3DN was lower than that of F3NI, but for the rest of the formulations studied the 
dummy nanoparticles had slightly higher zeta potential than the insulin loaded ones. 
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Table 6.2 Z-average, Pdi and zeta potential of PBA functionalised chitosan TPP insulin 
nanoparticles (FCTIN) formulated by ionotropic gelation 
 
Formulation Z-average (nm) Pdi Zeta potential (+mV) 
F1DN 140.37±0.67 0.275±0.008 21.53±0.72 
F2DN 170.77±1.53 0.280±0.005 18.67±0.50 
F3DN 158.37±1.34 0.272±0.010 18.63±0.75 
F4DN 167.00±1.15 0.242±0.024 19.60±0.92 
F5DN 145.57±0.60 0.290±0.002 18.07±0.71 
F1NI 183.77±8.17 0.265±0.024 18.80±0.85 
F2NI 185.20±6.50 0.277±0.029 17.60±0.80 
F3NI 189.57±5.39 0.210±0.012 21.57±1.27 
F4NI 198.17±5.05 0.241±0.007 17.10±0.75 
F5NI 171.37±3.74 0.257±0.060 17.27±1.75 
DN = Dummy nanoparticles 
NI = Insulin loaded nanoparticles 
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Table 6.3 Z-average, Pdi and zeta potential of PBA functionalised chitosan insulin 
nanoparticles (FCIN) formulated by polyelectrolyte complexation 
 
Formulation Z-average (nm) Pdi Zeta potential (+mV) 
F5PN 151.6±11.75 0.172±0.02 17.50±0.95 
F3PN 140.0±12.83 0.168±0.01 19.10±0.69 
 
The nanoparticles produced by polyelectrolyte complexation for conjugates F3 and F5 showed 
slightly lower z-average than the insulin loaded ones produced by ionotropic gelation and the Pdi 
IRUWKH3(&¶VZHUHORZHUWKDQWKDWIURPWKHLRQRWURSLFJHODWLRQVHUies which is an indication of 
better homogeneity (table 6.3). The zeta potential values were almost identical to the NI 
formulations. The positive values of the zeta potential are attributable to the unsubstituted amine 
groups within the conjugates used in the formulation.  The zeta potential values suggest a low 
stability since these are lower than 25  mV. 
Figure 6.1 (a and b) shows a near spherical images of F3PN and F5PN and figure 6.2 (a and b) 
shows their respective unimodal size distributions. 
                         
 
Figure 6.1: SEM image F3PN (a) and F5PN (b) 
 
 
(a) (b) 
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                                                                       (a) 
 
 
                                                                         (b) 
 
Figure 6.2 Size distribution profiles of F3PN (a) and F5PN (b) 
 
 
 
 
 
F3PN 
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Figure 6.3 also shows the representative zeta potential profile for F5PN. These figures 
corroborate with the data presented in table 6.3. 
 
Figure 6.3 Zeta potential profile of F5PN 
 
6.4.2 Stability behaviour of functionalised chitosan insulin nanoparticles (FCIN) produced 
via PEC 
Encapsulation of insulin in chitosan TPP nanoparticles has been studied widely but in the present 
work, we optimised the method for the production of functionalised chitosan TPP insulin 
nanoparticles (FCTIN) and functionalised chitosan insulin nanoparticles (FCIN) via ionotropic 
gelation and polyelectrolyte complexation respectively. There was therefore a need to ascertain 
the stability of the nanoparticle formulations. The colloidal stability of FCIN produced by PEC 
was studied over a period of one month, however the FCTIN formulations were not studied 
because of low stability and low encapsulation efficiencies observed earlier. The samples to be 
studied were subjected to different storage conditions as described under 6.3.5 and the z-average, 
zeta potential and Pdi were then measured weekly. Much is not reported on the stability of 
chitosan TPP insulin nanoparticles, but the stability of dummy chitosan TPP nanoparticles has 
F5PN 
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been thoroughly studied (López-León et al. 2005). The stability studies for chitosan and some 
modified chitosan insulin PEC has also been  done (Mao et al. 2006),  hence the conjugate±
insulin nanoparticles (FCIN) were also evaluated for stability.  
 
Figure 6.4 Average diameter of F3PN and F5PN stored at 25oC and 4oC as a function of 
time. 
 (A) = Nanoparticles stored at 4oC 
 (B) = Nanoparticles stored at 25oC 
 
Figure 6.4 shows the z-averages of F3NP and F5NP stored at 25oC and 4oC. The particle size for 
nanoparticles stored at 25oC shows a significant increase in size over the weeks. By the end of 
week 3 the size increase in F3PN was more than 10 fold with a significant increase in the Pdi 
(figure 6.5). Further evaluations were halted for F3PN stored at 25oC because of the presence of 
large aggregates and microbial growth.   
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Figure 6.5 Average Pdi of F3PN and F5PN stored at 25oC and 4oC as a function of time. 
 (A) = Nanoparticles stored at 4oC 
 (B) = Nanoparticles stored at 25oC 
 
The increase in size seemed more pronounced in the F3PN nanoparticles compared to the F5PN 
nanoparticles for samples stored at 25oC and the progression of size increase was slower for the 
F5PN nanoparticles. The significant increase in the Pdi of both formulations at 25oC is indicative 
of heterogeneity in the formulations and this is also confirmed by the size distribution profiles. 
Heterogeneous systems are not favourable in drug delivery because this will affect the drug 
release. 
In figures 6.4 and 6.5 it is apparent that samples stored at 4oC showed better stability than 
samples stored at 25oC. Furthermore, the size and Pdi changes of both formulations stored at 4oC 
did not change significantly.  Although the zeta potential measured are below 25 mV (suggesting 
poor stability), when samples were stored at 4oC they retained their stability for one month.  
Temperature relationship with Brownian motion of particles has been used to explain possible 
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aggregation in nanoparticulate systems (Tsai et al. 2011). Lower temperatures reduce the 
Brownian motion of particles, thereby reducing their kinetic energy. These reductions lead to an 
increase in interparticulate distance which reduces the tendency for particles to collide with each 
other and aggregate. Hence this may explain the significant difference seen in size profiles for 
the samples stored at 25oC with those stored at 4oC.  
Zeta potential is a parameter that ascertains the state of the nanoparticle surface charge and help 
in predicting the long term stability of the nanoparticle formulation. Nanoparticulate systems 
with zeta potential values above 25  mV are considered stable and those having values below, 
are liable to aggregation caused by van der Waal inter ± particle attractions. The zeta potential of 
both formulations was about +18 mV, which is clearly below the required 25  mV threshold. 
However, the zeta potential of both formulations stored at 4oC remained essentially unchanged 
during the one month of storage (figure 6.6) 
 
Figure 6.6 Average zeta potential of F3PN and F5PN stored at 25oC and 4oC as a function 
of time. 
 (A) = Nanoparticles stored at 4oC 
 (B) = Nanoparticles stored at 25oC 
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The zeta potential of F3PN and F5PN stored at 25oC showed large variation after storage over 1 
month. The zeta potential of the formulations stored at 25oC decreased drastically as the weeks 
progressed. Chitosan±insulin PEC studied by Mao et al (2006) were susceptible to aggregation 
when stored at room temperature (25oC) or at 4°C over just 2 days, but in contrast, some 
modified chitosan such as TMC and PEGylated TMC insulin complexes showed no indication of 
aggregation even within a month of storage at room temperature. The improvement in stability in 
those formulations was attributed to the higher hydrophilicity of the modified polymer surface 
(Jintapattanakit et al. 2007). They hypothesised that the surface coupling of polyethylene glycol 
(PEG) increases the hydrophilicity of the complexes and lower their surface free energy, thereby 
enhancing their physical stability in aqueous media. In the light of the above, our functionalised 
nanoparticles which showed a downward trend in the zeta potential as a function of storage time 
may be probably due to the enhancement of the hydrophobicity of the complexes in aqueous 
media by boronic acid moieties, thereby increasing surface free energy and thus increasing this 
tendency to agglomerate. The fall in zeta potential values of both formulations stored at 25oC can 
be attributed to the agglomeration that results due to increased Brownian movement as explained 
earlier. Such increase in kinetic energy is likely to cause more collisions between particles with 
increased chances of particles becoming agglomerated. The agglomeration would lead to charge 
condensation and consequently, a reduction in zeta potential. Albeit the progression was slower 
in the F5PN than the F3PN so probably the degree of boronic acid substitution may also have a 
role to play in the stabilisation of the nanoparticle matrices. 
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Figure 6.7 (a and b) shows images of samples stored at 25oC and 4oC for 4 weeks for F3PN and 
F5PN. Figure 6.7 a and b shows the appearance of F3PN and F5PN  respectively after 4 weeks of 
storage, it is evident that the samples stored at 25oC appear more opalescent than the same 
samples stored at 4oC in the figure 6.7 c and d. The F3PN sample stored at room temperature 
also showed signs of microbial growth with F5PN showing no such sign (figure 6.7 a and b) but 
the initial clear opalescence of F5PN was lost which manifested as an increase in the turbidity 
and this is indicative of the presence of larger aggregates in samples. 
 
 Figure 6.7 Visual images of F3PN and F5PN during 1 month of storage. F3PN stored at 
25oC (a), F5PN stored at 25oC (b ), F3PN stored at 8oC (c) and F5PN stored at 8oC (d) 
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(c) 
Figure 6.8 Size distribution of F3PN stored at 25oC (a), 8oC (b) and F5PN stored at 25oC(c) 
over 3 weeks 
 
Figure 6.8 (a-c) shows the size distribution by intensity of the formulations stored at the different 
temperatures over the period one month. The multi modal distribution of the size profile seen in 
the samples stored at 25oC shows heterogeneity in the system and hence a reflection in the 
drastic changes in the Pdi recorded (figure 6.5). The samples stored at 8oC always showed a 
unimodal size distribution profile, in contrast to those stored at 25oC also confirming the 
observations made earlier in the Pdi (figure 6.5). Therefore to preserve the stability of these 
formulations they would require storage at 8oC, where stability is retained for up to 4 weeks. 
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6.4.3 Percentage encapsulation efficiency (%EE) 
The amount of drug incorporated into the matrix of nanoparticle is important in assessing the 
release profile, functionality and cost effectiveness of pursuing the formulation to a 
developmental stage.  
Incorporating insulin into chitosan nanoparticle that has been modified by different chemical 
groups has been studied by several researchers and has proven successful.  Zhang et al, (2008) 
incorporated insulin into a polyethylene glycol grafted chitosan and nanoparticles produced gave 
an encapsulation efficiency greater than 78.6% whilst Zhu et al. (2007) synthesised PEG 
modified N-trimethylaminoethylmethacrylate chitosan nanoparticles in which insulin was 
encapsulated with %EE ranging from 10-84.0% depending on the initial weight of polymer used. 
This implies that modification of chitosan with different chemical groups to impart specific 
functionality does not necessarily impede its insulin encapsulating potential when formulated 
into nanoparticles. 
In the present study, chitosan functionalised by PBA was used to formulate insulin containing 
nanoparticles via ionotropic gelation and PEC. The PEC method was pursued further since the 
ionotropic gelation formulations method yielded formulations with low stability (evidenced by 
precipitation and aggregation with slight pH changes) and low encapsulation efficiencies. The 
%EE varied within not only the formulations studied but also according to the method used for 
the formulation. 
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Table 6.4 shows the %EE for the different functionalised chitosan nanoparticles prepared by 
ionotropic gelation, where the values ranged between 12-32% depending on the chitosan 
conjugate in the series F1-F5 being used. There appeared to be a gradual increase in the %EE as 
the degree of substitution of boronic acid unto the chitosan increased from F1 to F5, hence the 
possibility of the presence of the boronic acid groups in enhancing insulin association or 
incorporation into the nanoparticle matrix is apparent.  
Table 6.4 Percentage encapsulation of insulin in functionalised chitosan nanoparticles 
prepared by ionotropic gelation as a function of pH 
Formulation (pH 5.5) % Encapsulation(pH of FC 
solution 4.50) 
% Encapsulation (pH of 
FC solution 4.50) 
F1NI 12.05±5.61 9.05±7.53 
F2NI 18.87±7.99 - 
F3NI 15.04±4.53 12.04±3.69 
F4NI 34.36±8.14 - 
F5NI 32.51±8.69 24.51±9.65 
 
A pH of 5.5 has been considered as the optimum pH for formulating chitosan TPP nanoparticles 
by ionotropic gelation, because at this pH, it is believed that about 90% of the amine groups are 
protonated (NH4+) to facilitate interaction with TPP (Csaba et al. 2009). A of pH 5.5 was 
therefore used initially to formulate the nanoparticles, but formulation made at this pH became 
easily aggregated. Though the pKa of chitosan is around 6.5 and chitosan seem to precipitate out 
of solution only at pH above 6.0, our formulation easily precipitated at pH 5.5 (especially F5NI). 
There is a possibility that, the substituted boronic acid on the chitosan modifies pKa of the 
polymer and hence nanoparticles produced from the pure chitosan tend to show greater stability 
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towards aggregation with pH changes than nanoparticles produced from the functionalised 
chitosan at the same pH. In the light of the above constraint the pH was reduced to 4.5 and its 
effect was studied on three of the formulations.  
Table 6.4 shows that when the pH was reduced to 4.50 the encapsulation efficiency decreased.  
This pH dependent %EE has also been reported by Ma et al, (2002). In the series of experiments 
performed by that group in attempting to encapsulate insulin in chitosan nanoparticles, they 
observed that a %EE of 57-62% at pH of 6.1 dropped sharply to 12-13% at pH around 5.7 and at 
lower pH of 3 the %EE dropped to about 7%. Higher pH may have favoured interaction between 
chitosan and insulin because proteins are known to adsorb efficiently unto polymers at pH 
around their isoelectric point because of the minimisation of the electrostatic repulsion, increased 
conformational stability, coupled with smaller specific surface area of protein molecules (Ma et 
al. 2002). The association of chitosan with insulin has also been attributed to hydrogen bonding 
and hydrophobic interactions and such interactions are considered labile, hence the equilibrium 
rapidly shifts towards dissociation with small changes in the pH. The above explanation may 
also account for the decreased %EE as the pH was reduced in our formulation. 
The polyelectrolyte complexation method of making chitosan and modified chitosan insulin 
nanoparticles has also been widely explored (Sadeghi et al. 2008; Jintapattanakit et al. 2007; Wu 
et al. 2011). However, this method utilises the cationic nature of chitosan and the anionic nature 
of insulin for the formation of nanoparticles. Due to the lower %EE, lower stability and difficulty 
in the purification of the FCTIN (purification will be discussed in the next heading), the method 
of PEC was adapted to help increase the encapsulation efficiency of insulin and also improve 
ease of formulation and stability. 
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In the development of 3-aminophenylboronic acid grafted chitosan as a sensitive vehicle for 
controlled release of insulin using a caboxyacyl chitosan, Wu et al. (2011) achieved a %EE 
between 49.4-59.4 using the PEC method and the %EE depended on the initial amount of insulin 
used and the molecular weight of the polymer. In the present study, the PEC method was used to 
formulate nanoparticles from conjugates F3 and F5 (F3PN and F5PN respectively). The highest 
encapsulation efficiencies: 81% for F3PN and 91% for F5PN (table 6.5) were achieved. 
Furthermore, %EE increased as the initial pH of the FC solution was increased gradually and this 
implies that, the amount of insulin encapsulated within the nanoparticle matrix is pH dependent.  
Table 6.5 Percentage encapsulation (%EE) of insulin in formulation F3PN and F5PN  
pH F3PN F5PN 
4.50 s68.00±2.08 76.49±1.99 
5.00 78.04±2.19 86.25±3.16 
5.50 81.39±2.24 91.31±0.96 
 
An increase in pH causes more of the residual amine groups within the FC polymer to become 
more protonated and hence enhances the interaction between the cationic amine groups and the 
anionic insulin. However, when the pH of the FC solution was raised above 5.50, it led to 
precipitation of the nanoparticles, because further increase in pH causes the FC to become 
deprotonated and since protonation is necessary to keep the FC in solution, precipitation occurs 
as a consequence. 
It was also observed that during that formulation process, the F5 series was prone to precipitation 
with slight pH changes compared to the F3 series and since F5 had higher degree of substitution 
of the boronic acid (chapter 3) there is also a possibility that the degree of the PBA substitution 
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affected the pKa of the polymer and its stability in aqueous formulations. Hence the degree of 
boronic acid substitution on the polymer might also dictate their behaviour towards pH changes. 
 
6.4.4 Recovery and purification of nanoparticles 
Recovery of nanoparticles is one of the most important parameters that need thorough 
consideration in the process of developing a formulation. The recovery of colloidal nanoparticles 
poses more challenges than the recovery of solid nanoparticles, because colloidal nanoparticles 
have lower mass densities and are also more liable to structural deformation in the recovery 
process. Different methods have been used to recover nanoparticles from solutions depending on 
different properties of the nanoparticles. For example, Leo et al. (2004) recovered and purified 
polylactic acid nanoparticles containing a lipophilic drug by gel-filtration chromatography. Other 
methods including (Leo et al. 2006) and cross-flow filtration (Ma et al. 2005) but sometimes 
combinations of methods are used . The process of cross-flow filtration used by Ma et al. (2005) 
to remove free ions and insulin molecules from the chitosan±insulin nanoparticle dispersion. 
Cross-flow filtration was used because of the instability of the dispersion to centrifugation.  
 The method of centrifugation is the most widely used method in the purification and recovery of 
colloidal nanoparticles like chitosan TPP nanoparticles. These colloidal nanoparticles which 
encapsulate different drugs are normally recovered and redispersed in deionised water and used 
as suspensions or freeze-dried with or without cryoprotectant before further analyses. In the 
course of the present study, different methods were evaluated for suitability in the recovery of 
the nanoparticles. In each method, the benefits and constraints are discussed.  
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The method of dialysis attempted was unsuccessful because the cationic nature of the chitosan 
polymer caused most of the nanoparticles to stick onto the membrane due to the electrostatic 
interaction between the dialysis membrane and the cationic chitosan. This made nanoparticle 
recovery seemingly impossible.  
The method of centrifugation (high speed or ultra) is the widely reported method for the 
purification and recovery of insulin loaded chitosan and modified chitosan nanoparticles 
encapsulating insulin. The major setback with this method is the variability in the centrifugal 
speeds and forces used to separate nanoparticles from solution by different researchers, wherein 
the difference in these parameters will be dependent on the properties of the nanoparticles being 
formulated. The process of centrifugation with speeds ranging from 3000- 45000 rpm  and 10000 
± 74200g have been used in separating chitosan TPP nanoparticle encapsulating insulin (Damgé 
et al. 2007; Bruno Sarmento et al. 2006; Fernández-Urrusuno et al. 1999; Amidi et al. 2006). 
Some of the centrifugation was also done on a glycerol bed, where the pellet was then 
redispersed in purified water or freeze-dried and used for further analysis. 
In the present work, we observed that centrifugation did not help in the recovery, though the 
speed of centrifugation had a direct relationship with the amount of substance recovered (figure 
6.9).  
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Figure 6.9 Amount of nanoparticle recovered at different speeds of centrifugation 
Though this increase in speed with high recovery is plausible, one must be cognisant of the effect 
of speed of centrifugation on the redispersibilty of the nanoparticle pellet and the accompanying 
possible morphological changes that can occur. Dummy nanoparticle formulation of the F1NI 
was centrifuged at speeds between 4000-14000 rpm and the ease of redispersibilty of the 
recovered pellet at the various centrifugal speeds was studied. It was observed that nanoparticles 
recovered at speed 4000-6000 rpm were easily dispersed by vortexing or shaking but speeds 
above 6000 rpm produced a pellet that was difficult to redisperse. Few researchers have given 
highlights on the non-dispersible cakes or pellet formed when nanoparticles are recovered by 
high speed centrifugation (Leo et al. 2006). An attempt to recover the FCTN and FCTIN by 
centrifugation was met with minimal success because the pellet recovered at high speeds (speed 
which gave the highest weight of nanoparticle recovered) was not redispersible. The pelletization 
may have led to a possible destruction of the spherical morphology of the nanoparticles and this 
would eventually affect any further studies on the recovered nanoparticles. 
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Figure 6.10 shows the particle size distribution of nanoparticle formulation prior to and after 
centrifugation at 4000 rpm, where it was observed that at that speed most of the nanoparticles did 
not pellet out. As seen in the figure the intensity in the two distributions did not change 
significantly indicating that a lot of the particles were still remaining in suspension in the 
supernatant after centrifugation and the shift of the distribution towards the smaller particles 
(green label) also indicate recovery of only larger particles leaving the smaller particles still in 
suspension within the supernatant. In this regard any attempt to use the recovered nanoparticle 
for further study will affect the data in terms of accurate quantification of released drug as a 
function of the initial amount encapsulated, because we cannot tell whether more of the drug is 
encapsulated within the smaller particles or the larger ones. 
 
Figure 6.10 Size distributions of nanoparticle before centrifugation and the supernatant 
after centrifugation 
 
An attempt was also made to freeze dry the recovered pellet and redisperse after, but freeze-dried 
nanoparticles were not dispersible in deionised water. The use of common cryoprotectants which 
are mostly sugars or sugar derivatives (Abdelwahed et al. 2006) for the process of freeze drying 
Freshly prepared F1NI Supernatant of F1NI after centrifugation at 
4000rpm 
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was avoided in our work. This is because the boronic acid groups in the nanoparticle matrices are 
known to be sensitive to different diols and the effect of these cryoprotectants on the stability of 
the nanoparticles and their potential effect on the insulin release could not be predicted. 
In the light of the above difficulties encountered with nanoparticle recovery by dialysis and 
centrifugation, a mild and simple method was sought after to help recover and purify the fragile 
insulin loaded nanoparticles. It was speculated that, the method of centrifugation was harsh and 
therefore led to the destruction of the colloidal nanoparticle because of the non dispersibility of 
the pellet recovered after centrifugation.  
The Amicon® ultrafiltration system equipped with a membrane with molecular cut-off 100 kDa 
was therefore studied for its application in the recovery of nanoparticles. This system is used for 
protein purification and recovery and has the ability to concentrate formulations into small 
volumes whilst preserving the constituents and integrity of the formulations.  
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Figure 6.11 (a and b) is a representation of the setup of the ultrafiltration system, the internal 
magnetic stirring bar prevents the aggregation of the particle during filtration because as the 
volume of the medium decreases the nanoparticles occupy a small volume and the stirring action 
of the magnetic bar prevents aggregation.  
                  
Figure 6.11 (a and b) Set up for Amicon ultrafiltration system for the recovery of 
nanoparticles 
 
Though the process of recovery and purification was successful, other factors such as film 
formation on the membrane also limited the use of the above method. During the process of 
purification it was observed that a thin film formed on the membrane (figure 6.11b), thereby 
reducing the filtration rate. Some of the excess insulin and polymer still remained in the 
concentrate above and an attempt to clear the film from the membrane to enhance the filtration 
rate damaged the membrane. These membranes though reusable could not be used again and 
therefore added more cost to the process. 
 
 
 
(a) (b) 
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Table 6.6 % EE of insulin in F1NI and F3NI versus expected encapsulation as determined 
by ultrafiltration 
  
Determined % encapsulation after 
centrifugation 
% of insulin in 
filtrate 
Expected 
encapsulation (%) 
F1NI 14.30 60.42 39.60 
F3NI 23.60 84.40 15.60 
 
Table 6.6 shows the encapsulation efficiency determined by centrifugation and from the filtrate 
after concentration using the Amicon® filter. The determined encapsulation for F1NI by 
centrifugation was 14.3%, whilst the amount of unencapsulated insulin in the filtrate from the 
ultrafiltration was 60.42%, and this implies that about 26% of insulin was not accounted for. 
During the filtration process the film formed on the membrane as explained earlier, may have 
prevented the unassociated insulin from going into the filtrate. Therefore any further analysis 
with the concentrate will not be a true reflection of any determined parameters of the initial 
formulation. Also another constraint was the length of time it took to concentrate 12 ml volume 
to 1 ml, where approximately 2 hours was required to achieve the above mentioned concentrate 
and this implied the practicality of the upward scaling was in question. 
Therefore though the process of ultrafiltering was feasible and yielded concentrated 
nanoparticles, it will be advisable to thoroughly determine the molecular weight of the polymer 
and also ascertain the correlation between the sizes of the nanoparticles with the molecular 
weight cut-off of the membrane. This determination will help in choosing the right molecular 
weight cut-off for the membrane so that all the insulin loaded nanoparticles are retained in 
suspension but the excess drug and polymer filter out with less restriction making the process 
scalable and cost-effective.  
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6.4.5 Insulin release studies in various media 
The formulation of the functionalised chitosan into insulin containing nanoparticle was 
successful as discussed earlier, therefore the release profiles of the formulation were assessed in 
different media. The formulations made by PEC had proven to be superior in terms of stability 
and %EE. Therefore those formulations were used in the study of insulin release. The 
demonstration of a glucose dependent swelling of the nanoparticles warranted an assessment of 
the insulin releasing properties from the nanoparticles in different external media to help 
correlate the glucose dependent swelling behaviour with the insulin release profiles. To establish 
the insulin release profile from the insulin loaded nanoparticles (F3PN) phosphate buffer, 
glucose and fructose buffers at pH 7.4 were used. 
 
6.4.5.1 HPLC method for quantifying proteins 
The HPLC method used for quantifying proteins has been adapted by different researchers, 
which is also applicable for insulin analyses with the detection system as UV. A number of 
researchers utilised fluorescence detection mode,  using fluorescein isothiocyanate (FITC) 
labelled insulin as the flourophore (Damgé et al. 2007). 
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The amount of insulin encapsulated within the matrix were analysed by comparing with a 
constructed calibration curve as shown in figure 6.12. The retention time for insulin was about 6 
minutes and the HPLC method was validated with regards to linearity and the correlation 
coefficient value (R2) was 0.9995.  
 
Figure 6.12 Standard calibration curve of peak area of insulin 
In the analysis of proteins larger bore columns are known to be more efficient and they tend to 
give better peak resolution. This conventional column uses large volumes of solvent in 
comparison to the new narrow bore columns.  
The effect of temperature on elution of insulin was studied on the elution of insulin using a 2.1 
mm i.d Viva C18 column a narrow bore column. It was observed that  peak area did not change 
much as the temperature was increased, but peak height did change at 60oC  where, the peaks 
were sharper than the peaks at 25oC (figure 6.13). This implies that peak resolution and 
sharpness is enhanced when temperature is increased and this observation has also been reported 
by Ye et al. (2001). 
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Figure 6.13 Effect of temperature on peak height and peak area 
Figure 6.14 is a representative chromatogram of the insulin peaks detected at different 
temperatures.  
 
Figure 6.14 Representative chromatograms of insulin (50 µg/ml) detected at 25oC (a), 50oC 
(b) and 60oC (c) 
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The intensity scale shows an increment in height as the temperature is increased. The intensity 
reading at 25oC was 194.95 µV, that of 50oC was 243 µV and that of 60oC was 293 µV. 
Increased peak height with minimal changes in the peak area (as depicted in figure 6.13) is 
indicative of better peak resolution and sharpness.  
Furthermore an increase in the temperature led to a decrease in column pressure (figure 6.15). 
Temperature has an indirect relationship with viscosity; temperature increment in fluids known 
to cause a decrease in their viscosity. Hence as the temperature was increased, flow of the mobile 
phase was enhanced thereby reducing the pressure in the column and the tubes. The retention 
time of about 11 min was not affected by the changes in temperature. 
 
Figure 6.15 Effect of temperature on column pressure and peak retention time 
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6.4.5.2 In vitro insulin release 
The insulin release profile from nanoparticles is usually affected by the method of formulation, 
the ionic interaction between the drugs, auxiliary ingredients, regional residence (incorporation 
or by adsorption within the matrix) and the chemical composition of the release medium.  
The analysis of insulin released was performed using an Agilent C18 column as described in 
section 6.3.8. With this column, shorter retention times were recorded using the optimised 
parameters for analysis on the Viva C
`
 column. Figure 6.16 (a and b) is a representative 
chromatogram of pure insulin and insulin after release in buffer medium respectively. The 
retention time was about 6 minutes and it is can be seen that the peaks were completely resolved 
and free from interference from extraneous material.  More importantly, the release study 
suggests that no degradation of insulin occurred as these would have registered other 
chromatographic peaks. 
 
Figure 6.16 Chromatogram of pure insulin (a) and after release from formulation in buffer 
pH 7.4 media (b) 
a b 
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Other studies have however indicated the manifestation of degradation products of insulin 
following formulation into nanoparticles (Oliva et al. 2000). 
Characteristic insulin release profiles usually reported by different groups in insulin release 
studies from different formulation is characterised by an initial burst release phase (due to drug 
desorption from particle surface), followed by a plateau attributed to the diffusion of the drug 
through the matrix and lastly a constant sustained release of the remaining drug attributed to the 
diffusion of insulin through the polymer wall as well as its erosion (Wu et al. 2011). 
 
Figure 6.17 Release profiles of insulin from F3PN in phosphate buffer and various 
concentrations of phosphate buffered glucose solution 
 
Figure 6.17 is the representative release profile for insulin in buffer pH 7.4 and different glucose 
media, namely 1, 3, and 5 mg/ml glucose. At 1 mg/ml glucose, the release of insulin was more 
sustained, peaking slightly at 30 minutes. In 3 mg/ml of glucose, insulin release from the 
nanoparticles was manifested by an initial burst release which peaked 15 minutes followed by a 
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fall. A similar trend was observed in the 5 mg/ml glucose, with insulin release peaking at 10 
minutes. It is apparent from the foregoing that the higher the glucose concentration, the more 
interactions there are with the PBA groups within the nanoparticle matrices. Such interactions 
lead to an increase in the diameter of the matrices as discussed in chapter 5. The increase in size 
then allows permeation of insulin into the media. The speed and the extent of interaction of 
glucose with boronic acid is slowest at 1 mg/ml. 
In all the cases however, there is an apparent dip in insulin release, following the peak. This dip 
can be attributed to the bidentate interaction between the OH moieties of the boronic acid with 
glucose. In this regard, a sustained interaction of boronic acid groups with glucose leads to 
³NQLWWLQJ´RIWKHQDQRSDUWLFOHPDWUL[E\JOXFRVHZKLFKUHVWULFWVIXUWKHUGLIIXVLRQRILQVXOLQ 
From figure 6.17, it is also noticed that there was a significant release of insulin in buffer and this 
release profile shows an initial burst release which then tends to increase with time. This is in 
contrast to insulin release from the matrices in glucose media and suggests a different 
mechanism responsible for insulin release. Since insulin and the polymer are held in place by 
electrostatic interaction, it is apparent that ions contributed by the buffer effectively quenches 
these interactions. Consequently, the release of insulin continues to rise due to the loss of the 
integrity of the matrices. Fernández-Urrusuno et al, (1999) made a striking observation in a study 
on the profile of the insulin release from chitosan TPP nanoparticles in water and buffer. They 
observed that only 30% of the encapsulated insulin was released in water after 2 hours, but there 
was a 90% release in buffer in the same time frame. Hence they concluded that the dissociation 
of ionic complex within the nanoparticulate matrices caused by the components of the buffer was 
what governed the above observation. Therefore the role of buffer in aiding insulin release 
cannot be overlooked. 
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Studies have shown that fructose has a higher affinity for boronic acid than glucose (Springsteen 
and Wang 2002). The concept of the binding is related to the pKa of the sugar boronate ester in 
aqueous medium, where the pKa of the fructose boronate and glucose boronate esters have been 
determined to be 4.6 and 6.8 respectively. The lower pKa of the fructose boronate ester favours 
the reaction with PBA.  Though the concentration of fructose in the blood of a diabetic patient is 
<10 mM (Yao et al. 2012), concentration of fructose used in this current study was intentionally 
made the same as that used for the glucose studies in order to compare molecular affinities. This 
choice was to help gain a better understanding into the mechanism of insulin release from the 
sensitive matrix due to the complexity of the release profile portrayed by glucose.  
 
Figure 6.18 Release profiles of insulin from F3PN in phosphate buffer and various 
concentrations of phosphate buffered fructose solution 
 
Figure 6.18 shows that, at an initial low concentration of fructose (1 mg/ml) insulin release was 
less than that from 3 mg/ml, indicating that the binding of fructose with boronic acid moieties 
within the nanoparticles caused more release of the insulin as observed with glucose. However as 
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the concentration of fructose was increased to 5 mg/ml, the release was significantly lowered. 
This implies that, the high concentration of fructose makes more interactions possible between 
the boronic acid and the fructose molecule leading to the formation of more bidentate 
interactions which then tends to knit the nanoparticle matrix together and causes retention which 
retains the integrity of the matrix. Ultimately, this restricts further release of insulin. The buffer 
also has a role to play since it appears that whilst the buffer may be causing disruption of the 
matrix, the fructose also works to keep the matrix intact. But obviously the effects of fructose 
supersedes. Comparing insulin release from the matrices in glucose and fructose, it is apparent 
that more insulin was released from matrices in glucose media than identical concentrations in 
fructose media. The reason for this is clearly due to the stronger affinity that fructose has with 
the boronic acid OH groups compared to glucose. In other words fructose is better at knitting the 
matrices than glucose through bidentate interactions. 
In order to study the effect of buffer on insulin release further, three different buffers were used 
at pH 7.4: phosphate buffered saline (PBS), tris (tris (hydroxymethyl)aminomethane) (TRIS) and 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid). TRIS is one of the most widely 
used buffers in molecular biology and cell culture due to its low toxicity, stability, buffering 
capacity and its useful buffer range of (7-9) coincides with the physiological pH typical of most 
living organisms. HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) is a zwitterionic 
organic chemical buffering agent and HEPES is widely used in cell culture, largely because it is 
better at maintaining physiological pH. Phosphate-buffered saline (PBS) is set to have a pH 
within the range of 7 ~ 7.6, and often set to be 7.4 as the pH of blood nears 7.4, a value referred 
to as the physiological pH in biology and medicine. Aside the maintenance of constant pH, PBS 
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is known to have an osmolarity that matches those of the human body (isotonic) and is non-toxic 
to the cells and hence most release studies are done in PBS. 
 
Figure 6.19 Release profile of insulin from F3PN in different buffers at pH 7.4 
 
The release of insulin in these buffers was characterised by an initial burst release with the 
highest burst release recorded in PBS and the initial release in HEPES and Tris exhibiting almost 
a similar pattern (Figure 6.19). The release then plateaus with the highest release occurring in 
HEPES buffer, in this regard, the role of the individual components of the different buffers as 
contributors to insulin release from nanoparticle particles cannot be overlooked and must be 
considered when they are used in this kind of studies.  
Springsteen et al. (2002), tested two buffer systems phosphate buffer and HEPES buffer for its 
effect on the binding constants of a phenylboronic acid ± alizarin red (PBA/ARS) complex. They 
observed that the binding constants dropped dramatically with increasing buffer concentrations, 
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while the binding constant for the fructose/PBA complex stayed fairly constant. In HEPES buffer 
the PBA/ARS complex binding constant was independent of the buffer concentration over the 
tested range (0±0.1 M). However, the binding constant obtained at a given pH was different for 
the two buffer system. Therefore, if one is designing an experiment or comparing data from 
different experiments, the buffer composition and concentration needs to be thoroughly 
considered. The change in buffer system used will also have another effect. The difference and 
complexity of the release profile exhibited by the two diols in the above results might have 
resulted from a complex interplay between the effect of the buffer on the binding of the diol to 
boronic acid and the binding affinity of the different diols to boronic acid. 
 
6.4.6 Size changes of FCIN (F3PN) in different diol media 
Nanoparticles produced by the ionotropic gelation have been studied for their glucose-dependant 
swelling behaviour in Chapter 5. The release profile of insulin in the data above prompted more 
investigations into the behaviour of the PEC formulation (FCIN) in buffer and the diol media 
studied. In this regard, size changes prompted by the introduction of nanoparticles into buffer, 
fructose and glucose (1-5 mg/ml) over the course of time were studied for the PEC formulation. 
Because there is a significant release of insulin in the buffer and less in high concentration of 
fructose, the sugar-dependent size changes of the FCIN were investigated.  
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Size changes of F3PN in buffer and different concentrations of glucose and fructose is shown in 
figure 6.20. The size changes in buffer was more pronounced than those in glucose media, hence 
it is possible to assume that particles also swells in buffer and may lead to difficulties in 
deciphering any size changes prompted by glucose or fructose.  
 
Figure 6.20 Size changes in F3PN in buffer and various concentrations of glucose 
The progression of size increase in the nanoparticles at the different glucose concentration shows 
a slower progression as the glucose concentration was increased from 1 mg/ml to 5 mg/ml. The 
modulation of this size increase as the glucose concentration increased can be attributed to the 
interaction of the glucose with boronic acid moieties. The rate of size change in buffer was faster 
as compared to that in the glucose and in this regard, the buffer might be thought of as causing 
disruption of the matrices whilst the glucose might be working through bidentate interactions to 
keep them intact. This observation corroborates the insulin release studies described in section 
6.4.5.2. It must also be noted that, size changes in buffer or any media does not directly depict 
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swelling because photon correlation analysis measures anything considered as particles, whether 
these are fragments or intact particles.   
Figure 6.21 and 6.22 shows the z-average distribution profile of the nanoparticles after exposure 
to buffer and 3 mg/ml glucose respectively. The Pdi measured in buffer was much higher than in 
glucose and further points to the fact that an increase in polydispersity is occurring and as 
reflected in the multi modal nature of the size distribution. 
 
 
Figure 6.21 Size distribution profile of F3PN in buffer over 60 minutes 
 
B 0   min 
B 15 min 
B 60 min 
B 5  min 
B 30 min 
 
B 10 min 
B 45 min 
208 
 
 
 
Figure 6.22 Size distribution profile of F3PN in 3mg/ml of glucose over 60 minutes 
 
 
Figure 6.23 Size changes in F3PN in buffer and various concentrations of fructose 
Figure 6.23 shows changes in the size of F3PN in fructose and figure 6.24 shows a unimodal size 
distribution of samples exposed to fructose. The size change of the F3PN in glucose over 60 
minutes was significant whilst the change in buffer was drastic. 
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Figure 6.24 Size changes in F3PN in buffer and various concentrations of fructose 
Figure 6.25 depicts a clear contrast between the two sugars with the measured Pdi after 15 
minutes. The size change of nanoparticles in buffer is higher than in the sugar media. This trend 
seems to confirm a modulation of the size changes by the nature of the sugar present in the 
medium.  
 
Figure 6.25 Size changes in F3 in buffer and various concentrations glucose and fructose at 
15 minutes exposure 
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The higher affinity of fructose for boronic acid than glucose might have accounted for the slow 
changes of the particle size in the fructose medium. Furthermore, the decrease in size of the 
nanoparticles placed in fructose was accompanied by lower Pdi values compared to those 
observed in glucose. This also confirms that the knitting effect on the nanoparticles by fructose is 
more pronounced than glucose. It also suggest that the buffer effects on the nanoparticles are 
somewhat negated in the presence of fructose than glucose.  
             
               
Figure 6.26 SEM image of F3PN before (a) after exposure to buffer (b), after exposure TO 
3 mg/ml glucose (c) and after exposure to 3 mg/ml fructose (d)  
 
Figure 6.26 (a-d) are images of F3PN before and after exposure to glucose and fructose, it can be 
seen from 6.26b that the particles that were exposed to buffer were fragmented and appear to 
(a) 
(c) 
(b) 
(d) 
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have lost their integrity. Hence these images correlate with the photon correlation data. This 
implies that the size increase in the after buffer exposure was due to a combination of swelling 
and fragmentation of the particles matrices. Because the interaction of insulin and the polymer in 
the formation of the nanoparticle matrices are electrostatic in nature, any changes in the ionic 
environment will cause disruption of the matrices easily. This disruption will also lead to 
significant drug release. These images tend to shed more light on the results obtained in the 
insulin release studies. 
The presence of glucose and fructose seemed to help keep the structure intact, though there was 
an increase in the size of the nanoparticle initially. Thus the matrices were stabilised and not 
fragmented.  Figure 6.26 (c and d) are the SEM images showing the appearance of the particles 
after exposure to glucose and fructose respectively. The nanoparticles exposed to glucose were a 
bit fragmented as compared to those exposed to fructose. There are crystals of fructose appearing 
in figure 6.26 (d) but the nanoparticles present are very spherical and appear to have retained 
their structure. This data is in concert with the nanosight data in chapter 5 where dummy 
nanoparticles prepared by ionotropic gelation showed a lesser degree of glucose dependent 
swelling in high concentration of glucose than lower concentration. It follows that a higher 
concentration of diol will not induce more swelling over the course of time but rather a reduced 
swelling at a point due to bidentate interaction between the sugar and the boronic acid moiety. 
The higher affinity of fructose for boronic acids than glucose is established (Springsteen and 
Wang 2002; Hall 2006), in this regard the better protection of the nanoparticulate matrix offered 
by fructose is related to its affinity for boronic acid, this high affinity of the fructose for boronic 
acids than by glucose is related to the position of the cis diol in both sugars.  
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Figure 6.27 Structure of glucose and fructose and their possible interaction with boronic 
acid 
Figure 6.27 shows the structure of glucose and fructose and their possible molecular interaction 
orientation with boronic acid. The position of the two OH groups in the fructose makes it more 
favourable and easy for enhanced interaction with the boronic acid leading to the formation of 
the bidentate bond. It can be observed that for free interaction between the OH groups of glucose 
and those of boronic acid; it would require possibly, two molecules of the glucose to be oriented 
far apart and free from steric hindrance. It would be a lot more constrained for one molecule of 
glucose to align in order for its two OH groups to react with the two OH groups of boronic acid. 
This positioning of the OH groups within the sugar molecules may explain why fructose aids in 
Possible glucose - boronic acid 
bidentate orientation  
Possible fructose - boronic acid 
bidentate orientation  
213 
 
retaining the structure of the nanoparticles through bidentate interactions better than glucose and 
hence lower rates of insulin release in fructose media than glucose. 
 
 6.5 CONCLUSION 
The functionalised chitosan was successfully formulated into insulin containing nanoparticles via 
ionotropic gelation and polyelectrolyte complexation method.  The nanoparticles produced by 
PEC method were smaller in size and showed higher insulin encapsulation efficiency. The 
individual steps in the formulation process parameters have significant effect on the 
encapsulation efficiency of the system.  
The release of insulin from the nanoparticles depended on a complex interplay between the 
buffer effects and the sugar effects and hence choice of buffer for such studies must be carefully 
selected and its effects must also be rightly assessed. Though there was glucose and fructose 
dependent insulin release, the release is affected by the concentration of the sugar. 
High concentrations of sugars favour the retention of the nanoparticle integrity through 
interactions with the boronic acid moiety. This is particularly pronounced with fructose, where 
bidentate association with boronic acid ensures that the particle remain intact by a seemingly 
knitted matrix. This results in a diminished permeation of insulin into the media. 
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CHAPTER 7 
SUGGESTIONS  FOR FUTURE WORK 
The search for alternative insulin delivery systems have led to the developement of various novel 
systems in diabetes mellitus therapeutics. However, extensive research needs to take place before 
any new formulation can finally reach clinical trails. As an extension from this current project, a 
few suggestions for futher work are discussed below. 
1. Molecuar weight and degree of deacytyalation of chitosan 
In the present study, low molecular weight chitosan was used throughout the study. Many studies 
on polymers have shown that, their molecular weight and chemical properties do affect the ease 
of functionalization and also their formulation properties (Huang et al. 2004; Xu and Du 2003). 
It will be worthwhile studying the effect of molecular weight, degree of deacetylation  and the 
effect of source (type of crustacean used in the process of chitosan production ) on the tagging of 
boronic acid and how these parameters affect the degree of substitution of the boronic acid unto 
the chitosan and its effect on the glucose adsorption capacity, glucose sensitivity and selectivity  
The process of standardising a method for the production of consistent molecular weight and 
viscosity of chitosan should also be pursued. The molecular weight quoted by Sigma Aldrich as 
low molecular weight chitosan is in the range of 50,000 - 190,000 Daltons and the viscosity 20-
300 cP, (1 wt. % in 1% acetic acid at 25 °C, using a Brookfield viscometer).  The range is very 
wide and it is already established that molecular weight of chitosan affect size and different 
properties of nanoparticles, hence to get consistent products the starting polymer must have 
almost the same properties.  
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2. Stability studies of the solid and solution of functionalized chitosan conjugates  
The commercial production of chitosan yields different deacetylation grades, molecular weights 
and viscosities and this chitosan powder is normally stored at room temperature until used. 
Studies have shown that during storage certain changes occur in the viscosity and moisture 
content of the chitosan and thus influence the functional properties of the chitosan (No and 
Prinyawiwatkul 2009). This may lead to inter batch variations when used in formulation. 
The dissolution of chitosan in dilute acetic acid is also the start of most applications of chitosan 
and there have been reports of hydrolysis of chitosan in acetic acid if the acetyl content and 
molecular weight is high. It will therefore be worthwhile investigating into the effect of the 
degree of substitution of boronic acid on the stability of the polymer and also subject the 
functionalized chitosan to different environmental stress and assess stability with time.  
We noted that, some solutions of the functionalized chitosan stored at room temperature in vials 
started showing discolorations after about 30 days of storage and these colour changes were 
prominent in the F4 and F5 formulations. Hence, the solution of the functionalized chitosan 
should also be studied at different storage conditions so that appropriate storage conditions can 
be prescribed.  
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3. Cytotoxic studies of functionalised chitosan and functionalised chitosan insulin 
nanoparticles 
The biocompatibility of chitosan and some modified chitosan such as trimethyl chitosan and 
thiolated trimethyl chitosan has already been established (Yin et al. 2009; Mao et al. 2005). The 
non-cytotoxicity of the chitosan nanoparticles have also been reported by different groups and 
are known to be biocompatible and biodegradable. It will therefore be in the right direction to 
study the cytotoxic and biodegradation properties of the new chitosan PBA conjugates and their 
nanoparticulate insulin formulation to establish its safety for use as a drug delivery system. 
4. Tailoring the chemistry of the conjugate to make the system more glucose 
responsive 
The glucose and fructose swelling behaviour of the polyelectrolyte complexes showed that the 
boronic acid in the nanoparticles do interact with the diols, but the effect of fructose was more 
pronounced than that of glucose. The insulin release profiles of fructose gave a better 
understanding into the interpretation of the release data than glucose which seemed inconclusive. 
The chemistry of the conjugates could be looked at again in terms of the introduction of specific 
chemical groups into the conjugate that can help tailor the sensitivity of the nanoparticles more 
WRZDUGV JOXFRVH  7KH FRQMXJDWHV SURGXFHG E\ WKH 6FKLII¶V EDVH PHWKRG E\ Matsumoto et al, 
(2002) showed selective glucose adsorption than the commercial one used and this selectivity 
was between glucose and 1-alpha methyl glucoside. On this basis this method was used in 
making the conjugates to be used for the development of the glucose responsive nanoparticles. 
The selectivity of the conjugate for fructose was not reported. In this current work the non-
selectivity of the conjugate for fructose and glucose with fructose behaviour being more 
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pronounced have been reported. Therefore tailoring the chemistry of the conjugate to be more 
glucose sensitive will be worth exploring. 
5. Recovery of the insulin containing nanoparticles 
In order to improve the physical and chemical stability nanoparticulate suspensions, water must 
be removed. The major obstacle that limits the use of these nanoparticles in aqueous suspensions 
for extended periods is their physical instability (aggregation/particle fusion) and chemical 
instability (hydrolysis of polymer materials forming the nanoparticles, drug leakage of 
nanoparticles and chemical reactivity of medicine during the storage). The most commonly used 
process which allows for the conversion of solutions or suspensions into solids of sufficient 
stability for distribution and storage is freeze-drying. 
In the course of the project different processes were assessed for the possibility of recovering the 
colloidal nanoparticles. The method of centrifugation as reported did not work for our system 
and freeze drying without a cryoprotectant gave undispersible nanoparticles. Freeze drying with 
a cryoprotectant was also not attempted, because most of the cryoprotectants reported are sugars 
or derivatives of it (Abdelwahed et al. 2006). The reactivity of the boronic acid moieties in the 
nanoparticle matrix with some sugars has already been established. The possibility of reaction of 
these cryoprotectants with the boronic acid in the nanoparticle matrix and its effect on insulin 
release therefore needs to be assessed critically. Pursuing this formulation into making it solid 
will be plausible, because solid formulation will exhibit more stability than suspension. 
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6. Assessing different polymers for possible tagging with boronic acid 
Chitosan is a natural polymer of interest to many researchers because of its availability, 
biocompatibility and biodegradability. Though this polymer is widely explored as a vehicle for 
drug delivery, the exploration of other biocompatible polymers both synthetic and natural for the 
possibility of functionalizing them with boronic acid moieties and their potential use as a glucose 
responsive insulin delivery system could also be pursued. 
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